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SUMMARY
Swiss 3T3 fibroblasts were chosen as a model system to
study the role of arachidonic acid and/or its metabolites
in controlling serum— and PDGF—induced inositol lipid metabolism.
P G F ^  (0.01 - 10 ]iM) caused a rapid stimulation of inositol
phospholipid hydrolysis which was maximal within 1 - 2  minutes
of stimulation with the agonist. The level of Ptdlns was not
significantly affected by PGF^. The time course of [ -tl -
InsP accumulation suggests that InsP was not produced directly
from Ptdlns, but was formed by the dephosphorylation of
InsP and InsP_ at least within 1 minute after the PGF^2 3 2a
addition. 1.6 p,M P G F ^  caused a two-three fold increase in 
[ ^ Hj -PtdA levels, but did not affect the levels of any other 
major phospholipid measured.
Having shown that P G F ^  stimulated inositol lipid 
metabolism in 3T3 cells, it was postulated that the formation 
of prostaglandins from AA might be intermediatory in the 
action of PDGF on inositol phospholipid hydrolysis. In order 
to prove this, it was necessary to be able to inhibit their 
formation. Surprisingly, the cyclooxygenase inhibitors tested, 
(flurbiprofen and indomethacin), on their own caused a 
stimulation of inositol lipid metabolism. This was observed 
as an increase in C3h ]  -InsP levels and in C3h J -PtdA levels.
The inhibitors had no effect on the levels of any other major 
phospholipid. The effect of flurbiprofen on inositol lipid 
metabolism was shown to be dose—related, with 100 p-M 
flurbiprofen producing the maximum stimulation.
By inhibiting cyclooxygenase activity* it seemed possible 
that flurbiprofen might have re—directed free AA towards 
the lipoxygenase pathway and thus the possibility that a 
stimulatory lipoxygenase metabolite was responsible for the 
increase in inositol phospholipid hydrolysis was investigated. 
BW7 5 5C* an inhibitor of both eyelooxygenase and lipoxygenase 
also caused a stimulation of inositol lipid metabolism* in 
a dose—related manner. The effect was maximal with 100 p,M 
BW755C. Although it remains possible that BW755C did not 
inhibit all the l.o. enzymes, it seemed more likely that the 
stimulation of inositol phospholipid hydrolysis was due to 
AA itself. Further evidence which suggested this to be the 
case was that flurbiprofen and BW755C, in a dose-dependent 
manner* caused an increase in the level of free -AA in
the medium surrounding the cells. The drugs also caused an 
increase in the level of C3h] -arachidonyl PtdA.
Exogenously applied AA increased the level of -InsP
in a dose-related manner which was maximal with 100 p,M AA.
This concentration of AA was thought too high to be of 
physiological significance. However, one contributing factor 
here was that the majority of the exogenously applied AA 
bound to albumin in the BSS surrounding the cells. In 
albumin-free BSS 0.1 AA gave almost an equivalent increase 
in InsP formation as 100 ]iM AA in cells surrounded by albumin- 
containing BSS. Also, in experiments where the effects of 
BW755C and indomethacin on -AA release and on “
arachidonyl PtdA formation were studied, the results were
- xvi -
consistent with the idea that endogenously released AA was 
binding to albumin in the BSS surrounding the cells.
Further support for the theory that AA itself stimulated 
inositol lipid metabolism in 3T3 cells was that flurbiprofen 
and BW755C were not additive with exogenously applied AA in 
stimulating inositol phospholipid hydrolysis. This suggests 
that they have the same pathway of action.
Studies were then carried out to investigate the pathway 
by which AA was liberated. Melittin, a BLA^ activator, 
stimulated both AA release and inositol lipid metabolism in 
a dose-related manner. Dexamethasone, an indirect inhibitor 
of PLA^j abolished the BW755C- and flurbiprofen-induced 
increase in inositol lipid metabolism in a dose-related manner. 
These results suggest that the pathway is involved in
the liberation of AA from the membrane phospholipids in 3T3 
cells. The possibility that the phospholipase C/diglyceride 
lipase pathway is also involved was not studied.
In an attempt to prove the involvement of AA in the 
PDGF-induced increase in inositol lipid metabolism, three 
strategies were devised:
1) An investigation of the effect of combining submaximal 
concentrations of dialysed serum with BW755C. Enhancement 
of the serum’s effects by BW7 5 5C might suggest that they 
employed the same mechanism of action.
2) An investigation of the effects of pertussis toxin on AA 
release and inositol lipid metabolism. It had been suggested 
that pertussis toxin could selectively block agonist-induced
- xvii -
AA release leaving the increase in inositol lipid metabolism 
unaffected. Thus, if the pertussis toxin inhibited both 
AA release in inositol lipid metabolism in B¥755C-stimulated 
3T3 cells, then this would suggest that the increase in 
inositol lipid metabolism was dependent on the release of 
free AA.
3) An investigation of the effect of dexamethasone on PDGF- 
induced inositol lipid metabolism. If dexamethasone were to 
abolish or partially inhibit the PDGF-induced increase in 
inositol lipid metabolism, this might suggest that the 
liberation of AA via PLA^ was involved.
The results of these studies were inconclusive.
Synergism between BW755C and dialysed serum was observed 
with certain concentrations of the drugs. However, the 
results observed for other concentrations of drugs suggested 
the occurrence of additivity and even inhibition. Pertussis 
toxin had no effect on agonist-stimulated C3h 3 -AA release 
or on C3h J -arachidonyl PtdA formation. Finally, dexamethasone 
was observed to partially inhibit the PDGF-induced increase 
in inositol lipid metabolism. However, further study is 
necessary to support this finding. Also the effect of PDGF 
on inositol lipid metabolism was only inhibited by about 20% 
and this might suggest that the involvement of AA in the 
PDGF-induced turnover of inositol lipid metabolism might be 
only minor.
INTRODUCTION
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1. Introduction
In a nrulticellular organism, the individual cells 
exist in three states, with respect to proliferation. 
Post-mitotic cells, such as red blood cells, fused muscle 
cells and the bulk of the central nervous system neurons, 
are terminally differentiated and incapable of cell division. 
Actively-dividing cells, such as those of the intestinal 
crypt villi, are, as their name suggests, continually 
dividing. Quiescent or non-proliferating cells are cells 
which have the potential to re-enter the cell cycle and 
divide in response to an appropriate mitogenic signal. The 
stimulus for recruitment of this latter class of cells to 
divide is dependent on cell type. Hepatocytes respond to 
surgical resection, antibody producing cells to foreign 
antigen, mammary cells to elevated circulating levels of 
insulin and prolactin, and fibroblasts respond to wounding. 
Appropriate initiators, whether exogenous molecules, 
endogenous hormones and growth factors or physical injury, 
evoke a cell-type specific response in the non-proliferating 
cells which compels them to enter the division cycle. The 
regulation of growth control, that is, the decision to enter 
or exit the cycle in response to environmental cues, is an 
intricate and complex phenomenon for which much of the 
molecular basis is poorly understood (Herschman e_t al. , 1982).
1.1 The control of growth of mammalian, cells
In the whole animal, growth of cells is under three 
types of control. These can be exerted either alone, or
-  2  -
in combination with each other.
Endocrine control of* growth is due to the release of1 
hormones from endocrine glands such as the pituitary gland. 
These hormones e.g. growth hormone and melanocyte-stimulating 
hormone, are dispersed into the blood stream, which carries 
them to their site of* action. These hormones can act on 
cellular receptors some distance from the endocrine gland 
from which they were secreted, to cause a characteristic 
change in the cell's growth.
Paracrine control is exerted by one cell on a neighbouring 
cell by the release of growth-affecting molecules or ions.
For example, in response to wounding, growth factors, such 
as platelet derived growth factor, are released from blood 
platelets. The growth factors act on the receptors of 
neighbouring epithelial cells and fibroblasts to stimulate 
proliferation of these cells.
Autocrine control is the control of growth exerted by 
a cell on itself, either by releasing growth-influencing 
factors outside the cell, which in turn act on the cell's 
own receptors on the external surface of the cell's membrane, 
or by releasing these factors internally into the cytosol 
to react with receptors in the nucleus or on internal 
cellular membranes. An example of this is when a small T- 
lymphocyte is activated by a specific antigen, it divides 
and proliferates to produce a clone. These cells are known 
as "killer cells" and their combination with antigen results 
in the release of a number of factors including a substance 
that induces lymphocyte division (mitogenic factor). This
_ 3 -
mitogenic factor can act on neighbouring lymphocytes 
(paracrine control) and also on the lymphocyte itself in 
an autocrine fashion (Katz, 1977)*
All of these growth controlling mechanisms can be 
disrupted by neoplasia of appropriate cells. For example, 
oversecretion of growth hormone is often caused by an 
acidophil tumour of the pituitary, and this leads to a 
condition known as acromegaly, which is characterised by 
enlargement of the hands and feet and protrusion of the 
lower jaw.
In their search for a rational understanding of the 
processes which lead to neoplasia, scientists have examined 
cell growth in vitro, using cells grown in culture.
It is widely observed that normal, untransformed cells 
show "density-dependent regulation", that is, they tend to 
grow to a certain saturation density and then stop growing. 
The resulting quiescent cells can remain both healthy and 
quiescent for some time. In contrast, "transformed" cells 
have lost the process of density-dependent regulation and 
will grow continuously until the supply of nutrients in 
the medium has been exhausted. These cells will not become 
quiescent and must be transferred to fresh medium or they 
will die (Holley, 1975)-
Density—dependent regulation was initially thought to 
be due to "contact inhibition". It was postulated that 
specific surface receptors are activated by cell-cell contact 
and generate a negative signal which halts further growth 
(Rozengurt, 1980). Although the term "contact inhibited" 
is still used in the literature to describe quiescent cells, 
many lines of evidence indicate that quiescence is not caused
-  k -
by cell-cell contact. Instead? arrest of growth, of 
mammalian cells is explained by the "humoral hypothesis". 
This proposes that high cell density limits the availability 
of medium components? particularly growth factors present 
in serum (Holley? 1975)•
In support of this theory? it has been observed that 
the growth of Swiss 3T3 cells? a mouse embryonic cell line? 
is normally controlled by macromolecules in serum (Holley 
and Kiernan? 1 9 6 8 ). The saturation density is directly 
proportional to the initial serum concentration in the 
medium. However? if a growth factor like PDGF is added 
further growth will occur. Thus? the growth of normal cells 
is probably controlled by interactions of the cells with a 
variety of polypeptide hormones or hormone-like growth 
factors present in the surrounding medium. Transformed or 
malignant cells escape from normal growth controls by 
requiring less of the hormones or growth factors (Holley? 
1 9 7 5 )9 and thus can initiate growth in response to lower 
external concentrations of growth factors. It is important 
to note that most transformed cells retain some dependence 
upon growth regulatory factors of exogenous or endogenous 
origin and thus manipulation and production or action of 
growth factors has a role to play in the treatment of 
proliferative disorder.
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1.1.1 Growth promoting molecules
As discussed above? under usual cell culture conditions 
the limiting component for proliferation is the concentration 
of serum present in the medium (Holley, 1975)* The addition 
of serum to quiescent cultures enhances the rates of protein 
and RNA synthesis and dramatically stimulates DNA synthesis 
and cell division. A molecular approach to the study of 
growth regulation requires the use of defined external 
stimuli (mitogens). Thus, pure molecules such as outlined 
in Table 1 constitute the necessary tools with which to 
explore the nature of the surface receptors related to 
growth control.
1.1.2 The use of Swiss 3T3 cells in studying proliferation
Swiss 3T3 cells originated from cultures of 6-8 day
old Swiss Mouse embryos (Todaro and Green, 1 9 6 3). They are 
a good model system for studying proliferation as they 
respond to a vast number of chemically diverse molecules which 
can stimulate quiescent cells (in the Gq state) to enter 
the proliferating pool (G^). The receptor types for these 
growth-promoting molecules can be split into three broad 
groups on the basis of their proposed transduction pathways.
It is important to point out here, that the action of some 
of these growth-promoting molecules mentioned (Table l) 
may not be limited to one of these pathways.
Table 1 : Receptors present on Swiss 3T3 cells
Receptor
type
Transducing
mechanism
Fully
Mitogenic?
Co-mitogenic 
with, insulin?
PDGF )
Tyrosine/pt , 
Kinase ' camj> } Yes Yes
EGF ) Tyrosine kinase No Yes
Insulin< Tyrosine kinase No -
PGF2a | Ptdlns No Yes
)
Bombesin } Ptdlns/cAMP (t) Yes Yes
Vasopressin) Ptdlns No Yes
PAF ) Ptdlns No ?
Adenosine ) cAMP (t ) No Yes
PGEl/PGI2 ) cAMP(t) No Yes
The ta b le  skows scw\<z_ o f th e  reccpbsvl prese^vb ok  -Suhss 3rT3 ce ils , 
O^ yck d/teu" posed- Svg/voJL braxsc^ctiox TRe fceriM
" fudJU j rvuTcgevixe" re fe rs to th e  ^ b d c h j © f n  fe xo te ry
C>k 0 5  receptor ko a  d r  eo/Ty u t  th e  tra p e su te rx  fro m  iU e  gu^esccK t 
slcetal (Tao) be (Ti t° 'f&cjJiihxbL the su.b6ecjUJ2ret actums °f
0 (Tier grobJ+U -fictz5Y5. lb  does Kob u^xpU j tM ceb cerb te iK . gruiefU . 
fzecbars ( d c tk tg  o n  tP ie x / reccpbzrvi; a /e  cMeffecfcbi/e ck  ccujlsu^  
haxtos^s (fpro(T fera jbu3V L) o f  3T% c e lls  . ° C o -  motcge*'U_c u j UtK
oKsecbue7 re fe rs  to  th e  a b T x ix j o f  g^jLobU 'fxohsvs, a_cbeKg e x  -fT e x  
bece»at3>s, t o  s y K £ / t jL £ &  lo lH - i ,  l x s u X u v  O l  s tL T K x x ta J b x g  p > s J A  
ty n X U ji& is  c lkO  -tUxas p rtrlA fe /a jb c rx  o f  S T T  calXs.
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1.1.3 Tyrosine kinase
Protein kinases transfer the (terminal) % -phosphate 
of the cellular energy carrier adenosine triphosphate (ATP) 
to an appropriate amino acid residue in a protein and thus 
alter the action of that protein.
Most protein kinases phosphorylate proteins on either 
serine or threonine residues. Certain growth factor receptors (seti 
later in this section) and enzymes encoded by oncogenes 
(ref. Section 1.2) such as Mpp60srcn were found instead to 
catalyze the transfer of phosphate from ATP to tyrosine 
(Cooper and Hunter, 1 9 8 3 ).
Tyrosine phosphorylation has been implicated in the 
complex regulatory systems that maintain cellular shape 
and control of growth of cells, but its role and mechanism 
of action are still largely unknown.
1.1.3*1 Tyrosine kinase-linked receptors
To understand how protein-tyrosine kinases regulate 
cell growth necessitates the identification of their sub­
strates. This quest has involved various approaches 
including, for example, electrophoresis to analyse phospho- 
proteins found in normal versus transformed or growth 
factor-stimulated cells (Cooper _et al • , 1982), and the 
development of both poly- and monoclonal antibodies directed 
towards phosphotyrosine or analogues thereof, (Ek and Heldin,
1984 ;Friedman _et al. , 1984).
If the common enzymatic activity of tyrosine phosphorylation
reflects a common mechanism of cell transformation, one might•/
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predict that certain proteins should be universal targets.
The murine 39 kilo-dalton (kDa) protein appears to be 
homologous to a phosphotyrosyl protein in transformed chick 
embryo fibroblasts, suggesting it could represent a key 
target. This protein, termed p36, has a molecular mass 
variously reported to be 3^-39 kDa (Radke and Martin, 1 9 7 9 ). 
The transforming protein of Rous sarcoma virus, pp6oV srcj 
can directly phosphorylate p36 in vitro, most likely at the 
same site that is found in vivo (Erikson _et_ a_L_. , 1 9 8 0 ). By 
cell fractionation and immunofluorescence studies, p36  
appears to be a peripheral membrane protein, located on the 
cytoplasmic face of the plasma membrane (Nigg e_t al. , 1 9 8 3; 
Radke et al., 1983 )-
The complementary DNA (cDNA) sequences of rat lipocortin, 
a phospholipase A^ inhibitory protein (see Section 1.1.6), 
and murine p36 have been determined and show an overall 
homology of 5®%° at the deduced amino acid level (Geisow 
et al., 1 9 8 6 ). This led to the proposal that tyrosine 
kinase-linked growth factors may act through arachidonic 
acid (AA) metabolism (see Sections 1.1.6 and 1.3)«
Another candidate as a protein-tyrosine kinase substrate 
is "enolase", which is involved in the glycolytic pathway 
in cells. Cooper e_t al. (1 9 8 3b) demonstrated by immuno-
precipitation, that enolase became phosphorylated on tyrosine 
following transformation by a variety of retroviruses.
Eigenbrodt e_fc al. (1 9 8 3 ) purified enolase from transformed 
chick embryo fibroblasts and showed it to be a kl kDa protein.
Finally, two other phosphotyrosyl-proteins have been 
investigated in some detail in transformed cells: a protein 
of 50 kDa (termed pp50) and pp6oV” S rc  itself. In cells 
transformed by Rous sarcoma virus (RSV), the pp50 protein
• s "V— S 2T* Cis found in a complex with pp60 and a third protein
pp90 (Oppermann eib al • , 1981a; Eigenbrodt _et al. , 1 9 8 3 )*
Both pp90 and pp50 are cellular proteins unrelated structurally 
V ™  S X' cto pp60 . The function of pp30 in normal cells remains
to be established. The protein, pp90, appears to be a 
"stress" protein, whose synthesis is induced by either heat 
shock or glucose deprivation (Oppermann et; al_, , 1981b; Lanks 
et al., 1 9 8 2 ). The pp50-pp6oV SrC-pp90 complex is cytoplasmic 
and may be involved in the transport of newly synthesized 
pp60V SrC to the membrane (Courtneidge et al., 1982; Brugge 
et al., 1983)•
1.1.3.1.1 Epidermal growth factor
Epidermal growth factor (EGF) is a polypeptide isolated 
from the submaxillary glands of the male mouse (Savage et al.,
1 9 7 2 ), which exhibits growth-stimulating activity on various 
epidermal and epithelial tissues, both in vivo and in vitro. 
Amino acid analysis revealed that mouse EGF is a 53“resiciue 
polypeptide (Taylor efc al., 1972). The primary sequence of 
mouse EGF and the position of the three internal disulphide 
bonds have been determined (Savage ejb al. , 1972; Savage >et al. ,
1973).
Human EGF has been purified from urine and urogastrone, 
a gastric antisecretory polypeptide also purified from urine
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(Gregory , 1975)> which is probably identical to human
EGF, has been sequenced# It is also a 53—residue polypeptide 
with a very high degree of homology to mouse EGF.
A wide variety of* in vivo and in vitro responses to EGF 
have been documented (Carpenter and Cohen* 1979)* For 
responsive cells in culture* certain biochemical changes 
can occur within seconds or minutes of* the addition of* EGF 
to the medium, while others require hours. Some or all of* 
these responses might be involved in the pathway leading to 
mitosis. A431 cells are useful models for studying the action 
of EGF. These cells, derived from a human epidermoid 
carcinoma (Girard _et al. * 1 9 8 3 ) have an abnormally high 
number of plasma membrane receptors for EGF (Haigler et; al. » 
1978). EGF is not mitogenic for this cell line* but rather 
is inhibitory to the growth of A^-31 cells (Gill and Lazar, 
1981). In contrast, EGF stimulates DNA synthesis in many 
other cell types including Swiss 3T3 fibroblasts (Carpenter 
and Cohen, 1979)*
The 170 kDa receptor protein for EGF has been identified 
and purified by Cohen _et al. (1982). Experiments by Carpenter 
et al. (1975) and Carpenter and Cohen (1976), suggested that, 
after binding to the receptor, the EGF-receptor complex is 
clustered in "coated pits" which invaginate to form 
endocytotic vesicles (i.e. the complex is internalized).
These vesicles merge with primary lysosomes which fuse with 
secondary lysosomes in which the hormone and, most probably, 
the receptor are degraded.
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Within the single polypeptide chain of the EGF receptor, 
there is a domain which functions as an EGF binding site 
and as an EGF-stimulable tyrosyl-specific protein kinase.
This protein is disposed as a transmembrane allosteric 
enzyme in the plasma membranes of target cells, such that 
the effector site (i.e. the EGF binding site) is on the 
outside of the cells and the catalytic site is accessible 
to the cytoplasm (Yarden _et al • , 1986 and Figure l). The 
primary transmembrane signalling event is thought to be the 
activation of the kinase which results from binding of EGF 
to the receptor site.
The cell surface receptors for EGF and insulin (see 
Section 1.1.3»1»^+) appear to share a common evolutionary 
origin as suggested by structural similarity of cystein-rich 
regions in their extracellular domains and a highly conserved 
tyrosine-specific protein kinase domain (Riedel e_fc al. , 1 9 8 6). 
Only minor similarity is found outside this catalytic domain, 
as expected for receptors that have different ligand 
specificities and generate different biological signals. 
Studies using a chimaeric receptor molecule comprising the 
extracellular portion of the insulin receptor joined to the 
transmembrane and intracellular domains of the EGF receptor, 
have shown that the EGF receptor kinase domain of the 
chimaeric protein, is activated by insulin binding (Riedel 
et al., 1986). This suggests that insulin and EGF receptors 
employ closely related or identical mechanisms for signal 
transduction across the plasma membrane.
Insulin
Receptor
EGF/TGF-a
Receptor
v-erb  B
PDGF
Receptor
c-fm s/CSF-\
Receptor
plasma
membrane
v -k it
extracellular
domain
transmembrane
domain
cytoplasmic
domain
T
Figure 1 : Topological comparison of the two groups of
tyrosine-kinase receptors and their oncogenic 
variants
All proteins shown are oriented so that their 
carboxy-termini are in the cytoplasm. Hatched 
boxes indicate regions that are rich in cysteine 
residues. Protein domains that share high 
homology with other tyrosine-kinases of the src 
gene family are shown by stippled boxes. Solid 
lines show stretches of sequences inserted within 
the tyrosine-kinase regions of PDGF receptor, 
c-fms, and v-kit. The distribution of cysteine 
residues in the extracellular domains of PDGF- 
receptor and c-fms/CSF-1 receptor is indicated 
by closed circles, whereas hatched boxes show 
cystein-rich repeat domains found in the extra­
cellular ligand-binding regions of EGF receptor 
and insulin receptor. Taken from Yarden e_fc al. 
(1986).
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The transforming protein of RSV (pp60V”"SrC) is a 
protein kinase specific for tyrosyl residues, as are the 
gene products of a number of other transforming viruses 
(Hunter and Setton, I9 8O; see also Section 1,2), Also, 
other mitogenic or co-mitogenic polypeptides including PDGF 
and insulin have been demonstrated to stimulate receptor- 
associated tyrosyl protein kinases. Thus, the regulation 
of tyrosyl kinase activity is thought to play an important 
role in growth regulation.
s r cSince the EGF-stimulable kinase, like pp6o , was 
found to be specific for tyrosyl residues (Ushiro and Cohen, 
1 9 8 1 ), considerable attention has been focussed on the 
possible relationship between the EGF receptor/kinase and 
the products of various oncogenes (see Section 1.2). Interest 
was greatly heightened when it was found that there is a 
close sequence homology between the EGF receptor/kinase 
and one of the two transforming gene products of avian 
erythroblastosis virus, "v-erb" (Downward ejb al. , 1984).
Addition of tumour promoters, such as 12-0-tetradecanoyl 
phorbol-13—acetate (TPA) to cells, results in a number of 
alterations in the EGF receptor. Studies in a variety of 
cell types, including both mouse and human epidermal and 
fibroblast lines, have shown that the addition of TPA 
induces the loss of EGF binding (Lee and Weinstein, 1978; 
Shoyab ejfc al. , 1979)* The majority of studies indicate 
that this decrease in EGF binding results from a decrease 
in affinity rather than receptor number (Friedman et al.,
-  1 2  -
1 9 8 4 ) .  It has been suggested that protein kinase C (thought 
to be activated by TPA) may act as a normal cellular 
regulator of EGF (Hunter e_t al • , 1 9 8 4 ) .  Addition of EGF 
to certain cell types (e.g. A431 cells) can induce a small 
transient turnover of phosphatidylinositol and other 
inositol—containing lipids, resulting in the production of 
diacylglycerol and the internal release of calcium ions 
(see Section 1 . 1 . 4  and Habenicht _et al_. , 1 9 8 1 ) .  This may 
result in the activation of protein kinase C, thereby 
acting as a feedback inhibitory mechanism for desensitization 
of the EGF receptor (Friedman et al., 1 9 8 4 ) .
1.1.3•1•2 Platelet-derived growth factor
Platelet-derived growth factor (PDGF) is a polypeptide 
that, in particular, stimulates the proliferation of connective 
tissue cells. It has been purified to homogeneity by 
Antoniades e_fc al. (1979) and Heldin e_fc al. (l979)> as a 
heat stable (lOO°C), cationic protein composed of two 30 kDa 
disulphide-linked chains, denoted A and B (johnsson e_fc al., 
1982).
Evidence based on both in vivo and in vitro studies
indicates that the binding of PDGF to its cell surface
receptor leads to the activation of a receptor-associated
protein-tyrosine kinase (Ek e_fc al. , 1 98 2 ;  Ek and Heldin, 1984
and Figure l). Incubation of plasma membranes from human
32fibroblasts, Swiss 3T3 cells or glial cells with P-ATP, 
for example, revealed a protein-tyrosine kinase activity 
which could be stimulated by PDGF (Ek _et_ a-L. , 1982 ;  Nishimura 
et al., 1 9 8 2 ). The major endogenous phosphate-acceptor was
a protein of 170-180 kDa, which, appears to correspond to
the PDGF receptor itself (Heldin e_fc al. , 1 9 8 3 )* Similar
82results have also been obtained by in vivo studies of P- 
labelled fibroblasts stimulated with PDGF and subjected 
either to gel electrophoretic analysis or immunoprecipitation 
with an ant i-phospho tyro sine antibody (Ek e_t al • , 1984).
Thus* PDGF is similar to EGF in stimulating tyrosine 
kinase activity. Like EGF it also stimulates a number of 
growth associated responses such as cytoskeletal rearrangement 
(Mellstrom jet al. , 1 9 8 3 ) and enhanced expression of a family 
of genes including the c-myc (Kelly _et al. , 1 9 8 3 ) and c-fos 
(Greenberg and Ziff, I9 8 3 ) oncogenes (see Section 1.2).
However unlike EGF, PDGF can stimulate hydrolysis of 
phosphatidylinositol 4 , 5-bi,s^phosphate (PtdlnsP^) in 3T3 
cells (Berridge ejb al. , 1984a, ;Besterman je_fc al. , 1986 ) .  (EGF 
has been shown to stimulate PtdlnsP^ hydrolysis in A431 cells).
Similarly to EGF, after binding, PDGF is rapidly 
internalized and degraded in the lysosomes (Rozengurt, 1980). 
Also, PDGF has been shown to generate a transient (less 
than 1 hour) production of diacylglycerol (DG) (Habenicht 
et al., 1 9 8 1 ), and the conversion of inactive cytoplasmic 
protein kinase C to an active, membrane-associated state.
Thus, a further consequence of PDGF action is the enhanced 
phosphorylation of the EGF receptor on serine and threonine 
residues (Rosner e_fc al_. , 1 9 8 3) and a reduction of EGF 
binding to the population of high affinity receptors 
(Rozengurt at al« , 1 9 8 3a; Brown _et al_. , 1984).
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1.1.3*1*3 Fibroblast-derived growth factor
Fibroblast-derived growth factor (FDGF) is a 
polypeptide of apparent molecular weight 24 kDa. It can 
be isolated from the conditioned medium of SV-40 (simian 
virus)-transformed BHK cells (Bilrk, 1976; Dicker e_t al. ,
1981). Rozengurt (1 9 8 0) noted that FDGF stimulates DNA 
synthesis in 3T3 cells. This growth factor has certain 
PDGF-like characteristics and Dicker e_b al. (1 9 8 1 ) suggested 
that FDGF and PDGF belonged to the same family of growth 
factors. Stroobant e_fc al. (1 9 8 3 ) purified a FDGF-like 
molecule from SV-28 conditioned medium and reported it to 
be a hydrophobic and cationic protein of apparent molecular 
weight 31 kDa, containing disulphide-linked polypeptides. 
These properties are shared by PDGF. Also, FDGF is 
immunologically related to PDGF, as human PDGF antiserum 
immunoprecipitates with purified FDGF (Stroobant jet al. ,
1 9 8 3)* Further evidence linking these two growth factors 
is that FDGF is a potent mitogen for Swiss 3T3 cells 
comparable in potency to PDGF (Dicker e_fc al. , 1 9 8 1).
1.1.3*1*4 Insulin and insulin-like growth factors 
Insulin
Insulin is a small polypeptide of M.W. 3700. It has 
been isolated from the ^-cells of the Islets of Langerhans 
in the endocrine pancreas, and is primarily responsible for 
the stimulated uptake of glucose by muscle and adipose tissue 
in response to elevated blood glucose from the portal vein 
of the liver. It is composed of two peptide chains united
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by disulphide bonds. The A chain has 21 and the B chain 
30 amino acid residues. As a major hormonal regulator of 
certain metabolic processes, it interacts with growth 
hormone, glucagon, glucocorticoids, adrenaline, and 
noradrenaline to promote nutrient storage, synthetic 
processes and to regulate the energy supply to tissues 
(Houslay, 1 9 8 5 )*
Insulin acts at its receptor in the plasma membrane 
and like the PDGF and EGF receptors, it becomes phosphorylated 
at tyrosine in insulin-treated hepatoma cells (Kasuga _et al. , 
1982a5band see Figure l). Various studies have demonstrated 
that the insulin binding site lies on a 135 kDa protein 
subunit of the receptor (Houslay, 1 9 8 3 )* This has been 
termed the a-subunit of the insulin receptor. A small amount 
of labelling has also been noted on a component of about 
90 kDa. This was subsequently shown to be the P-subunit 
of the receptor (Massague e_fc al. , 1980; Czech, 1981).
Studies on the insulin receptor have revealed that both 
TPA and P-adrenergic agonists modulate insulin action.
Enhanced phosphorylation of the P-subunit of the insulin 
receptor on phosphoserine residues following treatment with 
TPA have been reported. In hepatoma cells, TPA appears to 
have no effect on binding despite a 2-fold reduction in the 
ability of insulin to induce phosphorylation of its receptor 
and to activate the enzymes glycogen synthase and tyrosine 
amino transferase (Takayama e_fc al_. , 1984).
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As in the case of EGF, P-adrenergic agents also 
decrease the binding of insulin in rat adipocytes (Pessin 
et al., 1 9 8 3 ) and numerous studies have documented antagonism 
between insulin and elevated cAMP levels (e.g. Foulkes 
et al., 1982).
Insulin-like growth factors
In blood only a small proportion of insulin-like activity 
is represented by insulin (Zapf _et al_. , I9 8I). Antibodies 
specific for insulin, when added to serum, blocked the 
effects of insulin, but did not block the major "insulin 
activity". This activity was termed "non-suppressible 
insulin-like activity" or NSILA (Froesch e_fc al., 1 9 6 3)*
NSILA consists of at least three substances! a large 
molecular weight protein, NSILA-P (Poffenbarger, 1 9 6 8), 
and two small molecular weight polypeptides that have been 
purified to homogeneity and whose chemical structures have 
been elucidated. These two polypeptides have been termed 
"insulin-like growth factors (IGF) I and II (Rinderknecht 
and Humbel, 1978a, b). There is a striking similarity 
between proinsulin, IGF I and IGF II, suggesting that the 
three polypeptides are homologs (Zapf e_fc al. , I9 8I).
The IGF I receptor is structurally similar to the 
insulin receptor and is composed of a and P subunits
= 130 kDa and 98 kDa respectively. The IGF II receptor 
is a monomeric structure which has an apparent = 220-230 kDa
(Kasuga ef al_. , I9 8I; Jacobs et_ al. , 1983)* The primary 
structure of the human IGF II receptor, predicted from the
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cDNA sequence, reveals a transmembrane receptor molecule 
with, a large extracellular domain, made up of fifteen repeat 
sequences and a small region homologous to the collagen- 
binding domain of fibronectin. The structural and biochemical 
features of the IGF II receptor appear identical to those of 
the cation-independent mannose-6-phosphate receptors (Morgan 
et; al. , 1987).
IGF I is generally accepted to be a highly potent mitogen 
acting through its own type I IGF receptors. Although IGF II 
has been shown to stimulate DNA synthesis and cell replication 
in a number of cell types (Houslay, 1 9 8 5 )* cross—reactivity 
of IGF II with IGF I and insulin receptors has complicated 
interpretation of these studies in terms of the function of 
the type II IGF receptor. IGF I, IGF II and insulin all 
interact to some degree with the others* receptors, with 
the exception that insulin does not appreciably bind to 
IGF II receptors (Massague and Czech, 1982).
IGF I receptors have been shown to have an associated 
tyrosine kinase activity (Jacobs e_fc al. , 1983; Rubin at al. ,
1983) but the transduction pathway for the typ£ tX-recepfco" kccs qat to 
be established. In 3T3 cells, insulin alone does not have 
appreciable mitogenic activity, but it can markedly 
potentiate the effect of mitogens e.g. EGF (Jimenez de 
Asua _et al. , I98I). Another unresolved question is whether 
3T3 cells contain receptors for insulin or for IGF I.
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1*1.4 Inositol llpld metabolism
Myo-inositol has long been known as an essential 
nutrient promoting animal growth (Kuksis and Mookerjea, 1 9 7 8) 
and cell division (Eagle et; aL_. , 1957). The growth-promoting 
action of myo-inositol is believed to be mediated through 
its function as a substrate for the biosynthesis of three 
minor membrane lipids namely, phosphatidylinositol (Ptdlns), 
phosphatidylinositol 4-phosphate (Ptdlns(4)p) and 
phosphatidylinositol 4,5-bisphosphate (Ptdlns(4,5)P2)
(Figure 2). Inositol lipids have a characteristic fatty 
acid pattern; a high proportion of molecules contain a 
stearoyl (C18:0) residue at position 1 and an arachidonyl 
(C20:4) residue at position 2 (Michell, 1975). Although the 
polyphosphoinositides are present in smaller amounts than 
Ptdlns, it now appears that these lipids may play a central 
role in signal transmission (Berridge and Irvine, 1984).
The possible role of the phosphoinositides in cell 
function emerged from the experiments conducted by Hokin 
and Hokin (l953)> who noted that incorporation of [ 3  - 
phosphate into phospholipids in pancreas (i.e. turnover of 
inositol phospholipids) was stimulated by acetylcholine, 
acting via a muscarinic receptor. It later became clear 
that a stimulated catabolism of inositol lipids occurs in 
many different cells in response to a wide variety of 
external signals (Michell, 1975; Downes and Michell, 1982; 
Berridge, 1984). Initially, Ptdlns was regarded as the 
primary inositol-containing lipid that was degraded after
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receptor occupancy. The term "phosphatidylinositol or PI 
response" was used to describe a sequence of events which 
was believed to be initiated by the breakdown of plasma 
membrane-located Ptdlns (Figure 2) (Michell, 1973). However 
recent evidence suggests that the initial receptor—controlled 
reaction is the hydrolysis of Ptdlns (4,5)?2 the action
of phospholipase C (Berridge , 1984)* PtdlnsP^ is
located in the inner leaflet of the plasma membrane and is 
formed by a two-stage phosphorylation of Ptdlns; firstly 
at the 4-position of its inositol head group by a specific 
kinase, to form Ptdlns(4)P and secondly at the 3-position 
to give Ptdlns(4,3)^ 2 (Berridge, 1984 and Figure 2). As 
well as the two kinases responsible for the stepwise 
phosphorylation of Ptdlns to Ptdlns( 4 , 3 there are 
corresponding phosphomonoesterases which convert Ptdlns(4,3 
back to Ptdlns. These kinases and phosphomonoesterases 
constitute two linked phosphatidylinositol/Ptdlns(4,3)^2 
futile cycles whereby phosphates are constantly being added 
to and removed from the 4 and 3 positions of the inositol 
head group. These futile cycles expend metabolic energy 
and this may explain why metabolic inhibitors are so effective 
in curtailing this signal transduction pathway (Berridge,
1984). Receptor occupation by an agonist transfers 
PtdlnsP^ out of the futile cycle by activating phospholipase C, 
which hydrolyses the lipid to form 1,2-diacylglycerol 
(DG) and inositol (l,4,3)-trisphosphate (ins,(l, 4 , 3 )
(Figure 2 and Berridge and Irvine, 1984). At first it was
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considered possible that this reaction was a consequence 
of an increase in the free cytosolic calcium concentration 
(the calcium signal in stimulated tissue) rather than its 
cause. However in 1975  Michell noted that enhanced
phosphoinositide metabolism could be experimentally dissociated
2 + 2 +from Ca mobilization. Depletion of cellular Ca with
2+
Ca -deficient medium inhibited various cellular responses 
2+dependent on Ca mobilization with little effect on phospho-
2+mositide turnover. Further* when cytosolic Ca was
2+artificially increased using Ca ionophores, a variety of 
2+Ca -dependent cellular responses were activated* but
phosphoinositide turnover was increased very little. From
this and other approaches, he argued that the inositol lipid
cycle might, in some way* serve as a biochemical coupling
2+mechanism linking receptor activation to cellular Ca 
mobilization.
2 +It now seems that receptor-mediated Ca changes
occur in two phases (Putney* 1978; Putney e_t al. * 1 9 8 1 ) ,
2+a release of Ca to the cytosol from internal pools and
2+a sequential or concomitant entry of Ca into the cytosol
from the extracellular space. The available evidence
2+suggests that the internal pool from which Ca is released
is most likely a component of the endoplasmic reticulum
(Burgess et_ al. * 198 3 ;  Smigel e_fc al_. * 1 9 8 4 ) .  To couple
2+receptor activation to internal Ca release, it has been 
suggested that a second messenger is formed at the plasma 
membrane, which signals this release from the appropriate
-  2 1  -
intracellular pool. Berridge (1 9 8 3 ) first suggested that 
the second messenger might be a product of polyphospho­
inositide breakdown, specifically, inositol (1,4,5) 
trisphosphate (ins (l, 4, 3)P^) • It has been shown for a 
number of different cell types, including Swiss 3T3 cells 
(Berridge e^t al. , 1984a), that InsP^ is rapidly formed in
response to receptor activation and is capable of releasing 
2+
Ca from the endoplasmic reticulum (Berridge, 1 9 8 3 ;
Streb _et al. , 1 9 8 3 ; Berridge and Irvine, 1984; Streb _et al. ,
1984; Putney, 1 9 8 6 ).
The rate at which Ins(l,4,3)P^ is formed after cell
stimulation, is fast enough for it to be the second messenger
2+causing mobilization of Ca (Berridge, 1 9 8 3; Berridge and 
Irvine, 1984; Berridge ejfc al., 1984b) and the concentration 
which it can reach in stimulated tissues may be in the 
micro-molar range which is within the levels active on 
permeabilized cells (Berridge and Irvine, 1984).
Ins(l,4,3)P^ is dephosphorylated to inositol 1,4— 
bisphosphate (lns(l,4)p^) and then further dephosphorylated 
to either inositol-l-phosphate (insl-P) or inositol 4— 
phosphate (lns4-P).
Recently, two naturally occurring isomers of InsP^ 
have been identified: inositol (l,4,3)P^ and inositol (l,3»4)P^ 
(irvine e_fc al. , 1984). Presently much research into the 
routes of formation and degradation of these isomers is being 
carried out. This has led to the discovery of inositol 
1 9 3 f 4, 3-tetrakisphosphat e (ins(l,3>4,3)f^) (Batty ejb al. ,
-  2 2  -
1 9 8 5)? which, is formed from the phosphorylation of 
Ins(l,^-,5)P^ through a newly discovered 3-kinase (Irvine 
et al. , 1 9 8 6 ). Ins (l, 3 j  > 3 was first identified in 
brain cortical slices (Batty et al., 1 9 8 3 ) and appears to 
be the precursor of Ins(l,3,4)P^ (Batty ej; al. , 1 9 8 3 ;
Hawkins e_fc al. , 1 9 8 6 ; Downes e_t al. , 1 9 8 6). When cells 
are stimulated by an agonist, not only do they produce 
Ins(l,4,3)P^ but, after a short lag? they also begin to
form Ins(l,3 >^ ) (irvine et al. , 1 9 8 6 ). When Ins(l,4,3)P^
is produced by phospholipase C it can thus be metabolised 
by two separate routes, a degradative pathway to free inositol 
as outlined above or via a novel pathway to generate other 
inositol polyphosphates which could have additional messenger 
functions (Batty e_fc al. , 1983; Irvine e_t al_. , 1 9 8 6 ) (Figure 2).
Ins(l,3f^93)P^ like Ins(l,4,3)P^ metabolized rapidly 
by a 3-pbosphatase and this, and its rapid formation after 
receptor stimulation, has provoked debate on its potential 
as yet another inositol lipid-linked second messenger 
molecule (Downes, 1 9 8 6). Very recently, the first evidence 
that this may be the case has been supplied by Irvine and 
Moor (1 9 8 6 ), who suggest that Ins (l, 3 > 1 5 )P^ may control
some aspect of calcium influx across the plasma membrane, 
in particular that concerned with the refilling of the 
Ins(l,kj3)P^-sensitive calcium pool in the endoplasmic 
reticulum. Figure 2 outlines the steps which yield the 
inositol phosphate isomers found in mammalian cells, and 
reviewed in more detail by Downes (1 9 8 6).
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Pathways of inositol lipid metaholism in mammalian cells and their sensitivity to 
blockade by lithium ions.
Figure 2 : Pathways of inositol lipid metabolism in
mammalian cells
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Lithium and inositol lipid metabolism
Lithium is a useful pharmacological tool for studying 
the inositol lipid cycle as it is one of the few agents 
which interferes with the cycle in a selective manner. The 
brain of animals receiving lithium shows a large decrease 
in inositol and increase in total inositol monophosphate 
(Sherman ejt al • , 1 9 8 6). This is due to the blockade of the 
metabolic cascade at the monophosphate level; a feature 
which is evident in intact cells at extracellular concentrations 
above 0.1 mM (Drummond) 1 9 8 7 )* The metabolic pathways 
thought to be blocked by lithium are shown in Figure 2.
Thus, while the effects of lithium are clearly more complex 
than was originally surmised, the dominant effect of the 
ion to block inositol monophosphatase activity, allows it 
to amplify agonist-stimulated inositol lipid turnover.
Diacylglycerol and protein kinase C
The other product of Ptdlns(4,5)?2 hydrolysis by 
phospholipase C, is 1,2-diacylglycerol (DG) . Phosphorylation 
of DG by DG-kinase results in the formation of phosphatidic 
acid (PtdA) (Figure 2). PtdA is subsequently conjugated 
with cytidine triphosphate (CTP) to form cytidine diphosphate 
diacylglycerol (CDP-DG). Ptdlns is finally formed by 
exchange of the nucleotide with free inositol by the enzyme 
CDP-DG inositol phosphatidyltransferase.
DG and PtdA can both supply arachidonate for prosta­
glandin synthesis (irvine, 1982 and see Section 1.6) since 
most of the Ptdlns molecules in mammalian tissues and those 
of its metabolic precursors and products contain arachidonate 
at position 2.
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DG is now accepted as a second messenger responsible 
for the transmembrane control of protein phosphorylation 
through the activation of protein kinase C (Nishizuka, 1983). 
Protein kinase C is found in various tissues in mammals and 
other eukaryotic organisms (Kuo est al., I980). The enzyme 
is widely, although not homogeneously, distributed among 
tissues. Protein kinase C is a serine- and threonine-specific 
protein kinase that is dependent upon calcium and phospholipid 
for activity (Takai e_fc al,* » 1979)* However at physiological 
calcium concentrations DG is required for activity (Nishizuka,
1984). The enzyme has been purified to homogeneity from a 
soluble fraction of rat brain (Kikkawa _et al. , 1982) and 
more recently the complete primary structure of the 77 kDa 
protein kinase C has been deduced by recombinant DNA techniques 
(Parker et al., 1986). This has led to the identification of 
a new family of protein kinase C-related genes in bovine, 
human and rat tissues. The alpha-, beta-, and gamma-type 
protein kinase C sequences are highly homologous, include 
a kinase domain, and potential calcium-binding sites, and 
they contain interspersed variable regions (Park&r et_ al. , 
1986). It is possible that additional members of this gene 
family may exist and have yet to be isolated.
From studies on protein kinase C in vitro, it has 
become apparent that those phorbol esters (e.g. TPA) capable 
of tumour promotion can mimic the effect of DG in enzyme 
activation (Castagna erfc al. , 1982). More recently, other 
structurally related and unrelated tumour promoters have 
also been shown to activate protein kinase C in vi tro
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(Fujiki et al., 1984; O ’Brian et al., 1 9 8 5)* The implication
is that these tumour promoters elicit their characteristic
responses through protein kinase C. Indeed, there is
evidence that phorbol esters do act via high affinity
binding sites to provoke cellular responses (Collins and
Rozengurt, 1 9 8 2 ) and there is both indirect and direct
evidence that identifies this high affinity phorbol ester
receptor as a protein kinase C itself (ParKer ejfc al. , 1 9 8 6 ).
However, phorbol esters may sometimes be unsuitable for
studies of the physiological activation of protein kinase C,
since DG is present only transiently in membranes, while
phorbol esters are only slowly degraded. Therefore phorbol
ester may extend a usually limited phase of cellular response,
thereby distorting the normal sequence of events.
Protein kinase C has been postulated to modulate ion
conductance by phosphorylating membrane proteins such as
ion channels, pumps and ion exchange proteins (Nishizuka,
2 +1 9 8 6 ). It may also have a role in the extrusion of Ca
immediately after its mobilization into the cytosol (by e.g.
2+InsP^) and the Ca transport ATPase is a possible target 
of this protein kinase (Drummond, 1 9 8 5; Albert and Tashjian, 
1 9 8 5 ) .
Similarly, a possible role of protein kinase C is
activating Na+-transport ATPase in peripheral nerve has been
suggested. The Na+/H+ exchange protein appears to be another 
target that is activated by phorbol ester or by membrane- 
permeable DGs and, thus protein kinase C may also function
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to increase cytoplasmic pH (Burns and Rozengurt, 1 9 8 3 ; 
Moolenaar _et al. , 1984a,).
A major function of protein kinase C appears to be 
intimately related to negative feedback control of cell 
surface receptors, termed down-regulation. The stimulation 
of the a^-adrenergic receptor is well known to induce 
inositol phospholipid breakdown. Recent evidence from 
hepatocytes and smooth muscle (Corvera and Garcia-Sainz,
1984; Leeb—Lundberg et al., 1 9 8 5) strongly suggests that 
protein kinase C exerts negative feedback control of the 
receptors of adrenaline and angiotensin II. Similar findings 
have been suggested for the receptors coupled to inositol 
phospholipid breakdown in other cells e.g. platelets 
(Rittenhouse and Sasson, 1 9 8 5 ) pituitary cells (Drummond,
1 9 8 5) and 3T3 cells (Brown et al., 1987).
Down-regulation by protein kinase C also extends, 
for example, to the EGF receptor, where protein kinase C 
phosphorylates the receptor with a concomitant decrease in 
both its tyrosine-specific protein kinase and growth factor- 
binding activities (Brown e_t al. , 1984; Hunter e_fc al. , 1984). 
Phorbol esters markedly reduce EGF binding in many mito- 
genically responsive cell types (Lee and Weinstein, 1978;
King and Cuatrecasas, 1 9 8 2 ). However, activation of protein 
kinase C by phorbol esters does not inhibit either the 
autophosphorylation of PDGF receptor molecules at tyrosine 
residues or the hydrolysis of membrane polyphosphoinositides 
by PDGF (Sturani et al., 1 9 8 6).
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1.1.4.1 The role of InsP^ , and DG In cell proliferation
The two signal pathways stimulated by the second
2+messengers InsP^ and DG? namely Ca mobilization and protein 
kinase C activation? may also play roles in long-term 
responses such as gene expression and cell proliferation.
For example? the two pathways are both essential and act 
syngergistically to cause DNA synthesis in macrophage-depleted 
human peripheral lymphocytes (Kaibuchi ejfc aT. ? 1985; Nishizuka?
1986). However? in order to stimulate rapid cell proliferation? 
some growth factor is still needed? indicating that an 
additional signal is involved in eliciting full activation 
of cell proliferation. For example? phorbol esters and a 
growth factor (e.g. PDGF) have been known for many years to 
act in concert to stimulate cell proliferation (Mastro and 
Mueller? 197^)* Insulin is needed in addition to phorbol 
ester for the growth response of Swiss 3T3 cell lines (Rozengurt 
et al. ? 198^-). EGF appears to provoke inositol phospholipid 
breakdown in only a few tissues? such as human A^31 cells 
(Sawyer and Cohen? I9 8I ). However? several growth factors 
including PDGF (Habenicht e_fc al. ? I98I) induce rapid breakdown 
of inositol phospholipids.
Phorbol esters are known to induce gene expression of 
several enzymes e.g. ornithine decarboxylase (jetten et al.?
1 9 8 5)* A relationship between the phosphoinositide-protein 
kinase C pathway and the expression of the c-myc protooncogene 
(see Section 1.2) has been suggested by the observation that 
PMA stimulates the expression of c-myc in Balb/c-3T3 cells
-  2 8  -
(Kelly et al. , 1 9 8 3 )* Further, control of gene expression 
at the level of transcription has been demonstrated for 
c-fos protooncogene (Greenberg and Ziff, 1984).
Phorbol esters (e.g. TPA) are also known to induce 
arachidonic acid (AA) release from cellular phospholipids 
and the release of cyclooxygenase and lipoxygenase metabolites 
synthesized in many cell types including fibroblasts (Butler- 
Gralla e_t al. , 1983 and see Section 1.1.6).
1.1.4.2 The role of GTP and its binding proteins in inositol 
lipid metabolism
G-proteins respond when a receptor protein is stimulated, 
by releasing guanosine diphosphate (GDP) and binding guanosine 
triphosphate (GTP). In its GTP-bound conformation the 
protein can regulate the function of an effector, e.g. 
phospholipase C (for the as-yet-uncharacterised G^-protein). 
Hydrolysis of bound GTP to GDP terminates the regulatory 
effect of a G-protein (Bourne, 1 9 8 6 ).
There are now known to be at least three related families 
of GTP binding proteins: the G proteins; the ras proteins;
and the elongation factors (such as bacterial EF-Tu) and 
related proteins involved in protein synthesis (Bourne, 19 86).
The heterotrimetric G-proteins contain three distinct 
chains: an a-chain that binds GTP and determines the
specificity of the proteins for its detector and effector, 
and the / % complex that probably serves as an anchor to 
the cytoplasmic face of the plasma membrane (Northrup, 1 9 8 5)* 
Molecular cloning studies now show that there are two different
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a—chains in Gg, (a G protein that stimulates adenylate cyclase).
The two a-chains result from alternatesplicing of the transcript
of a single gene (Bourne, 1 9 8 6 ).
Complementary DNAs encoding a-chains of two other purified
G proteins G. and G have also been cloned. G. mediates 
1 0  1
inhibition of adenylate cyclase by several hormone and 
neurotransmitter receptors, (e.g. the muscarinic cholinergic 
receptor), and is a substrate for pertussis toxin-catalysed 
ADP-ribosylation, a covalent modification that uncouples G^ 
from its receptors (Northrup, 1 9 8 3 )* The function of Gq is 
unknown.
It has been suggested, that the receptor-mediated
stimulation of inositol lipid metabolism is mediated through
a guanine nucleotide regulatory protein called G (or N )
P P
(Gomperts, 1 9 8 3 ). Although such a species has not been
identified, there is now strong experimental evidence that
this process is mediated by a G—protein distinct from the
stimulatory or inhibitory G-proteins G and G. respectivelys 1
(Haslam and Davidson, 1984; Gonzales and Crews, 1 9 8 3 ;
Houslay et al., 1 9 8 6 ).
The ras protein family includes two RAS proteins that 
control adenylate cyclase in yeast and three p21 proteins 
that are the products of the mammalian ras protooncogenes,
Ha-ras, Ki-ras and N-ras (Harvey, Kirsten and Normal)
(Bourne, 1 9 8 6 ).
Wakelam _et al. (1 9 8 6 ) reported that the controlled 
expression of p21^~raS in NIH 3T3 fibroblasts leads to the 
increased coupling of certain growth factor receptors (e.g.
- 30 -
for bombesin) to stimulated inositol phosphate production.
They proposed that the N-ras protooncogene encodes a protein 
which couples the receptors for certain growth factors to 
the stimulation of phospholipase C, and thus may be the 
putative G^ or a functionally related protein.
1 .1 .4.3 Inositol lipid metabolism-linked receptors in 3T3 cells 
1.1.4.3*1 Vasopressin
The neurohypophysial hormone vasopressin, is a nonapeptide 
and has been documented by Rozengurt at al. (1979) to increase 
DNA synthesis in Swiss 3T3 cells. Vasopressin binds to 
specific, saturable receptors in Swiss 3T3 cells that are of 
the pressor (V^) type as judged by; the relative potency of 
vasopressin-related peptides to elicit various cellular 
responses, including mitogenesis (Rozengurt e_t al. , 1979) J 
the lack of a direct effect on cyclic AMP levels (V^ receptors 
are linked to increases in cAMP) (Rozengurt ^t al_. , 1987); 
and the selective inhibitory effects of vasopressin antagonists 
which counteract the pressor response of the hormone
(Kruszynski at al_. , I98O; Rodriguez-Pena and Rozengurt, 1 9 8 6).
+ + / +Vasopressin stimulates Na influx and Na /K ATPase
(Mendoza at al. , 1980) and increases intracellular pH (Burns 
and Rozengurt, 1 9 8 3 )* The peptide also increases the uptake 
of deoxyglucose (Dicker and Rozengurt, 1 9 8 0 ) and uridine 
(Becker at al., 1 9 8 3 )? induces the activity of the enzyme 
ornithine decarboxylase (Sreevalsan et al., 1980) and decreases 
the affinity of cellular receptor for EGF (Rozengurt et al.,
1981a). In addition, vasopressin induces phosphoinositide
, . 2 +
breakdown (Brown et al . , 1984) and stimulates the efflux of Ca
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from an intracellular pool (Lopez-Rivas and Rozengurt, 1984)
2 +which leads to a transient increase in intracellular Ca 
concentration (Hesketh et al. , 1 9 8 5 )* The effect of vasopressin 
on DNA synthesis is potentiated by the addition of insulin,
EGF and/or PDGF (Dicker and Rozengurt, I9 8I). Vasopressin 
does not, however, synergize with the phorbol esters 
(Dicker and Rozengurt, 1981; Collins and Rozengurt, 1982), 
suggesting a convergence in their mechanisms of action.
This possibility is strengthened by the findings of Rodriguez- 
Pena and Rozengurt (1 9 8 6 ) who have shown that vasopressin 
rapidly stimulates protein kinase C in Swiss 3T3 cells.
1.1.4.3*2 Bombesin
Bombesin is a tetradecapeptide obtained from the skin
of certain European species of frog; it is the amphibian
equivalent of gastrin-releasing peptide and is structurally
related to the neuromedins (McDonald erfc al. , 1979)* These
peptides are potent mitogens for Swiss 3T3 cells (Minamino _e_t
al, 1 9 8 3; 1984). They bind to high-affinity cell-surface
receptors in Swiss 3T3 cells (Zachary and Rozengurt, 1 9 8 5)*
A major component of the receptor for peptides of the
bombesin family, in 3T3 cells, has been identified as a
surface protein = 75-85 kDa (Zachary and Rozengurt, 1 9 8 7)*
Bombesin elicits a complex array of early biological responses
including enhanced phosphoinositide metabolism (Brown _et_ al.,
1984; Wakelam ejfc al., 1 9 8 6), stimulation of Na+/H+ antiport
2+activity and mobilization of Ca from intracellular stores 
(Mendoza ejfc al_. , 1 9 8 6).
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Like vasopressin, it has also been shown to activate 
protein kinase C, inhibit EGF binding and act synergistically 
with insulin and other growth factors in increasing DNA 
synthesis. Rozengurt and Sinnett-Smith (1 9 8 7) very recently 
have shown that bombesin and vasopressin can induce the 
expression of the cellular protooncogenes c-fos and c-myc 
(see Section 1.2).
Bombesin, however, differs from vasopressin, in its 
ability to stimulate reinitiation of DNA synthesis in serum- 
free medium in the absence of any other added growth factor. 
This contrasts with many other ligands including insulin 
(Rozengurt ejb al. , 1979; 1981a), vasopressin (Rozengurt et al., 
1979; 1981a), phorbol esters (Collins and Rozengurt, 1 9 8 2 ), 
cAMP-increasing agents (Rozengurt, 1 9 8 2 ), EGF (Dicker and 
Rozengurt, 1980), and P G F ^  (Jimenez de Asua _et al. , 1979;
Otto et al., 1982), which stimulate DNA synthesis in Swiss 
3T3 cells only when added in the presence of other synergistic 
growth factors. Interestingly, vasopressin and phorbol 
esters, which modulate diverse cellular functions by a common 
mechanism (Rozengurt et al., 1981a), or the cAMP-increasing 
agents (cholera toxin and 8-bromo cAMP) (Rozengurt, 1982a), 
fail to enhance the maximal level of DNA synthesis induced 
by bombesin in 3T3 cells. This suggests (Rozengurt and 
Sinnett-Smith, 1 9 8 3 )* that the pathways converge with 
those utilized by two different classes of mitogenic agents.
However, Rozengurt e_fc al. (1 9 8 7) have shown that although
vasopressin does not increase the basal level of cAMP (like 
bombesin), or stimulate adenylate cyclase in membrane prepared
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from Swiss 3T3 cells, it does enhance cAMP accumulation in 
response to cholera toxin and forskolin. The modulation 
of cAMP production by vasopressin was mediated by 
receptors (which are not coupled directly to adenylate 
cyclase). Rozengurt e_fc al. (1987) suggest that this is due 
to activation of protein kinase C which they propose amplifies 
cAMP production in Swiss 3T3 cells.
1.1.4.3*3 Prostaglandin
Among the biochemical events observed upon stimulation
of confluent, resting 3T3 cells, by different mitogens, are
rapid changes in surface membrane properties (the pleiotypic
response) and, importantly, the metabolism of inositol
phospholipid (Michell, 1982). Addition of foetal calf
serum, FDGF, or PDGF to Swiss 3T3„ cells increases inositol
lipid metabolism (Ristow _et al. , 1980; Habenicht ejfc al. ,
1981; Berridge ejfc al^ . , 1984a). Sawyer and Cohen (1 9 8 1 ) have
shown that the addition of EGF bo A-431 cells (human
epidermoid carcinoma cells) causes a marked increase in
2+inositol lipid metabolism and Ca uptake. As has been 
discussed already, 1,2-diacylglycerol is formed in the 
breakdown of Ptdlns (4,5)1*2 anc  ^this can lead to the production 
of arachidonic acid and to prostaglandin biosynthesis. This 
led Jimenez de Asua and colleagues (Jimenez de Asua ejfc aJ^ . , 
1979; Otto ejfc al • , 1982) to look at the effects of a series 
of structurally closely related prostaglandins on cell 
division in 3T3 fibroblasts. They found that PGF^, when 
added to quiescent Swiss 3T3 cells, initiated DNA synthesis 
and cell proliferation in a small proportion of cells.
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Insulin markedly potentiated this effect when added in
combination with P G F ^  and together they caused a simultaneous
decrease in intracellular cAMP, and an increase in cGMP
concentrations, similar to those observed after serum addition.
PGEn and PGE» were found to be less effective than PGF„ in 1 2  2a
initiating DNA synthesis (Taylor and Polgar, 1977; 0 'Farrell 
et al., 1979)* Further, it was found that the mitogenic 
effect in mouse fibroblasts is selective for PGFg among 
naturally occurring prostaglandins (Jimenez de Asua _et al. , 
1983) but PGEX and PGE2 at concentrations that are not 
mitogenic have a synergistic effect in DNA synthesis 
stimulated by PGF^ (Otto _ejt al_. , 1 9 8 2).
Macphee e_fc al. (1984) showed that in confluent, resting 
Swiss 3T3 cells, P G F ^  stimulated the incorporation of C^^PJ - 
PO^ into Ptdlns and increased the cellular content of 1,2- 
DG. These effects were not seen with EGF or PGE^.
1.1.4.3*4 PDGF-linkage with inositol phospholipid hydrolysis
PDGF, which as discussed above, can activate tyrosine 
kinase activity (see Section 1,1*J»1,2) has also been shown 
to cause an increase in the formation of DG (Habenicht et al., 
1981) and InsP (Berridge et_ al_. , 1984a). One area of this 
project is aimed at studying the mechanism of action of 
PDGF, as it has yet to be documented whether inositol lipid 
metabolism is an indirect response to PDGF receptor 
activation, mediated, perhaps, via tyrosine kinase, or if 
receptor activation is directly linked to inositol phospholipid 
hydrolysis.
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1.5 Cyclic-AMP
Most cells possess at least two major classes of
receptors for transducing information across the plasma
membrane. One class, as has been discussed in Section 1.1.4,
accelerates the breakdown of inositol phospholipids, leading
to the generation of Ins(l, 4 , 5 > which mobilizes intracellular 
2+Ca , and DG, which activates protein kinase C. The other
class of receptors influences cell activity through the
altered synthesis of cAMP.
The enzyme responsible for the formation of cAMP is
adenylate cyclase. It is present in the plasma membrane
2+of most cells. In the presence of Mg ions this enzyme 
catalyzes an intramolecular condensation of ATP in the 
cytoplasm to produce cAMP.
Cyclic AMP has the property of activating several 
protein kinases. It is now accepted as a second messenger 
in mediating the effects of a number of hormones and neuro­
transmitters (e.g. adrenaline and thyrotrophin). These, 
following the interaction with specific receptors, regulate 
adenylate cyclase by allowing GTP-regulatory proteins to 
interact and control the enzyme's activity (Rodbell, 1 9 8 0 ).
The GTP-regulatory protein (see Section 1.1.4.2) can either 
be stimulatory (Ns) or inhibitory (Ni) in nature, thereby 
increasing or decreasing, respectively, the production of 
cAMP.
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Cholera toxin acts to increase the production of cAMP 
in a cell by ADP-ribosylating the a-subunit of N . This 
results in the inhibition of the GTPase activity of Ng and 
converts GTP to a superactive nucleotide like its non— 
hydrolysable analogues (e.g. GMP-P(NH)P) (Milligan and Klee, 
1985; Northrup, 1 9 8 5)*
In contrast, pertussis toxin also stimulates the production 
of cAMP, but in this case, by ADP-ribosylating the a-subunit 
of N_ .^ This is thought, ultimately, to lead to blockade of 
the N^-GDP complex, very likely by inhibiting its dissociation 
to give free JNL and GDP (Northrup, 1 9 8 5)*
1.5.1 Cyclic AMP-linked receptors
The possibility that cAMP may regulate the proliferative 
response of quiescent fibroblasts has been the subject of a 
large and controversial literature (e.g. Hammarstrom, 1982; 
Rozengurt e_fc al. , 1981b).
Cyclic AMP is known to act synergistically with insulin 
and other growth promoting agents in stimulating confluent 
and quiescent cultures of Swiss 3T3 cells to reinitiate DNA 
synthesis and cell division (Rozengurt, 1982b). The levels 
of cAMP in these cells can be increased by cholera toxin 
(Rozengurt e_fc al_. , 1981b), adenosine agonists (Rozengurt,
1982b), cAMP analogues or E-type prostaglandins (Minna and 
Gilman, 1973; Rozengurt, 1982a).
Recently several investigators have found that there 
is "cross-talk" between the cellular signalling pathways, 
cAMP and inositol phospholipid hydrolysis. Both systems are
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controlled through, guanine nucleotide regulatory proteins
(G—proteins) to lead ultimately to specific activation of
2+either cAMP-dependent protein kinase of Ca /phospholipid- 
dependent protein kinase C. Rozengurt e_t al. (1 9 8 7 ) 
demonstrated that protein kinase C activation of phorbol 
esters, in Swiss 3T3 cells, was coupled to cAMP production 
via a pertussis toxin sensitive substrate (which they assume 
to be a G protein). Furthermore, Yoshimasa e_fc al_. (1 9 8 7) 
showed that in frog erythrocytes TPA produces phosphorylation 
of the catalytic subunit of adenylate cyclase. Moreover 
purified protein kinase C can directly phosphorylate in vitro, 
the catalytic unit of adenylate cyclase purified from bovine 
brain (Yoshimasa et; al_. , 1987).
Activation of protein kinase C can also inhibit the 
accumulation of cAMP promoted by activators of adenylate 
cyclase in different cell types (Rozengurt ejb al_. , 1 9 8 7 )* 
Inhibition is frequently caused by phosphorylation and 
inactivation of receptors linked to adenylate cyclase.
1.5.1.1 The prostaglandins
E-type prostaglandins are potent stimulators of adenylate 
cyclase in a number of tissues (Samuelsson e_t al. , 1978).
An increase in cellular levels of cAMP, in response to E type 
prostaglandins has been measured in a variety of cultured 
cells (Samuelsson, e_t al. , 1978) including Swiss 3T3 cells 
(Rozengurt e_fc al. , 1 98 3b). Some reports have indicated that 
PGE^, at high concentrations, increased cAMP levels and 
inhibited the initiation of DNA synthesis in Swiss 3T3 
cells (e.g. Hammarstrom, 1 9 8 2). However other workers have
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demonstrated that in the presence of insulin PGE^ stimulates 
DNA synthesis (Rozengurt e_t al. , 1 9 8 3b). These workers also 
found that the inhibitory effects produced by adding high 
concentrations of PGE^ on the initiation of DNA synthesis 
in Swiss 3^3 cells were not mediated by cAMP and suggested 
that they were non-specific effects.
PDGF causes a marked accumulation of cAMP in the presence 
of phosphodiesterase inhibitors (Rozengurt et; al. , 1 9 8 3c). 
However, this increase in cAMP is much slower than the 
elevation of cAMP observed in the presence of e.g. PGE^, 
which results from the receptor-mediated stimulation of 
adenylate cyclase (Rozengurt _et al. , 1 9 8 3c).
It is thought that PDGF stimulates the breakdown of AA 
by cyclooxygenase (see next section) to yield metabolites 
such as prostaglandins which in turn stimulate adenylate 
cyclase. Indeed Habenicht e_t al. (1 9 8 5 )? have suggested 
that PDGF greatly activates cyclooxygenase, an effect which 
appears to be mediated by both activation and rapid de novo 
synthesis of the enzyme. The addition of AA has also been 
shown to have a stimulatory effect on cAMP in 3T3 cells 
(Claesson et_ al • , 1977)* This effect of AA might be mediated, 
at least in part, through the formation of prostacyclin 
(PGI2) (Claesson et al., 1977)*
1,^.1.2 Adenosine agonists
Adenosine binds to cell Surface receptors of a variety 
of cell types and either stimulates or inhibits the activity 
of adenylate cyclase (Fain and Malbon, 1979)* The most
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potent of the adenosine analogues, that binds selectively 
to stimulatory receptors is 5'-N—ethylcarboxamide—adenosine 
(NECA) (Londos et al., 1 9 8 0). Addition of NECA caused a 
rapid increase in the levels of cAMP, an effect markedly 
potentiated by Ro20^-1724 (cAMP phosphodiesterase inhibitor) 
(Rozengurt, 1982b). Subsequently, the adenosine analogue 
was shown to stimulate -thymidine incorporation into
the acid-insoluble material in cultures of Swiss 3T3 cells 
maintained in the presence of Ro20-1724 and insulin. The 
increase in cAMP levels and stimulation of DNA synthesis 
produced by addition of NECA to Swiss 3T3 cells were completely 
and selectively blocked by aminophylline (Rozengurt, 1982b). 
(adenosine antagonist). Thus the mitogenic activity of NECA 
closely parallels its ability to increase the intracellular 
levels of cAMP.
1.6 Arachidonic acid liberation and metabolism 
Arachidonic acid liberation
As mentioned previously both DG and PtdA can supply 
arachidonate for prostaglandin and leukotriene synthesis.
The mechanisms underlying arachidonic acid liberation have 
been extensively investigated. For example, in blood platelets, 
arachidonic acid (AA) is predominantly found esterified in 
the sn-2 position of membrane phospholipids, particularly 
phosphatidylcholine (PtdCho), phosphatidylethanolamine 
(PtdE) and phosphatidylinositol (Ptdlns). Four major routes 
of AA liberation have been postulated (Figure 3)«
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Figure 3 : The possible pathways of arachidonate liberation
from membrane phospholipids
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Studies by Shier (l979> 1980) have shown that cultured 
cell lines, such as 3T3 mouse fibroblasts, contain high 
levels of activatable cellular enzymes capable of releasing 
labelled AA which had been biosynthetically incorporated 
into the phospholipids of the cells. The major enzyme activated 
by PDGF in these cells is phospholipase A^ (PLA^) (Shier and 
Trotter, 1980). Phospholipases of the A^ type are considered 
to be Ca^+-calmodulin-dependent and, as such, susceptible 
to activation by an increase in intracellular free Ca^+
(Pollock at ad., 1 9 8 6 ).
Anti-inflammatory glucocorticoids, such as hydrocortisone 
and dexamethasone, are thought to inhibit PLA^, indirectly, 
by stimulating the production of phospholipase inhibitory 
proteins, e.g. lipomodulin (Hirata afc al_. , I98O; Hirata afc al. , 
1 9 8 2); macrocortin (Blackwell et al., 1978); renocortin 
(Rothhut _et al. , 1 9 8 3)* Steroids can also produce a more 
rapid effect which may be due to a "direct" 
phospholipase activity. This effect was illustrated by 
Kato e_b al. (1 9 8 5 )? who found that the hydrolysis of PtdCho
by PLA.., could be inhibited by incubating the PLA^ with 
dexamethasone for 3-10 minutes.
Recently, many studies have focussed on identifying 
the phospholipase inhibitory proteins. Several proteins, 
collectively known as "lipocortins" have been described 
which inhibit PLA2 (e.g. Touqui _et al. , 1 9 8 6).
Interestingly, the cDNA sequence of rat lipocortin I 
and murine p3^ (the 36 kDa subunit of calpactin I - see 
Section 1.1.3»l) have been determined and show an overall
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homology of 50% at the amino acid level (Huang ejfc al. ,
1986; Saris ejb al. , 1 9 8 6 ). p3 6 , As already di scussed is 
a widely distributed cellular protein (0 . 1  - 0.k% in 
fibroblasts, Hutton, 1 9 8 6 ). In the guise of the porcine 
intestinal protein calpactin I, p36 has been postulated to 
be a substrate for the tyrosine kinase associated with
gpQ .
pp60 (see Section 1.2), EGF and PDGF receptors. The
p36 subunit is phosphorylated, fn vivo, on both tyrosine 
and serine residues, the latter by protein kinase C (Hutton, 
1986).
The homology of p36 with lipocortin I and its ability
to inhibit pancreatic suggests a possible, but unproven,
role as an inhibitor of intracellular phospholipases (Huang
et al., 1 9 8 6 ). Also, the observation that the 40 kDa-
protein kinase C substrate, whose phosphorylation state
changes dramatically upon platelet activation, may partially
cross-react with an antibody raised to rat renal lipocortin,
is of great interest (Touqui _et al. , 1986). Touqui ert al.
(1 9 8 6) suggest that protein kinase C phosphorylates the
anti-PLA^ protein (40 kDa) and suppresses its anti-PLA^
activity. This, in agonist-stimulated platelets, combined 
r 2+-iwith a rise in J_Ca J_^ , via InsP^ formation leads to optimal 
activity of PLA^*
PLA^ activity can be stimulated by an array of toxins 
(Shier, 1 9 8 0). One such toxin is melittin, a 26-residue 
peptide, which is the most abundant component of wasp venom 
(Argiolas and Pisano, 1 9 8 3 )* Melittin has been shown to
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increase the activity of* the Na^-K+pump in quiescent 3T3 
cells (Rozengurt ejt al_. , 1981c). It also stimulates DNA 
synthesis in quiescent mouse cells, acting synergistically 
with insulin, EGF and PDGF. In contrast it does not act 
synergistically with either phorbol esters or vasopressin 
(Rozengurt e_t al. , 1981c).
1.1.6.1 Arachidonic acid metabolism 
Cyclooxygenase products
Arachidonic acid and certain other polyunsaturated 
fatty acids (Needleman et al., 1986) may be transformed into 
prostaglandins by the enzyme prostaglandin endoperoxide 
synthase (PES); for review see Needleman et al. (1 9 8 6).
Figure k shows formation, by the PES family of enzymes, of 
the various prostaglandins and thromboxanes.
The enzyme cyclooxygenase can be inhibited using the 
non-steroidal anti-inflammatory agents, such as aspirin 
(which irreversibly binds to the enzyme) (Pace - Asaak 
and Smith, 1 9 8 3 ) and ibuprofen (which reversibly binds to 
the enzyme. Indomethacin is a relatively non-specific 
blocker of cyclooxygenase whereas flurbiprofen (one of 
the ibuprofen class of drugs) has been shown to be more 
specific for cyclooxygenase (Brodgen e_t al_. , 1979)* Certain 
acetylenic fatty acids such as eicosa-5>8,11,14-tetryoic 
acid (ETYA) also inactivate cyclooxygenase possibly by 
acting as suicide substrates (Needleman e_fc al., 1 9 8 6).
Numerous studies have shown that, in vivo as well as 
in vitro, prostaglandins can regulate the rate of proliferation 
and differentiation of certain mammalian cells (e.g. Powles
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et al. , 1 9 8 2 ). In a number of malignant tumours the synthesis
and release of prostaglandins is markedly increased (Levine,
1 9 8 2 ). The production and release of PGE^, ^ ^ 2  or ^ ^ 2 a
is increased in several cell lines transformed by chemicals
or oncogenic viruses, and proliferation in these cell lines
is reduced when prostaglandin synthesis is inhibited
(Hammarstrom, 1977)* Furthermore TPA and several other
growth factors and tumour promoters, increase the synthesis
of PGEjl, PGE2 and/or PGF2a (Levine, 1 9 8 2 ).
PGE^ and PGE2 have been shown to enhance the mitogenic
effect of PGF_ alone, or in combination with insulin in 2a
3T3 cells (Otto ejfc al., 1 9 8 2 ). This group of workers also
showed that the addition of EGF with PGF_ enhanced the2a
stimulatory properties of EGF with respect to DNA synthesis. „
This was further enhanced by the addition of insulin. In
contrast PGE^ or PGE2 had no such effect. Macphee e_fc al.
(1984) showed, as mentioned later, that PGF2a rapidly
stimulated the turnover of Ptdlns and increases the level
of DG within minutes of its addition to resting Swiss 3T3
cells. In contrast, EGF which is mitogenic for these cells
(Macphee e_t al. , 1984) did not increase Ptdlns turnover.
PGE^ did not potentiate this effect of PGF2a» even though
it interacts with PGF2a to synergistically increase DNA
synthesis. This indicates that the synergistic interaction
of PGF_ and PGEn occurs at a biochemical event different 2a 1
from Ptdlns turnover.
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1.1.6.2 Lipoxygenase products
Arachidonic acid can also be metabolised by a different 
group of enzymes known as the lipoxygenases (Figure 4).
The formation of 12-S-hydroperoxy-3>8,10,l4-eicosatetraenoic 
(12-HPETE) in human platelets was the first lipoxygenase-type 
reaction reported in animals (Hamberg and Samuelsson, 1974).
More recently, leukotrienes (LT) were isolated and 
found to be the products of a lipoxygenase (1.0.) acting 
specifically at the C-3 position of arachidonic acid 
(Samuelsson, 1983) • 3-Lipoxygenase catalyzes the dioxygenation 
of AA at C—3 and initiates the synthesis of leukotrienes.
AA is first transformed to (3S)-3-hydroperoxy-(E,Z,Z,Z )- 
6,8,11,l4-eicosatetraenoic acid (3-HPETE). This is rapidly 
metabolized, by what is thought to be a peroxidase enzyme, 
to (3S)-3-hydroxy-(E,Z,Z ,Z)-6,8,11,l4-eicosatetraenoic acid 
(3-HETE), or by an enzymatic hydrolysis to (3S» 6s)-3(6)- 
oxido-(E»E,Z,Z)-7f9 911fl4-eicosatetraenoic acid (leukotriene 
A^, LTA^) (Borgeat et al., 1983)-
LTA^ is highly unstable and is rapidly converted to 
LTB^ by a hydrolase or to LTC^ by glutathione-S-transferase. 
LTD^ is formed from LTC^ via. the X -glutamyl-transpeptidase 
enzyme. Further metabolism of LTD^, by a peptidase, leads 
to the formation of LTE^. Reincorporation of a glutamyl 
moeity by )i -glutamyl-transpeptidase on LTE^ yields LTF^
(Figure 4, Borgeat _et al. , 1 9 8 3)*
Little work on the effects of lipoxygenase metabolites 
in fibroblasts has been carried out. Baud et al. (1 9 8 7)
studied the role of leukotrienes on fibroblast growth and
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its modulation by the endogenous synthesis of* PGE^.
LTB^ has been shown to have no significant direct effect 
on fibroblast proliferation. However, the sulfidopeptide 
leukotriene series (LTC^, and E^) was demonstrated to 
stimulate fibroblast proliferation (Baud et al., 1 9 8 7) 
in the presence of a cyclooxygenase inhibitor (indomethacin, 
aspirin and ibuprofen).
Another group of compounds carrying a conjugated triene 
unit, but derived from 15-lipoxygenase, has been reported 
(Borgeat et_ al. , 1 9 8 5) (l5S)-15-hydroperoxy- ( Z, Z, Z, E)- 
5,8 ,11,13-eicosatetraenoic acid (15-HPETE) is the product 
of the action of 1 5-1 on AA and is rapidly reduced into 
15-HETE (Borgeat and Samuelsson, 1979; Turk ejfc al., 1 9 8 2) 
or metabolized into an unstable allylic epoxide in analogy 
with the mechanism of formation of LTA^ from 5-HPETE 
(Figure 4). The allylic 14,15-epoxy-acid undergoes facile 
hydrolysis into several dihydroxy-acids (l4,15-Di-HETE$ 
and 8,15-Di-HETEs).,
Human neutrophils incubated with 15-HPETE and A23l87>
(a calcium ionophore), form at least two trihydroxylated 
compounds with a conjugated tetraene structure: 15>16,17(l)- 
trihydroxy-7>9>11>13-eicosatetraenoic acid (lipoxin A, LXA) 
and 5(h), 14,1 5 (l)-trihydroxy-6,8,10,12-eicosatetraenoic 
acid (Lipoxin B, LXB) (Serhan et^  aJL. , 1984a; 1984b). Analogous 
products are formed from the 1 5-hydroperoxy-derivative of 
eicosapentaenoic acid (Wong _et al. , 1 9 8 5 )* It appears likely 
that the 5-lipoxygenase participates in the formation of
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these compounds (Serhan ejb al. , 1984b). LXA stimulates 
superoxide anion generation without provoking aggregation 
when added to human neutrophils (Serhan e_t al. , 1984b).
Human natural killer cells exposed to either LXA or LXB 
are unable to provoke target cell lysis (Ramstedt e_t al_. ,
1 9 8 5)* In addition, LXA also stimulates contraction of* 
parenchymal strips and microvascular changes (Serhan ejb al. ,
1 9 8 6). Moreover, lipoxins have recently been shown to 
activate protein kinase C in vitro (Hansson e_fc al. , 1 9 8 6 ; 
Serhan ejfc al. , 1 9 8 6). LXA activates protein kinase C and 
is 30 times more potent than DG and 300 times more potent 
than AA in this respect. LXB is ten times less potent 
than LXA in this assay (Serhan e_t al. , 1 9 8 6 ).
1.2 Oncogenes and their relationship with growth factors 
In 19119 Peyton Rous discovered the first oncogenic 
virus, the avian sarcoma virus, which is today known as 
Rous sarcoma virus (RSV). However, it was not until the 
early 1 9 7 0 's that the gene responsible for rapid oncogenesis 
(leading to cancer in chickens) was identified. The gene 
was named 'src' and the protein for which it encodes 
was isolated by Brugge and Erikson (1977)• It was designated 
p60src because its molecular mass is 60 kDa.
Siuce then, a number of viruses have been discovered 
which produce some type of cancer in experimental animals. 
Several studies indicated that the viral genome was in whole 
or in part incorporated into the genome of the host cell and 
eventually produced transformation (for review see Bishop,
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1 9 8 5)* In the last few years, the molecular biology of 
carcinogenesis has seen extraordinary advances largely due 
to the knowledge acquired on the mechanisms whereby certain 
oncogenic viruses, the acute transforming retroviruses, 
have an oncogenic gene (e.g. src): only if this gene is
present does retroviral infection lead to transformation 
of cells (Bishop, 1983).
Retroviruses have an RNA genome and they use reverse 
transcriptase to make a complementary DNA copy of this RNA, 
which then becomes double stranded DNA, and is eventually 
incorporated into the genome of the host cell. During this 
process the retrovirus picks up a cellular gene and 
incorporates it into its own 'provirus1 DNA. Somewhere 
along this path the host gene (protooncogene) mutates and 
gives rise to an oncogenic gene (oncogene) (Ochoa, 1 9 8 5)*
The virus now becomes oncogenic. It is important to understand 
that viral oncogenes are mutants of normal cellular genes 
(protooncogenes). The normal function of the protooncogene 
is unknown, although it has been assumed that protooncogenes 
participate in the regulation of cell proliferation. This 
view has gained support from recent data that seem to link 
certain oncogene products (transforming proteins as well as 
their normal cellular homologs) to different compartments 
along the mitogenic pathway of a normal cell.
The biochemical mechanisms involved in the action of 
oncogenes are proposed to fall into three categories listed 
in Table 2.
Table 2 : The biochemical mechanisms involved in the action
of oncogenes (Bishop, 1 9 8 5)
1. Phosphorylation (with both proteins and phospholipids as 
potential substrates - Hunter and Cooper, 1 9 8 5)*
The transforming protein may be a factor that elicits 
phosphorylation, such as a ligand that binds to a receptor 
on the cell surface; it may be the catalytic kinase 
itself; or it may act on phosphorylation, at a distance, 
by regulating adenylate cyclase and thus the activity of 
protein kinases controlled by cAMP. In each of these 
instances, the primary action occurs at the plasma 
membrane: the responsible protein strikes at the cell
surface, spans the plasma membrane, or resides at the 
inner surface of the membrane.
2. Initiation of DNA synthesis (Martin, 1 9 8 1)
Unrestrained synthesis of DNA is an inevitable component 
of the neoplastic phenotype. Some transforming 
proteins allegedly elicit this property by acting directly 
to initiate DNA synthesis.
3» Regulation of transcription (Kingston _et al_. , 1 9 8 5 )
Several of the transforming proteins may influence 
transcription from cellular genes, either by stimulation 
or by inhibition. They could do so by interacting with 
other proteins, with promoters for transcription or 
with enhancers.
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Twenty or more oncogenes are now known. Their onco­
genicity is due to the products of the gene expression, 
namely, proteins encoded by the oncogenes. As has been 
discussed, these proteins have a biochemical function.
Many of the products of retroviral oncogenes have a tyrosine 
kinase activity (Hunter and Cooper, 1 9 8 5 )* This activity 
leads to self-phosphorylation as well as to phosphorylation 
of other proteins (Table 2). This property is, therefore, 
one which is shared with certain of the growth factor 
receptors (see Section 1.1. 3 . )•
All of the protein-tyrosine kinases that have been 
studied, to date, are related to catalytic domains of about 
30 kDa in which reside a series of amino acid sequences 
that are a common feature of protein kinases in general, 
and of protein-tyrosine kinase in particular (Hunter and 
Cooper, 1 9 8 5 )* The members of this enzymatic family have 
so far taken either of two forms: transmembrane receptors
for growth factors or cytoplasmic proteins affiliated with 
membranes (Hunter and Cooper, 1 9 8 5? Yarden et al., 1 9 8 6 ). 
Retroviral transforming proteins are found in both classes.
Further evidence linking oncogenes with growth factors
has emerged from studies on the PDGF structure. A partial
amino sequence analysis of separated PDGF polypeptide chains,
denoted A and B (johnsson et_ al. , 1 9 8 2 ), has shown that the
N-terminal 109 amino acids are virtually identical with the
v— sispredicted sequence of the transforming protein p28 of
simian sarcoma virus (residues 67-175) (Doolittle e_t al. , 
1983; Waterfield _e_t al_. , 1 9 8 3)*
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Furthermore, there is evidence for the internal structural 
homology within the PDGF molecule. Of the 75 amino acid 
residues sequenced in the A-chain about GO°fo are homologous 
to the B-chain (johnsson e_fc ad., 1984). Following its 
synthesis the 28 kDa product of v-sis assembles into a 
homodimer (Robbins e_fc al., 1983)* Some cells appear to 
release a homodimer of v-sis, whose structure and activity 
resemble those of PDGF (Johnsson <ejfc al. , 1 9 8 5 )* Also, ssv- 
transformed cells contain, in their cytoplasm, a growth 
factor whose activity is neutralized by PDGF antibodies 
(Deuel e_fc al. , 1 9 8 3 )* The use of PDGF antibodies has also 
indicated that FDGF has similar characteristics of PDGF, 
as FDGF, isolated from the conditioned medium of SV-40 
transformed BHK cells, binds to a PDGF antibody (Stroobant 
et al., 1985).
Not only have oncogenes been related to the molecular 
structure of a growth factor also, it has been found that 
oncogenes can be related to the structure of the receptor 
for a growth factor. For example, the product of v-erb B 
(the transforming protein of avian erythroblastosis virus - 
AEV) has been demonstrated by Downward et al. (1984) to be
a truncated version of the receptor for EGF.
Very recently, it has been suggested (Wakelam et_ al. ,
1 9 8 6 ) that oncogenes may also encode proteins which are 
very similar normal cellular proteins involved in other types 
of receptor activated signal transduction mechanisms.
Wakelam ejb al. (1 9 8 6) demonstrated that the expression of
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normal p21^ raS in NIH 3T3 fibroblasts leads to the coupling 
of certain growth factor receptors (e.g. bombesin) to 
stimulated inositol phosphate production. They proposed 
that the N-ras protooncogene encodes a protein which couples 
the receptors for certain growth factors to the stimulation 
of phospholipase C. Thus? they concluded> N-ras p21 may be 
the putative G^ (G protein which links receptor activation 
to PLC).
A particularly intriguing possibility is that the 
activated 1ras1 gene (from Kirsten and Harvey sarcoma viruses) 
may transform cells by causing an uncontrolled stimulation of 
PLC. The normal ras gene can both bind and hydrolyse GTP> 
but on activation by a point mutation at codon 12> the 
resulting oncogenic protein can still bind GTP> although its 
ability to hydrolyse the nucleotide is severely impaired 
(Wakelam et_ al. > 1986). If ras were involved in the hydrolysis 
of Ptdlns (4> 3 2 9 -*-oss °-^  GTPase activity would imply
that the oncogenic protein might continue to activate the 
formation of Ins(l, 4 , 5 ) and DG in an uncontrolled way* 
independently of the presence of growth factors (Wakelam et al., 
1986).
The mechanism by which growth factor-induced mitogenic 
signals are transmitted further into the cell to the nucleus 
are still largely unknown. Recent data have introduced the 
idea of cellular protooncogenes (e.g. c-myc) which carry the 
mitogenic signals induced by growth factors to the nucleus 
where DNA synthesis is initiated.
The gene,c-myc,is transcriptionally silent in Gq until 
activated by a mitogen. Recently? pentadecadeoxyribonucleotide 
complementary to the initiation codon and four downstream
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codons of human c-myc mRNA has been reported to specifically
inhibit the proliferation of the human leukaemic cell line
HL - 6 0  (Wickstom e_t al. , 1 9 8 6). Heikkla e_fc al. (1 9 8 7 ) reported
that this same c-myc complementary oligonucleotide (antisense)
inhibits mitogen-induced c-myc protein expression in human
T-lymphocytes and prevents S phase entry. Interestingly
the c-myc antisense treatment did not inhibit G to Gno 1
traverse.
Addition of PDGF to quiescent BALB/c 3T3 cells for 2 hours 
induces a several-fold increase in the expression of c-myc 
mRNA, as does addition of mitogens to mouse lymphocytes 
(Kelly ejt al. , 1 9 8 3 )* Since the c-myc product is a nuclear 
protein (Abrams e_t al. > 1 9 8 2) one might envisage a functional 
role for it in the regulation of the expression of the genetic 
program that controls cell proliferation. The c-myc gene? 
as transduced by several retroviruses, transforms a whole 
array of target cells of different histogenic origins (Graf 
and Beug, 1978). Abnormal or amplified expression of the 
c-myc gene has also been implicated in human malignancies e.g. 
Burkitt’s lymphoma (Dalla Favera e_fc al. , 1 9 8 2). It may be 
that the post receptor pathways of several mitogens converge 
at the regulation of the myc gene expression and hence this may 
be the explanation for the wide variety of neoplasias associated 
with the abnormal expression of this particular oncogene 
(Armelin e_fc al . , 1984).
Another cellular protooncogene c-fos has been found to be 
rapidly induced by growth factor or mitogens in fibroblasts 
and hematopoietic cells (Kelly et al. , 1983) suggesting that
c-fos also may play an important role in the control of cell 
prolif eration.
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1 • 3 The aims of the pro.ject
It must be stressed, from the beginning, that it was 
not the aim of this project to look at mitogenesis in 3T3 
cells. Initially it was concerned with following up the 
experiments of Macphee ejb al^ . (1984). Thus, the effects of 
PG-F^ on inositol lipid metabolism were studied in more 
detail•
However, in a broader sense, the project was concerned 
with investigating the effects of arachidonic acid and its 
metabolites on inositol lipid metabolism, and in particular 
whether it, and/or its metabolites, plays a role in mediating 
the action of PDGF on inositol lipid metabolism.
As discussed in previous sections, PDGF can act through
the tyrosine kinase activity of its receptor. The PDGF
receptor is structurally unrelated to G-protein-linked
receptors such as the ^-adrenergic receptor (Yarden _et al_. ,
1986), which might suggest that its signal transduction
pathway does not involve a G protein. However, PDGF also
stimulates inositol phospholipid hydrolysis and thus by
analogy with other receptors may act through a G protein,
(G type, possibly), to stimulate phospholipase C. One 
P
possibility is that there may be more than one type of PDGF 
receptor, one which employs a G protein, the other which 
does not.
There are a number of possible ways in which arachidonate 
metabolism might be envisaged to play a role in the mitogenic-
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and inositol lipid cycle-stimulating action of PDGF.
One theoretical model is illustrated in Figure 3» This 
proposes that PDGF binding to its receptor stimulates its 
tyrosine kinase activity, which leads to the phosphorylation 
and, hence, the inhibition of a lipomodulin (p36 type protein). 
The inhibition of this inhibitory lipomodulin would allow 
PLA^ to hydrolyse phospholipids in the plasma membrane to 
liberate arachidonic acid (AA) . The AA could then, itself, 
be metabolised by cyclooxygenase to yield PGE^ and PGF^a > 
on the one hand, and PGI^ on the other. It is thought that 
PGI^ causes a rise in cAMP (Claesson ejb al • , 1977) and this 
could contribute to mitogenesis. The P G F ^  and PGE^,, in 
contrast, could induce an increase in 1,2-diacylglycerol 
(DG) and thus may also contribute to mitogenesis.
PDGF is a more powerful mitogen than, for example,
PGF^. This is presumably due to the ability of PDGF to 
act through more than one transduction pathway e.g. tyrosine 
kinase and inositol lipid metabolism. The resultant 
stimulatory effects of these pathways could be synergistic 
in stimulating mitogenesis.
Another possibility (Figure 3) is that PDGF receptor
activation is coupled directly to phospholipase C activation.
This enzyme hydrolyses Ptdlns(4,3)?2 yi-eld Ins(l,4,3)P^
and DG. An increase in DG formation activates protein kinase
C which leads to cell proliferation and it also increases
cellular pH (a signal associated with mitogenesis). Ins(l,4,3)P^
2 +formation leads to intracellular Ca mobilization. This.
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Figure 5: Potential mechanisms by which platelet derived
growth. Factor can influence inositol lipid 
metabolism and mitogenesis
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2+rise in intracellular free Ca might itself lead to 
mitogenesis or> along with the rise in DG> could activate 
PLA2 and result in the formation of free AA. As before> 
this may be metabolised by cyclooxygenase and other enzymes 
to yield PGE2 and PGF2a and to PGI^j but the formation of 
PGE^ and P G F ^  here? would act to amplify the action of 
phospholipase C.
MATERIALS AND METHODS
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2. Materials and Methods
2.1 Methods of cell culture
Swiss mouse 3T3 fibroblasts can be grown as monolayers 
on either plastic or glass surfaces. They can also be grown 
in roller bottles in combination with microcarrier beads.
In this study* the methods of cell culture were essentially 
those used by Dr L. Jimenez de Asua (personal commun.).
Swiss 3T3 cells were grown in monolayer culture at 37°C 
in an automatic 00^ incubator (Forma Scientific* Marietta*
Ohio* U.S.A.) under a humidified atmosphere of 95% air/5% CO^ 
in Dulbecco’s Modification of Eagle's Medium (DMEM). The 
medium was supplemented with foetal calf serum (6.2%)* new 
born calf serum (l%), benzyl penicillin (80 Iu/ml) and 
streptomycin (80 pg/ml).
2.1.1 Maintenance of aseptic conditions
All aseptic manipulations were performed in a vertical 
laminar flow hood (Microflow Ltd.* Andover* Hants.* U.K.).
Every operation utilising sterile solutions included the use 
of either 1 ml sterile graduated pastettes (Alpha Labs.* 
Eastleigh* England) or 10 ml sterile graduated plastic pipettes 
(Falcon)* when necessary. Operations with 10 ml pipettes 
were made easier by the use of an automatic 'Pipetus' obtained 
from Flow Labs.* Irvine* Scotland. When solutions were to 
be sterilized either 0.2 micron.Nalgene filter units (Nalge 
Company* Rochester* U.S.A.) for volumes over 50 ml* or 0.2 
micron microflow 25 filters (Flow Labs.) were used* depending 
on the filtration volume.
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2.1.2 Passaging of Swiss 3T3 cells
k
Cells were seeded at a density of approximately 5 x 10
 ^ kper 60 mm plastic petri dish, or approximately 2 x 10 cells 
per 20 mm plastic well (6-well multidish), in 6 ml or 2 ml 
culture medium respectively. On the day of passaging, the 
appropriate number of confluent dishes were taken to give the 
required seeding density of the new passage. Normally a 
split ratio of 1:10 was used, and this yielded the cell 
plating numbers shown above.
Firstly, the 'spent' medium from the confluent petri- 
dishes was aspirated off using an autoclaved pasteur pipette 
attached to a suction line. 1 ml of a trypsin-EDTA solution 
(0.05% trypsin 1:250 and 0.02% EDTA in a special salt solution; 
Flow Labs.) was added to each dish, which was then gently 
shaken back and forth. The trypsin-EDTA was aspirated off 
and another 1 ml was added to the dishes. The process was 
then repeated. Finally, 0.2 ml trypsin-EDTA was added to 
each dish. Again the dishes were gently shaken and then 
placed in the incubator at 37°C for ?>-k minutes. After this 
time, the dishes were inspected under an inverted microscope 
to check that the cells were floating as single cells. 6 ml 
fresh serum-containing medium was next added to each dish 
(this inactivated the trypsin-EDTA solution) and this and 
the floating cells were then accumulated in a 250 ml flask 
(Nunc). Fresh medium was added to the flask to give a cell
O
concentration of approximately 9 x 10 cells/ml medium. A 
haemocytometer was used to check the Swiss 3T3 cell concentration
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of* this final suspension. 6 ml or 2 ml (for dish or well) 
aliquots were then added to new petri-dishes or multiwells.
2.1.3 Feeding of Swiss 3T3 cells
3-4 days after plating, the cells were fed. The cells 
were then left for one week to allow them both to become 
confluent and to round up and form the characteristic 
"cobblestone” appearance.
The process of feeding the Swiss 3T3 cells was relatively 
simple. 'Spent1 medium was aspirated as described above 
and 6 ml/2 ml fresh medium was then added to each dish/well.
The petri-dishes/multiwells were then placed in the incubator.
It should be pointed out that one of the problems which 
can arise when Swiss 3T3 cells are grown is that the cells 
can spontaneously transform. This can be detected by observing 
the petri-dishes under a microscope. One can observe "foci" 
which are small areas of the dish where cells have transformed. 
The foci appear as small white spots as the cells are densely 
packed together and are no longer growing in a monolayer.
The appearance of transformed foci in the petri-dishes 
renders the passage of cells useless and, upon detection, a 
fresh batch of cells would be thawed from liquid storage 
and grown for further experiments (see later). The experimental 
"lifetime" of each batch of cells is therefore rather short; 
about 3-4 months.
Another source of variability experienced in growing Swiss 
3T3 cells to confluence is that the more passages cells are 
given, the faster they grow. In some cases, cells were
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passaged and not fed, before being used in experiments 
seven days after plating. Fortunately, this did not appear 
to affect the results of the experiments, in that P G F ^  
induced a similar increase in, for example, InsP formation, 
in both 'fed' and 'unfed* cells.
2.1.4 Storage of Swiss 3T3 cells in liquid nitrogen
Confluent dishes were taken and the Swiss 3T3 monolayers 
trypsinized in the usual manner. Cells were resuspended in 
fresh growth medium at a concentration of 3-5 x 10 cells/ml. 
The cell suspension was cooled in an ice-water bath prior 
to the addition of glycerol to give a final concentration of 
10% (v/v). 1 ml aliquots of the cell suspension were trans­
ferred to sterile plastic ampoules (Flow Labs.) using a 
syringe with an 18G needle. The ampoules were heat-sealed 
before being attached to metal straws, which were then placed 
in polystyrene boxes and put into a -70°C freezer for 
approximately 2 hours. It has been shown that this procedure 
gives a cooling rate of approximately 1°C min The straws
were then placed in a canister in the vapour phase of a 
liquid nitrogen (N^) container (Union Carbide, Darlington, 
U.K. ) .
When frozen Swiss 3T3 cells were to be recovered, an 
ampoule was carefully removed from the liquid N2 container 
and placed into a 37°C water bath for thawing. The ampoule 
was then washed with 70% ethanol and allowed to dry at room 
temperature. The end of the ampoule was broken off and the 
cell suspension aseptically transferred to a 90 mm petri-dish 
(Nunc), using a sterile syringe. 9 mis of fresh serum-
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containing medium was added and the cells placed into 
the incubator at 37°C. The cells were grown until they 
were almost confluent (with medium changes every 3-4 days). 
Following this growth period the "new" Swiss 3T3 cells were 
used for passaging.
2.2 Dialysis of serum
Newborn calf serum (Flow Labs.) was dialysed at 4°C to 
remove, amongst other things, growth factors of a molecular 
weight less than 3 >5 0 0 , e.g. PGF^, vasopressin and gastrin- 
releasing peptide (GRP - a bombesin-like growth factor) using 
Micropor dialysis tubing (Spectra/Por 3> Pierce and Warriner, 
London), thereby leaving growth factors like PDGF and EGF 
remaining.
Tubing (about 25 cm long) was washed with filtered 
distilled water, one end was tied and the tubing then filled 
with 20 ml newborn calf serum (under sterile conditions).
The other end was then tied, and the tubing placed in a 
beaker containing 5 litres 0.9% (w/v ) NaCl. The beaker was 
stored at 4°C for 4 days, with the dialysing solution changed 
daily. The dialysed serum was then transferred to sterile 
tubes (Nunc) and stored in 5 ml aliquots. A second sample 
of newborn calf serum from the same batch was subjected to 
similar conditions of temperature etc., but was not dialysed. 
This non-dialysed serum was used as a control in experiments 
in which the effects of dialysed serum was compared to those 
of non-dialysed serum.
Previous work has shown that sera prepared in this 
way has unimpaired ability to stimulate cell proliferation 
(Besterman ejfc al. , 1986).
2.3 The radioactive precursors used
In this project, three precursors were used: C2-3h ]
glycerol (40 p,Ci/6 ml petri-dish) was used to allow the 
measurement of the cellular content of the major phospholipids 
i.e., phosphatidyinositol (Ptdlns), phosphatidic acid (PtdA), 
phosphatidylcholine (PtdCho), phosphatidylserine (PtdS) and 
phosphatidylethanolamine (PtdE). In such cases, dishes of 
Swiss 3T3 cells were pre-labelled for 2 days with the 
isotopically-labelled glycerol.
Myo- £ 2-^h J -inositol (5p-Ci/6 ml dish or 2 ml well), 
was used to allow the measurement both of the inositol- 
containing phospholipids: Ptdlns, phosphatidylinositol 4-
phosphate (Ptdlns 4p) and phosphatidylinostiol (4,5)- 
bisphosphate (Ptdlns (4,5)-P£) anc^  als° the measurement of 
cytoplasmic inositol-containing metabolites: inositol, 
inositol monophosphate (insP), inositol bisphosphate (insP^), 
inositol trisphosphate (insP^) and inositol tetrakisphosphate 
(insP^). Again, cells were pre-labelled for 2 days with 
C3h ] -inositol prior to the experiment.
C 5 , 6 , 8 , 9  ,11,12,14,1 5 -^ h J -Arachidonic acid (AA),
(0 . 5  pCi/6 ml dish or 2 ml well) was used to allow the 
measurement of free AA and prostaglandins in the medium 
bathing the cells. Radiolabelled -arachidonyl PtdA
was also measured with this protocol, to show any effects
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on the turnover of4 the inositol lipid cycle. Cells were 
pre-labelled for 20-2^ 4- hours with -AA prior to the
experiment•
Pre-labelling the Swiss 3T3 cells with the desired 
radioactive precursor, for these relatively long periods, 
leads to an isotopic equilibrium being attained, in this 
case changes in, for example the radioactivity associated 
with a particular phospholipid, were taken as reflecting 
changes in the absolute cellular content of that lipid 
(Drummond, A.H., unpublished results).
The basic protocol for each experiment was as follows: 
the medium from the radiolabelled cells was aspirated and 
discarded (except for experiments in which cells were pre-
O
labelled with £ -AA)• The cells were then washed twice 
with 6 ml/dish or 2 ml/well of a Hepes-buffered balanced 
salt solution (BSS; see Table 3 for constituents) at 37°C. 
and left in a final volume of 6 ml/2 ml BSS per dish/well.
The dishes were returned to the incubator and left for 10 min, 
so that the cells would equilibriate at the reaction 
temperature. Thereafter, drugs were added to the dishes in 
various concentrations and combinations and for various 
lengths of time. The reactions were stopped by removing 
each dish from the incubator at the desired time. The BSS 
was quickly aspirated and discarded (or kept, in the case
o
of experiments involving the measurement of Q Hj -AA release 
into the bathing medium) • OrtC- ml ice-cold 10^ (w/v) trichloro­
acetic acid (TCA) was then added immediately to the dish 
which was thereafter placed on an ice-bath until all of the 
samples had been collected.
Table 3 : Constituents of balanced salt solution.
135 mM
4.3 mM
1.3 mM 
0.3 mM 
3.6 mM 
10 mM 
0.1^ (w/v)
NaCl
KC1
CaCl2
MgCl2
glucose
HEPES
bovine serum albumin 
pH 7 ^
N.B. 10 mM NaCl was replaced with 10 mM LiCl where 
indicated in the text.
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2.4 Phospholipid extraction
Alter cell activation had been stopped for all of the 
dishes, cells from each dish/well were scraped, into test- 
tubes, using a "rubber policeman". These were centrifuged 
(3 0 0 0g; 10 min; 4°C). The supernatant was removed and kept 
for inositol phosphate analysis (if the radiolabel used was 
Q H] -inositol). The cell pellet was then extracted 
essentially by the method of Schacht e_t al. (1981). 1 . 5  ml 
chloroform: methanol (1:2 v/v), 0.5 ml 2.4N HC1 0.5 ml 
distilled H^O and 0.5 ml chloroform was added to the test- 
tubes (A). After 20 min, (to allow the lipids to be extracted 
into the organic phase), the samples were centrifuged (3000g;
5 min; 20°C). The lower phase (organic phase) was transferred 
to other test-tubes (b ), while the upper phase was further 
extracted with 1 ml chloroform. After a further centrifugation 
step to break the two phases, the lower phase was once again 
added to the test-tubes (b ). Finally 2 ml l'N HC1: Methanol 
(l:l v/v) was added to test-tubes (b ) and these were 
centrifuged as above. The upper phase was discarded and 
the lower phase transferred to glass vials. The lower phase 
was then evaporated to dryness at 40°C under oxygen-free 
nitrogen, using a sample concentrator (Techne Ltd., Cambridge, 
England) and the residue redissolved in 100 |il chloroform: 
methanol (9:1 v/v) and stored at -20°C until phospholipid 
separation was carried out. Generally, phospholipids were 
separated within 48 hours of extraction. The above method 
was used in all cases where phospholipids were extracted,
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whether the cells were radiolabelled with -glycerol,
3 3C ^0 —inositol or £ H]] -AA. The one exception to this,
was when very short time course experiments were carried out
to study the effects of PGF on the inositol—containing
phospholipids. In this case, the method used was essentially
that of Creba et al. (1 9 8 3 )* To the cell pellet was added
2 ml dist. H^O and 3*75 ml chloroform:methanol: 12M HC1
(30:100:1). After 20 min (to allow extraction of the lipids),
samples were centrifuged at 3000g for 3 min (20°C). The
upper phase was discarded and replaced by 2 ml of the
synthetic upper phase, obtained from a mixture of chloroform:
methanol: 1M HC1 (l:l:0.9)« After thorough vortexing and
centrifugation 1 ml of the lower (organic) phase was taken
and deacylated for 20 min at room temperature (20°C) with
methanolic NaOH (0.2 ml methanol plus 0.2 ml of 1M NaOH in
methanol:H^0 (l9:l))« After this time, 1 ml chloroform,
0.6 ml methanol and 0.6 ml distilled H^O were added and the
samples were mixed and centrifuged to separate the phases.
The upper phase (now containing the labelled deacylated
inositol lipids) was diluted to 3 ml to give a final
concentration of 3 mM Na2B^0^ before separating the deacylated
lipids on Dowex anion exchange columns (see next section).
2.4.1 Phospholipid separation
*3 -3For cells labelled with L H] -glycerol and L H] -AA,
phospholipids were separated by a rapid two dimensional
thin—layer chromatography (TLC) method on silica gel G plates
(0.23 mm; 10 x 10 cm, Polygram; Camlab, Cambridge, England)
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as described, by Yavin and Zutra (1977), but with, minor 
modifications. The following mixtures were prepared in a 
final volume of 200 ml; chloroformjmethanol: 40^ > (v/v) 
methylamine (13:6:1.3 > by volume) for the first direction; 
diethyl ether: glacial acetic acid (l9:l> by volume) for the 
intermediatory run (though in the second direction); and 
chloroform : acetone : methanol : acetic acid : dist. H^O 
(l0:4:2:3:l> by volume) for the third run (second dimension). 
The chromatographic chambers (Multitank, Camlab) were lined 
at both ends with Whatman filter paper, and the solvent 
mixtures added about 1-2 hours before samples were run.
All three organic mixtures were freshly prepared and at least 
30 plates could be run with a single batch of solvents, 
without loss of resolution. Phospholipid samples were 
applied using 10 yil disposable micro-pipettes (Camlab), to 
the lower left hand corner (2 cm from the edges) on a point 
lightly marked with a pencil. The solvent from each sample 
was evaporated in a stream of warm air from a blow dryer 
placed about 40 cm from each spot. Each glass vial (containing 
phospholipid sample) was washed with a further 30 y.1 of 
chloroform: methanol (9:1 v/v) which was also spotted as 
described above. Carrier phosphatidate (3 Ug) was used to 
aid visualisation of the PtdA spot in this system, since the 
cellular content of this lipid in Swiss 3T3 cells was rather 
low and only occasionally visible under iodine staining.
The chromatoplates, eight at a time, were placed in the 
first solvent. Plates were developed for approximately 20 min 
until the solvent front was 1 cm from the edge. Plates were
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removed, and placed on a tray for drying. This was performed 
with warm air from 3 blow dryers, located around the tray, 
for a period of 10-15 min. A thorough dry at this stage 
was essential to enable complete neutralisation of the 
base (methylamine) at the following stage. The silica gel 
layer was then exposed to the fumes of a concentrated HC1 
(lO.8m) solution for 5 min, the distance between the exposed 
gel and HC1 surface being about 2 . 5  cm. The plates were 
then dried with blow dryers, as above, in warm and ambient 
air for 5 min and 3 min respectively. They were then placed 
for about 15 min into the second chromatography chamber, 
the origin now at the lower right corner, to eliminate 
impurities, which would otherwise interfere with the subsequent 
second dimension elution. Following this ether/acetic acid 
wash, the plates were dried for 5 min at ambient temperature 
and were rerun in the same direction for about 25 min in the 
third chromatography chamber, containing the chloroform : 
acetone : methanol : acetic acid : dist. H^O mixture. After 
thorough drying, the phospholipid spots (PtdA, Ptdlns, PtdS, 
PtdCho, PtdE) were identified by comparison with reference 
standards using iodine vapour.
3
For cells labelled with C H] -inositol, the phospho- 
inositides (Ptdlns, PtdlnsP and PtdInsP2) were extracted 
by the method already described, except in the short-time 
course experiments where deacylated lipids were extracted 
by the method of Creba et al. (1983)> also described above.
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Generally, the phosphoinositides were separated on 
oxalate-impregnated HPTLC plates (20 cm x 10 cm, Merck) 
following the procedure of Jolles et al. (l9Sl).
It was found that an unknown phospholipid co—migrated 
with Ptdlns4-P in this system. This was thought to be 
lyso Ptdlns4—P, a phospholipid which is not present in GH^ 
pituitary cells, to any significant extent (Drummond, A.H., 
unpublished results). Due to the difficulty in separating 
the polyphosphoinositides from one 'unknown' phospholipid, 
a different method of separating them was used in the short- 
time course experiments with PGF^, where deacylated lipids 
were separated essentially by the method of Creba ejb a_L. (1 9 8 3 )* 
Samples (deacylated lipids) were placed onto columns 
(l x 2 cm) of Dowex (1X8 100—200 mesh, Cl form) anion exchange 
resin, which had been washed with 2.4M ammonium formate to 
change the resin to a formate form. 10 ml of 5 mM Na^B^O^/
0.18M NH^COOH was used to elute glycerylphosphorylinositol 
(GroPIns), 10 ml 0.1M formic acid/0.3M NH^COOH for glyceryl- 
phosphorylinositol monophosphate (GroPInsP) and 10 ml 0.1M 
formic acid/0.75M NH^COOH for glycerylphosphorylinositol 
bis-phosphate (GroPInsP^).
-32.5 Isolation of C Hj -inositol phosphates
As already described above, agonist-induced cell stimulation 
was stopped by the addition of 1 ml ice-cold 10% ("w’/v ) TCA.
The cells were then scraped off the petri-dishes into test- 
tubes and centrifuged (3000g; 10 min; 4 C). The resulting
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supernataut: (the acid—soluble fraction) was collected and 
frozen at —20 C until “inositol phosphates were to be
assayed. At this stage, the pellet for inositol—containing 
lipids was extracted as described above.
For the separation of acid-soluble -inositol
metabolites, frozen aliquots were thawed and extracted three
times with three volumes of water—saturated diethyl ether.
After driving off the residual ether in a boiling water bath,
the extracts were allowed to cool at room temperature. The
extracts were then placed on to columns (l x 2 cm) of Dowex
anion exchange resin (treated as described above). The
method used, thereafter, was similar to that described by
— 3
Downes e_fc al. (1 9 8 6). L HQ -Inositol was initially eluted 
with 7 ml distilled water, but due to the extremely high 
levels of jj H]] -inositol found in Swiss 3T3 cells, was 
subsequently eluted with 2k ml dist. H^O. [ H] -InsP was 
eluted with 8 ml 0.1M formic acid/0.2M NH^COOH; £"^ H]J -InsP^ 
was eluted with 8 ml 0.1M formic acid/0.4M NH^COOH; —
InsP^ was eluted with 8 ml 0.1M formic acid/0.8M NH^COOH and
-InsP^ was eluted with 8 ml 0.1M formic acid/l.2M 
NH^COOH. Unfortunately, the radioactivity measured for the 
InsP^ elution was similar to background, under the conditions 
of these experiments, and hence drug effects on InsP^ levels 
could not be determined.
2 .3 . 1  High performance liquid chromatographical analysis of 
the inositol phosphates
In order to detect the nature of the inositol phosphate 
isomers present in resting and agonist—stimulated Swiss 3T3
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cells, HPLC analysis of the acid soluble fractions were 
carried out.
Neutralised samples (0»5 ml) were injected on to a 
Partisil 10SAX analytical HPLC Column, (25 cm x 0.4 mm), 
preceded by a guard column of similar material (5 cm x 0.4 mm) 
(Hichrom, Reading, England), and the column washed with 
deionised, degassed, ultrapure H^O for 30 min at a flow rate 
o:^  1 • 25 ml/min. This prolonged H^O elution was found necessary 
to eliminate the extremely high levels of C"^ H ] -inositol 
found in Swiss 3T3 cells. Thereafter, a linear gradient of 
up to 2M NH^COOH, buffered to pH 3*7 with orthophosphoric 
acid (22°C) was applied over the subsequent 40 min period. 
Fractions were collected every 20s and counted by liquid 
scintillation spectrometry after addition of 3 ml Optiphase- 
Safe (LKB, FSA Labs, Loughborough, England). The column was 
calibrated with a series of standards both before and after 
running the 3T3 cell extracts.
2.6 Isolation of II^ Hl -AA metabolites
In experiments where -AA-derived metabolites were
to be measured, at the end of drug incubations, the 6 ml 
BSS/dish (2 ml/well) surrounding the cells was removed into 
test tubes and kept on ice. The cells then received 1 ml 
ice-cold 10% (w/v) TCA and were scraped off the petri-dishes 
into test-tubes and centrifuged, as previously described.
A fraction of the BSS (0 . 5  ml) was then placed directly 
in 5 ml Ecoscint and its radioactivity (cpm or dpm) was 
measured by liquid scintillation spectrometry. This gave
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3
a measure of* £ H] -AA—derived radioactivity released from 
the cells.
The remaining BSS was, on a number of occasions extracted 
for radiolabelled AA and more polar metabolites such as 
prostaglandins, essentially by the method of Ubatuba (1 9 7 8 ). 
The BSS was acidified with concentrated HC1 to pH 3 . The 
acidified samples were then extracted twice with two volumes 
of cyclohexane : ethylacetate (l:l v/v) and the upper phase 
collected each time. The combined upper phases were then 
dried under oxygen-free nitrogen (at kO°C) and reconstituted 
in absolute ethanol (100 p-l).
3
The labelled £ -AA metabolites were then separated by
TLC using the SMI solvent system as described by Ubatuba
(1 9 7 8 ): ethylacetate : acetone : acetic acid (9 0 :1 0 :1 , by
volume). This system was designed to allow greater separation
between 6 keto PGF., and PGE„ than other solvent systemsla 2
detailed by Ubatuba.
Metabolites were identified by comparison with reference 
standards, and visualised as described below. The TLC plates 
(20 cm x 20 cm, Merck) were marked lightly with a pencil 
and each sample was spotted on to 1 cm bands of the plates.
The origin was 2 cm from the bottom of the plates. The plates 
were placed in the chromatography chamber containing the 
solvent for about 2 5 - 3 0 min (until the solvent front was at 
least 2/3 way up the plates). The plates were then removed 
and the solvent evaporated at room temperature in a fume 
cupboard. The plates were sprayed in the fume cupboard with 
a reagent containing absolute ethanol: cone. H^SO^ :
anisaldehyde (lO:ljl, by volume). The 6 keto appeared
as a bright: yellow band* at this stage* and it was marked 
lightly with a pencil tor each sample. The plates were 
then placed in an oven and heated tor 10 min at approximately 
80—90 C until the other coloured bands appeared? PGD^, 
orange/brown; PGE2, brown; PGF and AA, dark blue/violet 
and Tx B^, grey/blue.
2.7 Determination ot radioactivity
Atter the iodine had sublimed, identitied lipid spots/ 
bands were scraped, using a surgical blade, and incorporated 
radioactivity quantified by liquid scintillation spectrometry 
(Packard, model 3390 Packard model 2000 CA). 1 ml aliquots
of the separated -glycerylphosphorylinositol phosphates
were quantified in a similar manner, as were 1 ml aliquots
O
of the separated C H J -inositol phosphates. The scintillation 
fluid generally used was Ecoscint (National Diagnostics, Ayles­
bury) 3 volumes/volume sample. Optiphase-Safe (LKB from FSA 
Labs, Loughborough) was used in experiments where HPLC 
analysis was carried out on the inositol phosphates.
2.8 Protein determination for Swiss 3T3 cells
Cellular protein content was determined by the method 
of Lowry e_fc al. (1951) using bovine serum albumin (Sigma) as 
standard. Petri-dishes (6 ml) or multiwells (2 ml) of 3T3 
cells were scraped into test-tubes and centrifuged at 3 0 0 0g 
for 3 min at room temperature. The pellet was washed twice 
with 0.9% (w/v) saline, undergoing vortexing and centrifugation 
each time (3000g/> min). This removed any serum albumin present.
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From random samples the cellular protein content of 
3T3 cells/dish or well was as follows: 0.48 - 0.045 mg
protein/lO cm diameter petri-dish; 0 . 1 7  - 0 . 0 1  mg protein/
6 cm diameter petri-dish and 0 . 0 5 - 0 . 0 0 5 mg / 2  ml diameter 
well •
2.9 Statistical presentation of results
Results are expressed as the mean - standard error of 
the mean. Data, where indicated, were subjected to a 
Student’s t-test to determine whether a significant difference 
existed at the 5^ level between the mean values. Levels of 
significance used throughout, unless otherwise stated:
*  p < 0 .0 5 , ** p < 0 .0 0 1.
2.10 Sources of chemicals used
The various drugs, culture materials and biochemical 
compounds used in addition to standard laboratory reagents 
are listed in Table 4, together with their sources. All 
solutions were prepared with glass distilled H^O unless 
otherwise stated.
Tabl e h : Chemicals and cell culture materials used and 
their sources
Material 
Swiss 3T3 cells
Petri-dishes? flasks? 
multiwells? filters etc.
Dulbecco's Modification of 
Eagle's Medium (DMEM)
Foetal bovine serum
Newborn bovine serum
L-Glutamine (200 mM)
Trypsin-EDTA solution
Penicillin (500 I.U./ml)/ 
Streptomycin (500 p,g/ml)
Trypan Blue solution
Micropor (Spectrapor 3) 
dialysis tubing
myo-C2-^h3 -inositol 
(l6 .4/mmol)
[2-3H] -glycerol (l Ci/mmol)
[5»6?8,9?11,12,1^?15-3h] - 
AA (135 Ci/mmol)
Dowex 1 x 8  (Cl form? 
1 0 0 - 2 0 0 mesh) resin
Partisil 10 SAX HPLC column
Optiphase-Safe
Ecoscint
Source
Kindly donated by the following 
people: Dr K.D. Brown (Cambridge? 
England); Dr G. Thomas (Basel? 
Switzerland) and Dr L. Jimenez 
de Asua (London? England)
Flow Labs.? Irvine? Scotland 
or Gibco-Europe? Paisley? Scotlanc
Flow Labs 
FIow Lab s 
FIow Lab s 
FIow Lab s 
Flow Labs
Flow Labs 
FIow Lab s
Pierce and Varriner? London?
England
Amersham International p.I.e.? 
Amersham? England.
Amersham International p.I.e.
Amersham International p.I.e.
Sigma Chemical Co. Ltd.?
Poole? England.
Hichrom? Reading? England
(LKB) F.A.S. Labs, Loughborough, 
England
National Diagnostics, Aylesbury, 
England
Table h (Contd).
Mat eri al 
HEPES
Folin and Ciocaltean1s 
phenol
Lithium chloride
Bovine serum albumin 
(99f° essentially Fatty 
acid Free)
-InsIP 
C Hj -Ins^P
-Ins(l,4)p
t’Hj -Ins(i|-» 5 ) ^ 2
C3H] -Ins(l,it,5)P
Prostaglandin F^a 
Prostaglandin standards 
Arachidonic acid 
AA analogues 
Lipid standards 
Melittin 
Dexamethasone 
Indomethacin
FlurbiproFen }H»0 soluble 
BV755C )Form
Source
Sigma Chemical Co. Ltd.
BDH Chemicals Ltd.? 
Poole> England
BDH Chemicals Ltd.
Sigma Chemical Co. Ltd.
Amersham International p.l.c 
Was prepared by alkaline 
hydrolysis oF (pHj -PtdlnsP 
(Amersham) by the method oF 
Gra.do and Ballou (1 9 6 1)
Amersham International p.l.c 
Was prepared by alkaline 
phosphatase action on C^h]- 
Ins(l»^-»5)Po (Amersham) 
(Hughes & Drummond , 19 S j )
Amersham International p.l.c
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Sigma Chemical Co. Ltd.
Kindly donated by Dr D.E
MacIntyre? Merck Labs? New 
York? U.S.A.
Table b (Contd)•
Material Source
PDGF - highly purified form Kindly donated by Dr C.-
Heldin? Uppsala? Sweden
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3• Results
3*1 The effects of* prostaglandin F _ ^ on inositol lipid 
metabolism in Swiss 3T3 cells
Research prior to this project had shown that PGF ,
2a
when added to quiescent Swiss 3T3 cells, not only led to a 
stimulation of DNA synthesis, but also stimulated the 
incorporation of [32p] -PO^ into Ptdlns. It had also been 
observed that P G F ^  caused a small increase in the cellular 
content of DG (Macphee et al. , 19 8 -^). However, at that time, 
little detailed work had been done to investigate the effects 
of PGF^a on the inositol lipid cycle in 3T3 cells. Therefore, 
the first section of this project was concerned with studying 
the effects of PGF^a on the inositol-containing phospholipids 
(phosphoinositides), the inositol phosphates and other 
membrane phospholipids.
—  o
3*1.1 Studies using Swiss 3T3 cells pre-labelled with L Hi - 
inositol
3*1*1.1 Amplifying responses using lithium chloride
In the following experiments, 10 mM lithium chloride 
was used to amplify receptor —stimulated responses (see 
Methods). The effect of using Li ions can be seen clearly 
in Figure 6. Here, the effects of PGF^a on the inositol 
phosphates are compared for cells bathed in normal (full Na ) 
balanced salt solution (BSS) and cells bathed in Li -containing 
BSS. It is apparent, that Li+ amplifies the increase m  
InsP levels, induced by P^F^*
Figure 6
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The effect of* 10 mM LiCl on acid soluble C^Hl - 
inositol phosphate levels in PGF -stimulated 
Swiss 3T3 cells
Swiss 3T3 cells were labelled to equilibrium with 
5 pCi -inositol/dish? (see Methods). They were
washed and left in BSS which either had a full Na+- 
complement or contained 10 mM Li in place of 10 mM 
Na+. PGF (1.6 pM) was used as an agonist and the 
reactions were terminated after 10 min. Acid-soluble 
C3h J -inositol-derived radioactivity was quantified 
as described in the Methods section. The values shown 
are from a representative experiment conducted in 
duplicate and repeated once.
This effect is due to lithium's ability to block 
the monophosphatase enzymes, which are involved in the 
hydrolysis of* InsP to inositol (Figure 2). However* lithium 
is also thought to affect other enzymes in the inositol 
lipid cycle and this has been discussed in Section 1.1.4.
Lithium had no significant effect on cellular inositol 
levels, and this suggests that Swiss 3T3 cells contain a 
very large pool of inositol, which is difficult to deplete. 
Care is necessary in separating Ins from InsP on Dowex 
columns, because of the marked disparity in their cellular 
contents and thus in later experiments 2k ml distilled H^O 
was used to elute the inositol fraction.
Lithium had no significant effect on InsP^ and InsP^ 
accumulation. However, if there was any trend to be seen 
in these results it would be that lithium slightly amplified 
the effects on InsP^ levels in response to PGF^a *
It is noteworthy that the radioactivity, in c.p.m., 
recorded for InsP^ and InsP^ is extremely low and this made 
it difficult to measure accurately any changes due to agonists.
In all subsequent experiments, unless otherwise stated,
10 mM lithium chloride was used to amplify the response to 
agonists, measured as a change in the level of InsP.
3• 1 * 1 • 2 The dose-response relationship for PGF^-induced 
changes in inositol lipid metabolism
Before the effects of 0X1 the various metabolites
of the inositol lipid cycle were studied in detail, a 
concentration-response curve for PG-F2a was constructed, in
which the increase in the level of InsP was taken as a 
measure of cycle stimulation# Therefore> 3T3 cells were 
incubated for 10 min with concentrations of PGF^ ranging 
from 1 nM to 10 p,M (Figure 7)* The maximum response was 
obtained using 1 pM P G F ^  and half-maximal stimulation at 
approximately 30 nM. In the following experiments» unless 
otherwise stated* a supramaximal concentration of PGF
2a
(1.6 p,M/500 ng/ml) was used.
3.1.1.3 The effect of PGF„ on the 3T3 cell content of the ------------------ 2a ------- -— -----------------------
inositol-containing phospholipids 
As before* 10 mM lithium chloride was used in these 
studies. Figure 8 shows the time course of the effects of 
PGF^a on cellular polyphosphoinositide levels. It must be 
pointed out that Figure S shows the results of one 
representative experiment of three* and in this case control 
samples were only taken at 0 and 5 minutes. However* in 
the other experiments control samples were taken throughout 
the 20 minutes duration of the drug incubation* and the 
results from these experiments (not shown) indicated that 
levels of PtdlnsP + PtdInsP2 did not change significantly 
over this time.
The combined levels of PtdlnsP and PtdlnsP^ in 3T3 
cells rose to a maximum within 40 seconds of administration
of PGF . Levels of the polyphosphoinositides remained 
2a
elevated above basal over the 20 minutes duration of the 
drug incubation.
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Figure 7 i The effect of increasing concentrations of PGF 
on -InsP levels in Swiss 3T3 cells
Cells were labelled to equilibrium with 5 p,Ci 
Q3h ] -inositol/well. They were washed and left 
in BSS containing 10 mM LiCl> and incubated for 
10 min with PGFpa « For experimental details see 
Methods section.a The data shown are from one 
experiment conducted in triplicate and repeated 
once with similar results.
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Figure 8 : The time course of the effects of PGF^ on the
polyphosphoinositide content of Swiss ^T3 cells
Cells were labelled to equilibrium with 5 P-Ci 
£3h 3 -inositol/dish. They were washed and left 
in BSS containing 10 mM LiCl> and incubated with
1.6 PGF . For experimental details see Methods 
section. T&e values shown are from a representative 
experiment conducted in duplicate and replicated 
twic e.
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However by analogy with the response of other cell 
types (e.g. GH^ pituitary cells) to hormones it was expected 
that there would be an initial decrease in Ptdlns and PtdlnsP^ 
levels occurring before resynthesis of the lipids can take 
place (Macphee and Drummond, 1 9 8^). In contrast, a rather 
rapid rise in the polyphospho—inositide levels was noted.
Thus it seemed important to repeat this series of experiments 
using a protocol in which earlier time points were measured.
In these experiments, a different method of analysing 
the phosphoinositides was used, which involved the deacylation 
of the extracted lipid and separation of glyceryl phospho- 
inositol phosphates on Dowex anion exchange columns (see 
Methods - Creba e_t al. , 1983)*
The results shown in Figure 9»a indicate that as before 
PtdlnsP levels rose after kOs of administration with PGF^. 
However, here the results show that a slight decrease in 
PtdlnsP content occurred within the first 10s of stimulation.
Levels of PtdInsP2 (Figure 9 )> again, showed only an 
increase that reached a peak after 40s. Unlike levels of 
PtdlnsP, there was no significant decrease in the level of 
PtdlnsP^ within the first 10s of the stimulation. The levels 
of Ptdlns, measured by either method, did not significantly 
increase in response to P G F ^  (Figure 9 8) •
3.1.1. k The effect of PGF^, on the 3T3 cell content of the 
acid—soluble inositol phosphates
The ability of PGF2a to alter the cellular content of 
the acid—soluble metabolites of PtdInsP2» namely, inositol, 
InsP, InsP2 , InsP3 and InsP^, was investigated (Figures 10,
12).
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Figure 9; The early time course of the effect of PGF 
on the inositol phospholipids
Cells were labelled to equilibrium with 5 P-Ci 
L3h] -inositol/well. 10 mM LiCl-containing 
BSS throughout the experiment and samples were 
incubated with 1 jaM PGF? ' '^or ° ^ er experimental 
details see Methods section. The values shown 
are from a representative experiment carried out 
in quadruplicate and replicated once.
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1.6 v-M PGF2a did not significantly affect the level
inositol over the 20 minutes of the incubation (data not
shown). In contrast? the levels of InsP almost doubled
within kOs of administration of PGF^, and fell toward, but
did not reach, basal within the 20 minutes stimulation with
PGF2a (Fi^are 10)• Likewise, InsP2 and InsP^ levels rose
within 40s of administration of PGF2 and fell, reaching
basal levels, with the 20 minute period monitored (Figures 11
and 12). The radioactivity measured in the InsP^ fraction
was too low to record any significant changes associated
with the administration of PGF0 (data not shown).2a v '
In an experiment where earlier time points were investigated
the same overall pattern emerged. PGF2a (l p,M) again, did
not affect the level of cellular inositol (data not shown).
The level of InsP (Figure 13a), as before, increased to a
maximum within 40-60s after administration of PGF„ . This2a
increase was maintained over the 2 min duration of the drug
incubation. InsP2 levels (Figure 13t») increased to a maximum
after 20s with PGF^ and fell back towards basal within the2a
2 min. InsP^ levels (Figure 13c) rose very rapidly to reach
a maximum within 5s of administration with PGF^. This
rise was maintained for up to k0sf whereafter, the level
of InsP^ fell back towards basal, again within the 2 min
stimulation with PGF0 •2a
3.1.1.5 HPLC analysis of the acid-soluble C^h ] -inositol
metabolites in PGF^ -stimulated Swiss 3T3 cells ------ - ------------2 a--------------------
High performance liquid chromatographical (HPLC) analysis
of the acid-soluble L^Hj -inositol metabolites was conducted
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Fiffare 10: The time course of the effect of PGF^ °-n C3Hl -
InsP levels in Swiss 3T3 cells
Cells were labelled to equilibrium with 5 p-Ci 
C -inositol/dish. 10 mM LiCl-containing BSS was 
US&d throughout the experiment and samples were 
incubated with 1.6 uM PGF0 . For otherPoc
experimental details see Methods section. The 
values shown above are from a representative 
experiment carried out in duplicate and replicated 
twice.
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Figure 11: The time course of the effect of PGF^ on C3h 1 -
-InsP^ levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 p«Ci 
L3h ]  -inositol/dish. 10 mM LiCl-containing BSS was 
used throughout the experiment and samples were 
incubated with 1.6 p.M PGF^. For other 
experimental details see Methods section.
The values shown above are Prom a representative 
experiment carried out in duplicate and replicated 
twice.
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Figure 1 2 : The time course of the effect of PGF on C~^ Hl -
InsP^ levels in Swiss 3T3 cells. a
Cells were labelled to equilibrium with 5 p,Ci 
L3h ]  -inositol/dish. 10 mM LiCl-containing BSS was 
used throughout the experiment and samples were 
incubated with 1.6 p,M PGF^. For other experimental 
details see Methods section. The values shown 
above are From a representative experiment carried 
out in duplicate and replicated twice.
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Figure 13; The early time course of the effect of PGFqq. 
on the inositol phosphates.
Cells were labelled to equilibrium with 5 p.Ci 
C3h ] -inositol/well. 10 mM LiCl-containing 
BSS was used throughout the experiment and 
samples were incubated with 1 p,M PGF . For 
other experimental details see Methods section. 
The values shown are from a representative 
experiment carried out in quadruplicate and 
replicated once.
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in an attempt to further elucidate the mechanisms underlying
stimulated inositol lipid metabolism in Swiss 3T3 cells.
This was made difficult due to the extremely high levels 
3 *
ot* £ Hj —inositol found in Swiss 3T3 cells? and required 
that the Partisil SAX column be extensively washed with 
distilled H^O prior to starting the salt gradient. However? 
the results shown in Figure 14 indicate clearly? that 
Ins(l?4)P2 levels rise in response to P G F ^  (l p.M). There 
does not appear to be a significant amount of Ins(4?5)P2 
present in resting or stimulated 3T3 cells? although? there 
may be some Ins(3>^)P2> seen in Figure 14 as the "shoulder" 
between the two InsP^ standards. The shoulder elutes close 
to Ins(3 >^-)P2 which has been chemically identified as the 
second-eluting InsP^ in GH^ cell extracts (Drummond? A.H.? 
personal commun.)• In resting Swiss 3T3 cells? the Ins(l)p 
isomer is the most abundant monophosphate? but it appears 
that some Ins(4)P may also be present. In PGF^-stimulated 
cells the Ins(l)P content is significantly increased? but 
not the Ins(4) content.
Unfortunately? these samples were run on an ageing HPLC 
column and the recovery of (]^ H J -Ins (l ? 4? 3 from this 
column was only about 20^. Because of this it was impossible 
to detect the nature of the [3h] isomers present in
the Dowex elutions. Also? only the region of the gradient 
corresponding to 0 to about 0*9^ ammonium formate is shown 
in Figure 1^ -. No further counts were detected in this series 
of experiments that might correspond? for example? to InsP^ 
or higher polyphosphates (data not shown).
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Figure 1^; HPLC analysis of the inositol phosphates in 
the presence and absence of PGF in Swiss 
3T3 cells 2a
Cells were labelled to equilibrium with 5 P-Ci 
L3h ] -inositol. 10 mM LiCl-containing BSS was 
used throughout the experiment and samples were 
incubated for 20s with 1 p,M PGF^a * For 
experimental details see Methods section.
The above data are from a representative 
experiment conducted in triplicate and 
repeated once.
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3 • 1 • 2' Studies using Swiss 3T3 cells pre-labelled with. C^H~] - 
glycerol
The effect of P G F ^  on the 3T3 cell content of the other 
major phospholipids was investigated using cells pre-labelled 
to equilibrium w i t h [ 3Hj -glycerol. The data in Table 3 
show the level of phosphatidic acid (PtdA), phosphatidyl- 
inositol (Ptdlns), phosphatidylserine (PtdS), phosphatidyl— 
ethanolamine (PtdE) and phosphatidylcholine (PtdCho) in 3T3 
cells in response to stimulation with V G F ^  (1.6 p,M) for 10 min. 
From this table, it is evident that there was no significant 
change in the levels of Ptdlns, PtdS, PtdE or PtdCho. However, 
the cellular content of PtdA more than doubled in response 
to PGF . The relative amounts of the phospholipids in 3T3 
cells appear to be (PtdCho : PtdE : PtdS : Ptdlns : PtdA)
40 : 33• 5 '• 13 : 12.3 : !• This agrees with other cell types 
(e.g. GH^ cells, Drummond, A.H., personal commun.) where 
PtdCho and PtdE are the major phospholipids present. Although 
not measured, other phospholipids appeared to be present in 
3T3 cells. Sphingomyelin, lyso Ptdlns and cardiolipid were 
the most evident of these, as identified by their co-migration 
with standards.
The response in PtdA to PGF2a was examined further, by 
measuring the cellular content of PtdA at various time points, 
following stimulation with PGF • The data in Figure 13 
reveal that the level of PtdA, like the polyphosphoinositides 
and inositol phosphates, increases to a maximum within UOs 
of administration and is maintained over the 20 min stimulation
with PGF0 (1.6 ]iM) •2a v
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Figure 15: The time course of the effect of PGF„ on l3h i  -
PtdA levels in Swiss 3T3 cells
o
Cells, labelled to equilibrium with kO p.Ci £ Hj- 
glycerol/dish, were stimulated with 1.6 pM PGF^. 
For experimental details, see Methods section.
The data shown are from a representative experiment 
conducted in triplicate and replicated once. In 
this experiment the control samples were taken 
only at 0 and 5 min. However, from previous 
experiments it was observed that the PtdA content 
in control cells did not change significantly 
over the 20 min. measured (data not shown).
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In summary, a supramaximal concentration of* PGF
2a
leads to rapid stimulation oF the inositol lipid cycle in 
Swiss 3T3 Fibroblasts• The response is classical in many 
aspects, although the rate oF stimulation appears to wane 
rapidly in the First minute aFter addition oF PGF
2a
Noteworthy, are the rapid increase in polyphosphoinositide 
levels that Follows agonist addition and the high levels oF 
inositol in 3T3 cells. This precludes the detection oF the 
increased Flux through the sugar that must occur in stimulated 
cells and makes it likely that many days oF stimulation in 
the presence oF lithium would be necessary to deplete the 
cellular content signiFicantly.
In the next section the physiological relevance oF the 
eFFects oF PGF^a on the major phospholipids and on the 
inositol lipid cycle is examined.
3•2 The eFFects oF arachidonic acid on inositol lipid 
metabolism in Swiss 313 cells
As previously stated in the introduction, platelet- 
derived growth Factor (PDGF) stimulates both inositol lipid 
metabolism and the Formation oF PGF^, anc* ^ ^ 2
Swiss 3T3 cells (Habenicht _et al. , 1981; Berridge ejt al. »
1984a JHasegawa-Sasaki, 1 9 8 5)*
Thus, in view oF the Fact that PGF2a and PGE2 stimulate 
inositol lipid metabolism (Macphee _et al.. , 1984), it seemed 
possible that the prostaglandins might be intermediatory 
in the eFFect oF PDGF on inositol lipid metabolism. The 
results in Section 3.1, clearly show that PGF2a causes an 
increase in the turnover oF the inositol lipid cycle. Also,
- 80 -
studies in a number of tissues including blood platelets 
(Seiss erb al • , 1 9 8 3 ) have revealed the involvement of cyclo- 
oxygenase products in the action of primary agonists that 
can stimulate inositol lipid metabolism. A number of possible 
mechanisms of action of PDGF are shown in Figure &  and 
discussed in Section 1»3* In Section 3»3> the effects of 
serum and PDGF on Swiss 3T3 cells were investigated. But 
first, the possible involvement of the prostaglandins in 
the action of PDGF was studied. To do this* it was necessary 
to be able to block their synthesis by inhibiting the cyclo- 
oxygenase enzyme (see Section 1.1.6).
Two cyclooxygenase inhibitors were chosen. Flurbiprofen 
(Figure 1 6 ) is a water soluble compound which is reported 
to be more potent in inhibiting cyclooxygenase than the other 
cyclooxygenase inhibitor used, indomethacin (Brodgen ejfc al. , 
1979 and Figure 16).
3.2.1 The effects of flurbiprofen and indomethacin on inositol 
lipid metabolism in Swiss 3T3 cells
In the first set of experiments, cells were labelled 
with 40 jiCi [3H] -glycerol/dish and incubated for 5 min with 
30 p,M AA, 20 ]iM flurbiprofen or 1.6 p,M PGF^. Some cells 
were first incubated with flurbiprofen for 5 min followed 
by 3 min incubation with AA. From the data presented in 
Figure 17, it is clear that 30 p,M AA can elicit a rise in 
PtdA levels. However, rather surprisingly flurbiprofen alone 
caused an even greater increase in cellular PtdA levels.
In cells given a 3 min pre—incubation with flurbiprofen, 
before addition of AA, there was an increase in PtdA levels
h3c
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Figure l6i The chemical structure of indomethacin» 
Flurbiprofen and BW755C.
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H
Figure 1 7 : The effect of Flurbiprofen on -PtdA
levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 4-0 p,Ci 
C^HU -glycerol/dish. Drug incubations were for 
5 min. In the case of samples receiving both 
20 p-M flurbiprofen and 30 p,M AA> the cells 
received the flurbiprofen for 5 min. before 
the AA. The data shown are from a representative 
experiment conducted in triplicate and repeated 
twice.
- 81 -
similar increase in PtdA levels to that recorded with 
flurbiprofen on its own. PGF^  used as a positive control 
in this experiment, gave a similar increase in PtdA levels 
to that recorded with flurbiprofen. There was no significant 
change in the levels of the other phospholipids measured, 
(Ptdlns, PtdS, PtdCho, PtdE), for any of the above agonists 
(data not shown).
Obviously, the question arose as to why flurbiprofen 
itself caused this marked increase in cellular PtdA content 
and it seemed important to investigate this phenomenon 
further. It was proposed that the effects of flurbiprofen 
and indomethacin on inositol lipid metabolism and on AA 
release from 3T3 cells should be studied.
However, before these experiments could be conducted, 
it was necessary to know the concentration of flurbiprofen 
required to give its maximum effect, and whether this was 
still within the range in which the drug could be envisaged 
to be acting specifically as a cyclooxygenase inhibitor 
(up to approximately 300 jiM, MacIntyre, D.E., personal commun. ).
The data in Figure 18 show the effect of increasing
O _
concentrations of flurbiprofen on £ Hj —InsP levels. It 
can be seen from this graph that an increase in InsP 
resulted from the addition of 3 flurbiprofen and that 
InsP levels rose in a dose—related manner to reach a maximum 
between 10 and 100 p,M flurbiprofen.
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Figure 18: The effect of increasing concentrations of* 
Flurbiprofen on C Hi -InsP levels in Swiss 
3T3 cells.
Cells were labelled to equilibrium with 5 P>Ci 
-inositol/well. Samples were incubated 
for 10 min. with flurbiprofen. For experimental 
details see Methods section. The data shown is 
from a representative experiment conducted in 
triplicate and replicated once.
3-2.1.1 The effects of cyclooxygenase inhibitors on the 
release of J 2 a i  -AA-derived radioactivity and on 
C3H] -arachidonyl PtdA formation in Swiss 3T3 cells
It was expected that flurbiprofen would prevent the 
metabolism of AA to more polar products. Although in the 
event that 3T3 cells contained significant levels of lipoxy­
genase enzymes it was considered possible that AA might be 
redirected towards this pathway (Figure k, and Hamberg, 1 9 7 6 ). 
Thus, in cells labelled to equilibrium with 0.5 )i.Ci -
AA/di sh or well, measurements of the release of C3h] -AA- 
derived radioactivity into the bathing medium and L3h]- 
arachidonyl PtdA formation in cells were carried out.
Concentrations of flurbiprofen which stimulate the 
inositol lipid cycle in Swiss 3T3 cells also enhance the
o
accumulation of radioactivity in the medium oT [ h] -AA- 
labelled cells. Table 6 shows that treatment with 100 p,M 
flurbiprofen led almost to a doubling in the accumulation 
of [ 3H]-AA in the medium and this increase was accompanied 
by the formation of £ 3hJ -arachidonyl PtdA. Similar results 
were found with indomethacin, and these are shown in Table 7«
When the time course of these effects was investigated 
(Figure 19), it was clear that with 30 pM flurbiprofen, £ 3h] " 
AA-derived radioactivity in the medium increased within 10 min 
and continued increasing, albeit at a markedly reduced rate, 
between 10 and kO min. The accumulation of £ 3h] -arachidonyl 
PtdA in response to 30 ]iM flurbiprofen (Figure 20) peaked at 
10 min and then fell back reaching basal levels within 2 5 -^ 0  
min.
Agent [^H]-arachidonate 
in the medium (cpm/well)
[3H]-arachidonyl Pfcd^  
(cpm/well)
Control 405 ± 32 4412 ±375
Flurbiprofen (10pM) 604 ± 27 5984 ± 242
Flurbiprofen (100pM) 788 ± 48 7931 ±250
PGF^1 pM) 625 ±49 8869 ± 328
(± S.E.M., n = 5)
Table 6: The effect of flurbiprofen on L3h 1 -AA release 
and on -arachidonyl PtdA levels In Swiss
3T3 cells
Cells were labelled to equilibrium with 0.5 
[3h] -AA/well. Drug incubations were for 10 min. 
For experimental details see Methods section.
The above data is from 2 experiments, one conducted 
in duplicate, one in triplicate.
Agent
£ Hj -AA-derived 
radioactivity in 
the medium (c.p.m/ 
well)
£ h ]] -arachidonyl 
PtdA (c.p.m./ 
well)
EtOH
(control)
Indomethacin (0.1 p,M) 
Indome thacin (l jiM)
819 - 21
1073 - 63 
1146 ± 78
2280 ± 37
2634 - 159  
3411 i 140
!
Table 7 i The effect of indomethacin on L Hjj -AA-derived „ 
radioactivity released into the medium and on L H 
arachidonyl PtdA formation in Swiss 3T3 cells
Cells were labelled to equilibrium with 0.5 v-Ci/ 
well -AA. Samples were incubated for 10 min
with indomethacin. For experimental details see 
Methods Section.
The above data are from two experiments, both 
conducted in triplicate.
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19 i The time course of the effect of Flurbiprofen 
on -arachidonate-derived radioactivity
in the medium surrounding Swiss 3T3 cells
Cells were labelled to equilibrium with 0.5 uCi 
[3h ] -AA/well> and incubated with 30 p.M 
flurbiprofen. The volume of medium per sample 
was 2 ml. The above data are from a representative 
experiment conducted in triplicate and repeated 
once.
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Figure 20: The time course of the effect of flurbiprofen
on C^Hl -arachidonyl PtdA levels in Swiss 3T3 
cells.
Cells were labelled to equilibrium with 0.5 p.Ci 
[pH-] -AA/well> and incubated with 30 p,M 
flurbiprofen. The volume of medium per sample 
was 2 ml. The above data are from a representative 
experiment conducted in triplicate and repeated 
once.
It is evident from these data that the formation of 
arachidonyl PtdA and, to a lesser extent, the release of 
AA, stimulated by flurbiprofen, is relatively short lived.
The reason for this is unclear, although it is possible 
that since phospholipase A^ can be inhibited by unsaturated 
fatty acids (Ballou and Cheung, 1 9 8 3)? a negative feedback 
loop may be operating.
3*2.2 The effects of BW755C, a lipoxygenase inhibitor, on 
inositol lipid metabolism in Swiss 3T3 cells
The relatively low concentrations of both flurbiprofen 
and indomethacin that elicit the changes in AA metabolism 
and inositol lipid metabolism, make it likely that these 
represent specific drug effects on the cellular cyclooxygenase 
It seemed possible, however, that the stimulatory effects of 
flurbiprofen and indomethacin on inositol lipid metabolism 
might be due to a redirection of endogenous arachidonic 
acid (AA)away from cyclooxygenase products and into the 
lipoxygenase pathway. This occurs in a number of tissues 
such as smooth muscle, when a cyclooxygenas e inhibitor is 
applied (Hamberg, 1976). In this event a leukotriene or 
other lipoxygenase product might be the agent which ultimately 
stimulates the inositol lipid cycle in 3T3 cells.
To investigate this possibility, the effects of the 
water-soluble compound BW 755C (3-amino-l- m-(trifluoromethyl) 
phenyl —2—pyrazoline) were investigated. This drug blocks 
both cyclooxygenase and the 3“ > 12— and 1 5—lipoxygenase 
enzymes (Needleman et al., 1 9 8 6) (Figure 16).
Table 8 shows the effects of 1, 10 and 100 \lM BW755C 
on InsP levels. Although not shown here, the concentration 
which gave the maximum response was about 100 p,M (in other 
experiments 300 p.M BW755C did not cause a significantly 
greater increase in InsP levels than 100 p,M).
3•2.2.1 The effects of BW755C on the release of —AA—
derived radioactivity and on j2sl -arachidonyl 
PtdA formation in Swiss 3T3 cells
From the data shown in Figure 21, it is clear that the 
concentration of BW755C which gave the maximum increase in 
InsP levels (100 p,M), also gave the maximum increase in the
__ o
release of Lj h ]  -AA-derived radioactivity into the bathing 
medium. This dose-response relationship is parallelled 
in Figure 22 which shows the effect of increasing concentrations 
of BW755C on -arachidonyl PtdA formation.
Thus, the results of these experiments render it unlikely 
that a stimulatory lipoxygenase metabolite is involved in 
the effect on inositol lipid metabolism mediated by the 
cyclooxygenase blockers. Also, there are no published results 
indicating that lipoxygenase activity has been detected in
Swiss 3T3 cells.
Further support for this derives from experiments in 
which the radioactivity release into the bathing medium was 
analysed by thin-layer chromatography (see Methods). More 
than 95% of the radioactivity co-migrated with standard AA 
whether flurbiprofen was present or not (Figure 23) • It 
is noteworthy from this figure that resting 3T3 cells 
appear to contain very little prostaglandins.
BW755C p.M -InsP c.p.m./well
0 17^ - 15
1 202 ± 8
10 2 3 6 .2 - 12
100 279.3 - 17
Table 8: The effect of BW75 5C on C^h U -InsP formation
in Swiss 3T3 cells
Cells were labelled to equilibrium with. 5 P-Ci/ 
well C^bQ  -inositol. Samples were incubated 
for 10 min with BW 755C* The data shown are 
from two experiments, each conducted in triplicate. 
The maximum increase in Q^Hj[ -InsP was observed 
with 100 p.M BW755C. 300 y.M BW755C did not
significantly increase the level of C EQ -InsP 
above that recorded with 100 BW755C (data 
not shown).
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Figure 21: The effect of increasing concentrations of
BW75 5C on f-^ H] -AA release from Swiss 3T3 cells.
Cells were labelled to equilibrium with 0.5 p.Ci 
C^H] -AA/well. For experimental details, see 
Methods section. Samples were incubated For 
10 min. with BW755C. The data shown are from 
a representative experiment conducted in 
triplicate and repeated once.
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The effect of increasing concentrations of 
BW7 55C on -arachidonyl PtdA levels in
Swiss 3T3 cells.
Cells were labelled to equilibrium with 0.5 p.Ci 
-AA/well. For experimental details, see 
Methods section. Samples were incubated for 
10 min. with BW755C. The data shown are from 
a representative experiment conducted in 
triplicate and repeated once.
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Figure 23: The effect of flurbiprofen on AA> 6 keto PGF^
and PGE^ content in Swiss 3T3 cells a
Cells were labelled to equilibrium with 0.5 P*Ci 
P hI -AA/dish (6 ml). Samples were incubated for 
10 min with 100 iiM flurbiprofen. For experimental 
details see Methods section. The data shown are 
from a representative experiment carried out in 
triplicate and repeated once.
However, on a cautionary note, it may be that BW755C 
is not specific enough for all the lipoxygenases and that 
an "Uncharacterised" stimulatory lipoxygenase metabolite 
is still formed in the presence of BW755C. This might, in 
addition, escape detection in the TLC analysis; some hydroxy— 
acids, for example, co-migrate with AA in this separation 
(MacIntyre, D.E., unpublished results).
3*2.3 The effects of arachidonic acid on inositol lipid 
metabolism in Swiss 3T3 cells
The results from the experiments using BW755C and, 
indeed, from the flurbiprofen studies suggested that changes 
in the content of arachidonic acid (AA), itself, might be 
the possible cause of the increase in inositol lipid metabolism. 
In Figure 2k, the graph shows the effect of increasing 
concentrations of AA on InsP levels, 100 -AA gave the 
maximum effect of about twice the control levels of InsP, 
although the graph does not show an extension of the dose— 
response curve (in other experiments 300 p,M AA, shown in 
Figure 25> gave a similar increase in InsP as 100 p,M AA).
3*2.3.1 The effects of analogues of arachidonic acid on 
inositol lipid metabolism in Swiss 3T3 cells
In an attempt to show if any structure activity relation­
ships for AA existed, analogues of AA were compared with AA 
itself. In particular, it was important to determine 
whether fatty acids which are not subject to metabolism to 
more polar metabolites e.g. prostaglandins and leukotnenes, 
were also active in stimulating inositol lipid metabolism m  
3T3 cells.
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Figure 24; The effect of increasing concentrations of AA on 
[^Hl -InsP levels in Swiss 3T3 cells'
Cells were labelled to equilibrium with 5 l^ Ci 
[3h ] -inositol/dish (6 ml). Li -containing 
BSS was used, as in previous experiments. No 
cyclooxygenase or lipoxygenase blockers were 
present in this, a representative experiment 
conducted in triplicate and repeated once.
Additions
Control
EtOH control
30jliM arachidonic 
acid
100jjM arachidonic 
acid
300jjM arachidonic 
acid
Di-homo-Y-1inolenic 
acid 1 OOjjM
Linoleic acid 10OjjM
P G F2 oc 1,6pM
[ H] - ins.P (c.p.m.)
0 100 200 300 400 500
 1----------- 1-----------1 L 1
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Fjgure 25: The effect of AA and its analogues on C3Hl -
InsP levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 p,Ci [3H]- 
inositol/dish (6 ml). No cyclooxygenase or 
lipoxygenase blockers were present in these 
experiments. Drug incubations were lor 10 min.
For experimental details see Methods section.
The data shown are From an experiment conducted 
in triplicate and repeated once.
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Di— homo-y -linolenic acid* from which, the prostaglandin 1 
series is derived and linoleic acid? which is the precursor 
of AA were the only analogues? tested? to have activity 
(Figure 2 5 )•
Eicosapentaenoic acid? from which the prostaglandin 3 
series is derived and eicosatrienoic acid? which is a man 
made (unnatural) Fatty acid had no activity. Not surprisingly? 
the two analogues of AA which were active are the closest 
in structure to AA itself. However? as we can see from 
Figure 25 they are not as potent as AA itself.
3*2.4 The effects of drugs which alter PLA^ activity in 
Swiss 3T3 cells
Phospholipase A^ (PLA^) is the collective name given to 
a group of enzymes which hydrolyse membrane phospholipids 
to yield arachidonic acid (see Section 1.1.6). If the 
level of intra- or extra-cellular free AA is an important 
factor in the control of inositol lipid metabolism in 3T3 
cells? other agents? which regulate the availability of the 
fatty acid should be able to influence PtdA formation.
Indeed? the best explanation of the data presented so far 
in this section is that the recruitment of basal PLA2 or 
DG lipase (see Section 1.1.6) activity by cyclooxygenase 
inhibitors leads to the accumulation of AA.
So? with this in mind? studies using drugs which inhibit 
of stimulate VTuA.^  were carried out and the effects of these 
drugs on inositol lipid metabolism was monitored.
3*2.4.1 The effect of melittin on the release of P h J - 
AA—derived radioactivity and j2«1 —arachidonyl
PtdA formation in Swiss 3T3 cells 
Melittin is a PLA^ activator? derived from wasp venom 
(Argiolas and Pisano? 1 9 8 3 ). It has been shown to increase? 
several fold? the activity of the Na+ — K+ pump in quiescent 
Swiss 3T3 cells. Like other growth factors? melittin 
increases the activity of the pump by increasing Na+ entry 
into the cell. In contrast? other early responses are not 
elicited by the toxin. At concentrations that promote ion 
fluxes? melittin stimulates DNA synthesis in quiescent mouse 
cells acting synergistically with insulin? EGF and with FDGF. 
In contrast? melittin does not interact synergistically with 
either phorbol esters or vasopressin (Rozengurt et a l .? 1981c) 
The data in Table 9 show that a 10 min incubation with 
0.2 pg/ml and 1.0 pg/ml melittin stimulates both AA release 
and arachidonyl PtdA formation in 3T3 cells. These 
concentrations of melittin do not lead to cell lysis? as 
judged by the ability of melittin-treated cells to exclude 
trypan blue (data not shown).
3.2.4.2 The effect of dexamethasone on flurbiprofen- and 
BW 755C-stimulated Swiss 3T3 cells
The anti-inflammatory glucocorticoid? dexamethasone?
was used in some studies to inhibit PLA^ indirectly.
Dexamethasone is thought to act by increasing the synthesis
of Tipocortin? a protein inhibitor of PLAg (see Bection 1.1.6),
Agent [^Hj-arachidonate 
in the medium (cpm/well)
[^H]-arachidonyl PtdA 
(cpm/well)
Control 414+11 1380± 187
Melittin (0.2pg/ml) 640 ± 49 4572 ± 643
Melittin (1.0pg/ml) 1307 + 195 6480± 577
(10 min incubation: means ± S.E.M., n= 4)
Tabl e 9 1 The effect of melittin on r3ni -AA release and on 
PhT -arachidonyl PtdA levels in Swiss 3T3 cells
Cells were labelled to equilibrium with 0*5 p.Ci 
C Hi -AA/well (2 ml). Samples were incubated with 
melittin for 10 min. For experimental details see 
Methods section. The data is From 2 experiments? 
each conducted in duplicate.
Firstly? the effect of dexamethasone on flurbiprofen- 
stimulated 3T3 cells was investigated* The cells were pre­
treated with 30 nM dexamethasone for 24 hours prior to the 
experiment (Figure 2 6 ). The results clearly show that 
dexamethasone abolishes the increase in InsP formation 
observed in the presence of flurbiprofen.
It must be pointed out here? that the results obtained 
in experiments with dexamethasone were variable? although 
not in respect of the dexamethasone itself. In 2 out of 5 
experiments no significant difference in InsP levels from 
controls was noted in response to flurbiprofen? and therefore 
dexamethasone had no response to abolish. The variability 
of 3T3 cells to respond to flurbiprofen (and to BW735C) is 
discussed in Section 4. However? in the majority of experiments 
the effect of dexamethasone could be seen clearly.
A further example of this is illustrated in Figure 27 > 
where the effect of cell pre-treatment with various 
concentrations of dexamethasone on BW755C-stimulated cells 
can be seen. As in the previous series of experiments? the 
3T3 cells were pre-treated with dexamethasone for 24 hours.
The cells were then stimulated with a saturating concentration 
of BW733C (100 pM). The graph shows that a concentration 
of dexamethasone as low as 0.1 hM significantly reduced 
(but did not abolish) the increase in InsP observed in the 
presence of BW733C. Concentrations of dexamethasone of 10 nM 
and above? clearly abolished the increase in cellular InsP 
observed in the presence of BW735^«
[^H]-InsP (cpm/well x 10
0 3 11
Control
Flurbiprofen 
(1OOpM)
Control
Flurbiprofen
(100jjM)
Plus
dexamethasone (30nM) 24hr previously
Figure 2 6 : The effect of dexamethasone on the flurbi pro Fen-
induced rise in il^ H3 -InsP levels in Swiss 3T3 cells.
O
Cells were labelled to equilibrium with 5 P-Ci CXI- 
inositol/well. Half the samples received 30 nM 
dexamethasone 2k hours prior to the experiment.
The control samples received an equal volume of 
ethanol. Samples were incubated with flurbiprofen 
(or 0.9% (w/v) saline) for 10 min. The data shown 
are from a representative experiment carried out 
in triplicate and replicated three times (see Text). 
In two other experiments flurbiprofen had no 
effect on InsP levels.
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Figure 27: The effect of increasing concentrations of* 
dexamethasone on the BW755C-induced rise in P h U- 
InsP levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 p,Ci C^h] 
inositol/well» and were treated with various 
concentrations of dexamethasone Zh hr prior to 
the experiment (control samples received ethanol 
vehicle). Samples were incubated for 10 min with 
100 ]iM BW755C. The above data are from a 
representative experiment and repeated once.
3*2.5 Studies using albumin-free balanced salt solution
Despite the evidence linking the presence of endogenous 
free AA with stimulated inositol lipid metabolism only rather 
unphysiologically high concentrations of exogenous AA (and 
other unsaturated fatty acids) stimulated InsP formation in 
3T3 cells in full (albumin-containing) balanced salt solution 
(BSS). Similar data have recently been reported for a number 
of other systems? including blood platelets and placental 
cells (Hashimoto et al., 1 9 8 5 ; Zeitler and Handwerger? 1 9 8 5 )* 
However AA is known to bind to albumin avidly (Hoak et al. , 
1 9 6 7 ) and it may be that the high levels of AA required to 
increase InsP formation in 3T3 cells are necessary because 
of its presence in the incubation mix at 0.1$ (w/v).
3 .2.3.1 The effects of AA in albumin-free BSS
In view of this, experiments were carried out to compare 
the effects of AA in 3T3 cells bathed in BSS containing 0.1% 
(w/v) BSA (bovine serum albumin), BSS containing 0.1% (w/v) 
fatty acid free BSA and BSS containing no albumin at all •
The results (Figure 28) quite clearly show that a 
concentration as low as 0.1 pM AA gives a significantly 
greater increase in InsP levels where there is no albumin 
present in the bathing medium than where either albumin or 
fatty acid-free albumin is present. It is also noteworthy 
that where albumin is present, a concentration of 100 p,M AA 
is necessary to yield a similar rise in InsP, to that seen 
with 0.1 p.M AA, where there is no albumin present. Thus, in
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Figure 28: The effect of increasing concentrations of AA 
on -InsP levels in albumin-free Vs. albumin-
present conditions? in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5p-Ci 
C3h3 -inositol/well. Samples were either washed 
and left in albumin-free BSS> fatty acid free- 
albumin-containing BSS (0.1% (w/v)) or normal 
albumin-containing BSS (O'. 1% (w/v)). As in 
previous experiments 10 mM LiCl was used to 
amplify responses. Samples were then incubated 
for 10 min with various concentrations of AA.
For other experimental details see Methods section. 
The above data are from a representative experiment 
carried out in triplicate and replicated once.
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Figure 29: The effect of increasing concentrations of BW755C
and indomethacin on f^H] -AA release from Swiss 
3T3 cells in the presence and absence of albumin*
Cells were labelled to equilibrium with 0,3 >iCi 
-AA/well. Half the samples were treated 
throughout the experiments with albumin-free BSS, 
while the other half were treated with (fatty acid 
free) albumin-containing BSS (0.1 fo (w/v)). Drug 
incubations were for 10 min.
(a) The data shown are from one experiment carried 
out in triplicate with BW755C.
(b) The data shown are from one experiment carried 
out in triplicate with indomethacin.
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Figure 30: The effect of increasing concentrations of BW755C 
and indomethacin on c m  -arachidonyl PtdA levels 
in Swiss 3T3 cells in the presence or absence of 
albumin.
Cells were labelled to equilibrium with 0.5 pCi 
£ -AA/well. Half the samples were treated 
throughout the experiments with albumin-free BSS> 
while the other half were treated with (fatty acid 
free) albumin-containing BSS (0.1% (w/v)). Drug 
incubations were for 10 min.
(a) The data shown are from one experiment carried 
out in triplicate with BW755C.
(b) The data shown are from one experiment carried 
out in triplicate with indomethacin.
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In the case of indomethacin * al so, the higher values for 
AA release are seen for cells surrounded by normal BSS 
(Figure 29b). However, here the effects of indomethacin are 
complicated by its ethanol vehicle* It is evident from 
Figure 29b that ethanol on its own causes a significantly 
greater increase in the release of AA than 0*9^ saline (control) 
Thus , it is not possible to conclude here? that removal of 
albumin from the bathing medium leads to the changes in AA 
release observed.
The corresponding data for C3 H] -arachidonyl PtdA 
formation is shown in Figure 30 (a+b). It can be seen, here, 
that higher levels of arachidonyl PtdA formation, stimulated 
by both J3W755C and indomethacin, are obtained from cells 
bathed in albumin—free BSS. However, again the effects of 
indomethacin are complicated by its ethanol control.
The results suggest that, as discussed above, the 
albumin binds AA outside the cell and prevents it from further 
interaction, either on the cell surface or within the cell.
The absence of albumin allows a greater concentration of free 
AA, released into the bathing medium, to further interact 
on or within the cells, and thus leads to a greater increase 
in arachidonyl PtdA formation.
It is noteworthy, the degree of similarity between the 
graph shown in Figure 28 compared to that shown in Figure 30a.
In Figure 28 the effect of increasing concentrations of 
exogenous AA on InsP levels in cells bathed in normal and 
albumin-free BSS, is illustrated. It can be seen that
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increasing the concentration of BW7 3 5C yields increases 
in arachidonyl PtdA, i.e. increases in inositol lipid 
metabolism, which parallel those seen in Figure 2 8 , due to 
increasing the exogenous concentration of AA. This might 
further suggest that the effects of BW755C, flurbiprofen 
and indomethacin on inositol lipid metabolism, are mediated 
by an accumulation of endogenous AA.
3* 2.3-3 The effects of AA in combination with cyclooxygenase 
or lipoxygenase inhibitors in albumin-free BSS
If flurbiprofen, indomethacin and BV753C, stimulate 
the inositol lipid cycle by increasing the level of endogenous 
free AA, in 3T3 cells, then their effects on InsP would not 
be expected to be additive with exogenously applied AA.
The data in Figure 31 show that this is indeed the case.
There is no significant difference between InsP levels 
recorded in response to a submaximal concentration of AA 
(10 pM) and that recorded in response to a  combination of 
BW733C (100 pM) and AA (10 pM) or of flurbiprofen (lOO pM) 
and AA (10 pM ) •
3 . 3  The effects of serum and PDGF on inositol lipid metabolism 
in Swiss 3T3 cells
The results from Section 3.2 suggested that arachidonic 
acid could potentially play a role in the mechanism whereby 
PDGF leads to the activation of inositol lipid metabolism. 
Indeed, it is known that PDGF can cause an increase in AA 
release (Shier & Trotter, I9 8O). However, the problem 
lies in proving the extent to which the effects of PDGF
Control 
Ethanol con.
IOOmH BW755C 
lOOpM flurbiprofen
10pM arachldonic acid 
BW755C + A.A. 
Flurbiprofen + A.A.
BW755C + flurbiprofen
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Figure 31: The effect of AA bn cornbinarion with B¥755C 
or flurbiprofen on £3h3 -InsP levels in Swiss 
3T3 cells in the absence of album!n.
Cells were labelled, to equilibrium with 3 pCi 
C3h 3 -inositol/well. The BSS contained 10 mM 
LiCl and no albumin. Samples were incubated 
Tor 13 min with the above drugs, except where 
combinations of drugs were added. In this case 
samples received 3 min. incubation with the c.o./ 
l.o. inhibitor before addition of AA (for a 
further 10 min). In BW735C + flurbiprofen 
samples, the BW735C was added first for 3 min 
followed by 10 min with flurbiprofen. The data 
shown are from a representative experiment 
conducted in triplicate and repeated once.
94570723247634
- 93 -
on inositol lipid metabolism are due to stimulated AA release.
To tackle this problem, three strategies were devised. 
Firstly, in Section 3*2 it was shown that eyelooxygenase 
and lipoxygenase inhibitors caused increased inositol lipid 
metabolism and AA release. This suggested that the increase 
in AA release might be the cause of the increase in inositol 
lipid metabolism. Thus, if AA was involved in the action 
of PDGF on inositol lipid metabolism, a submaximal concentration 
of flurbiprofen or BW733C when combined with a submaximal 
concentration of PDGF, might increase its effects on inositol 
lipid metabolism in a synergistic manner.
Secondly, Murayama and Ui (1 9 8 5 ) found that they could 
selectively block the increase in AA release, in thrombin- 
stimulated 3T3 cells, with pertussin toxin, leaving the 
increase in inositol lipid metabolism unaffected. Pertussis 
toxin interacts selectively with the guanine nucleotide 
regulatory protein N_^ , that is involved in the receptor- 
mediated inhibitions of adenylate cyclase (see Section 1.1.3)»
It was therefore possible, that if a similar pertussis toxin- 
sensitive G-protein was involved in mediating the effects of 
PDGF on AA formation then its effects on inositol lipid 
metabolism might be completely abolished.
Lastly, it was also noted in Section 3*2 that the 
effects of flurbiprofen and BW733C on inositol lipid 
metabolism could be abolished, by pretreating the cells 
with dexamethasone. Thus, it might also be possible to 
inhibit, at least partially, the effects of PDGF on inositol
- 9k -
lipid metabolism by pretreating the cells with dexamethasone•
Unfortunately, it was not possible to use pure PDGF in 
the following experiments. Thus, dialysed newborn 
calf serum was used in the initial experiments, and, in the 
later experiments, the effects of highly purified PDGF, 
kindly donated by Dr Carl Heldin (see Methods), were examined.
Serum contains many growth factors and, therefore, it 
is most unlikely that the effects, observed in response to 
serum, are due entirely to PDGF• Thus, in an attempt to 
reduce this complexity, small molecular weight growth factors 
such as gastrin releasing peptide (a bombesin-like growth 
factor), PGF^ and vasopressin, were removed by dialysing 
the serum using Micropor tubing, which has a molecular weight 
cut-off of 3,500 (see Methods). This left the large molecular 
weight factors such as PDGF and EGF in the serum sample 
(Besterman e_t al. , 1 9 8 6 ).
3.3.1 A comparison between non-dialysed and dialysed serum 
in stimulating inositol lipid metabolism in Swiss 3T3 
cells
To show that the dialysis tubing was effective in removing 
small m.w. growth factors, the potency of non-dialysed serum 
in stimulating inositol lipid metabolism was compared with 
dialysed serum (Figure 32). Both batches of serum were 
from the same bottle, originally, and the non-dialysed serum 
was exposed to the same temperature conditions while dialysis 
of the second batch of serum was carried out. At all 
concentrations of serum used, the non—dialysed serum gave a 
significantly higher increase in InsP than the dialysed serum.
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Figure 32: The effect of* increasing concentrations of non-
dialysed and dialysed newborn calf serum on ~I?Hl - 
Ina P levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 p.Ci 
inositol/well. Samples were incubated with various 
concentrations of serum (non-dialysed or dialysed) 
for 10 min. For other experimental details see 
Methods section (as in previous experiments 10 mM 
LiCl was present in the BSS). The data are from 
a representative experiment conducted in triplicate 
and repeated once.
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The 3% (v/v) non-dialysed concentration showed the greatest 
difference? being equivalent to 3 0% (v/v) dialysed serum 
in its effect on InsP levels.
In the following experiments, dialysed new-born calf 
serum has been used, in order to relate the results more 
closely (although not absolutely) to those of PDGF.
3.3.1.1 The effects of dialysed serum in combination with
BW755C on inositol lipid metabolism in Swiss 3T3 cells
From the previous experiments, it was clear that the 
largest increase in InsP levels was recorded with 30% (v/v) 
non-dialysed serum and a greater concentration of dialysed 
serum would presumably have been necessary to obtain this 
maximum increase in InsP levels. Now, if we are to believe 
that the release of free AA contributes to the action of 
PDGF on inositol lipid metabolism, then the effects of sub­
maximal concentrations of serum might be increased by using 
drugs which increase the availability of AA. Unfortunately, 
these experiments, in which serum is combined with BW755C 
are complicated by the probable binding of AA to albumin 
and other proteins present in the serum.
In the experiment shown in Figure 33> the effects of 
increasing concentrations of BW755C combined with two sub­
maximal concentrations of dialysed serum were examined.
Dealing firstly with the 1.5% (v/v) concentration of dialysed 
serum (D.S.), it appears that submaximal concentrations of 
BW755C are not synergistic with the 1.5% (v/v) D.S., with 
regard to levels of InsP. However, at higher concentrations
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Figure 33: The effect of combining various concentrations 
of BW7 5 5C with two submaximal concentrations of 
dialysed serum on [J>Hi -InsP levels in Swiss 3T3 
cells.
Cells were labelled to equilibrium with 5 p,Ci 
-inositol/well. Samples received 5 min. 
incubations with various concentrations of BW755C 
prior to a further 10 min incubation with 5%
(v/v) or 1 •5% (v/v ) dialvsed serum. For other 
experimental details see Methods section. The 
above data are from a representative experiment 
conducted in triplicate and repeated once.
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of BW755C there appears to be a parallel rise in InsP in 
both the BW735C samples and the samples where f. 3$ (y/v)
D*S* is combined with BW735C. This effect is difflenit bp 
explain and will be covered in more detail in Section 4#
Ihe results for 5^ (v/v) B*S. in combination with 
BW755C are somewhat different * Again* low concent rations of 
BW755C are not synergistic with the h. S i n  incr easing InsP 
fonffitioii) but concentrations of BF733C above 1 pH are 
additive with the serum. A synergistic effect results* when 
100 pH BW755C is combined with ftfo  (v/v) f..'S.. "That is* the 
increase in InsP is significantly higher than If (v/v) D. S• 
on its own or than the projected additive value of '^ '2 -k  
well —InsP.
3-3*l*2 Ihe effects of dialysed serum in combination .with
B¥755C* on E3B- — AA release and on tP $ l_  arachidonyl
PtdA formation
If the synergy between D. S. and BW7j5j5C i® to be believed > 
then it should also be observed when the release of .AA and 
format! on of arachidonyl PtdA are measured..
Ihe results observed for AA release in response to D.S. 
and BW753C are shown in Figure 3-4.. i.f-% (v/v) D-S*. appears
to he slightly inhibited when combined with a  low 'concentration 
©f BW755C (l pM) However* unlike the results for InsP 
formation* low concentrations of (l JIM) significantly
inhibit the increase in AA release in response to (v/v)
B-S- 'Concentrations of obove 1 pM are additive wi th
(v/v) DAb. Also^ here* no synergy was an*^renf for
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Figure 34; The effect of combining various concentrations 
of* BW755C with two submaximal concentrations of* 
dialysed serum on f-^ H] -AA release in Swiss 3T3 
cells.
Cells were labelled to equilibrium with 0*5 pCi 
-AA/well• For experimental details see 
legend for Figure 33 and Methods section. The 
data shown above are from a representative 
experiment carried out in triplicate and replicated 
once.
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100 p,M BW755C and 5% (v/"v‘) D.S., although, the trend of4 the 
data might suggest that it occurs very slightly.
Turning to the data presented in Figure 3 5  we can 
examine the effects of combining BU755C and D.S. on arachidonyl 
PtdA formation. Similar results were obtained here as for 
InsP formation (Figure 33), except where 100 p,M BW735C was 
combined with 1*5 °f° (v/'v) D.S. In this case synergy was 
observed, not just additivity.
Unfortunately phospholipid extraction and analysis was 
not carried out in the first of the two experiments carried 
out here, and therefore the results shown in Figure 35 are 
based only on one experiment. Thus the experiment would have 
to be repeated, in order to show if this effect was reproducible
Thus from the above data, it appears that BW755C, 
when combined with D.S. at certain concentrations can inhibit 
the effects of D.S., can have additive effects with D.S. or 
can synergise with D.S. to increase inositol lipid metabolism,
AA release and arachidonyl PtdA formation. However, the 
interactions of the two drugs are far more complicated than 
might have been imagined. Certainly, at submaximal 
concentrations of the two agents, there is no evidence of 
the anticipated synergy that might result from the mechanism 
discussed above.
3 .3 .I . 3  The effects of combining BW755C with other agonists 
on C3Hl -InsP formation in Swiss 3T3 cells
If BW755C could increase the effects of submaximal 
concentrations.of D.S. on inositol lipid metabolism then, 
it could be argued, it might also increase the effects of
* *
o
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Figure 3 5 : The effect of combining various concentrations
of B¥755C with two submaximal concentrations of* 
dialysed serum on C-^ Hl -arachidonyl PtdA levels 
in Swiss 3T3 cells.
As legend for Figure except that the above
data are from one experiment carried out in 
triplicate (but not repeated).
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other agonists. Figure 36 shows the effects of BW753C in 
combination with vasopressin? PGF^^j bombesin and 3% (v/v ) 
D.S. on InsP formation. As in previous experiments? an 
enhancement of the effects of 3°f° (v/v ) D.S. in InsP formation 
was observed, when combined with 100 )iM BW733C. This high 
concentration of BW733C also significantly enhanced the 
effects on InsP observed with 1.6 p,M PGF^. It had no effect 
on the response to vasopressin or bombesin.
3*3*2 The effect of pertussis toxin on serum-stimulated 
responses in Swiss 3T3 cells
The second strategy incorporated to elucidate any 
involvement of AA in the action of PDGF on inositol lipid 
metabolism, was to abolish the agonist-induced increase in 
free AA formation with pertussis toxin. This idea, as 
discussed at the beginning of Section 3*3> arose from the 
findings of Murayama and Ui (1 9 8 3 )* These authors abolished 
the rise in AA release from 3T3 cells, induced by thrombin, 
with pertussis toxin, but left the increase in inositol 
lipid metabolism unaffected. It was hoped that such a 
pertussis—sensitive G—protein might be involved in the effects 
which had been observed with BW733C, D.S., PGF^a or bombesin. 
If such a G-protein could be inhibited then, any effects 
on inositol lipid metabolism observed with the above agonists, 
would not be as a result of increased AA release.
Therefore, cells were incubated overnight (l8 hours) 
with 100 ng/ml pertussis toxin and then stimulated with 
various agonists for 10 min. The results (Figures 37 and 38)
Control 
1COpM BW 755C
O.IpM vasopressin 
1 .5jjM PGF2a  
0.1 pM Bombesin
5% (V/V) dialysed - 
serum
[5H]-lnsP (dpm/well x10~2)
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- BW 755C treated
Figure 3 6 : The effect of* 100 vlM BW755C on various agonist-
induced increases in -InsP levels in Swiss
3T3 cells.
Cells were labelled to equilibrium with 5P'Ci 
C3h] -inositol/well. LiCl-containing (10 mM)
BSS was used? and the samples were incubated 
for 5 min with 100 pM B W 7 p r i o r  to 10 min 
incubation with the above agonists. For other 
experimental details see Methods section. The 
data shown above are from an experiment carried 
out in triplicate and replicated once.
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serum
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□  - control
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Figure 37: The effect of pertussis toxin on agonist-
induced increases in " i ? s r  -AA release from 
Swiss 3T3 cells.
Cells were labelled to equilibrium with 0.5 P-Ci 
-AA/well. Half the samples were incubated 
for 18 hr with 100 ng/ml pertussis toxin prior 
to the experiment where 10 min drug incubations 
were carried out. For other experimental details 
see Methods section. The above data are from 
one experiment carried out in triplicate.
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Figure 38: The effect of pertussis toxin on agonist-
induced increases in -arachidonyl PtdA
levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 0.5 pCi 
-AA/well. Half the samples were incubated 
for 18 hr with 100 ng/ml pertussis toxin prior 
to the experiment where 10 min drug incubations 
were carried out. For other experimental details 
see Methods section. The above data are from 
one experiment carried out in triplicate*
did not suggest the involvement of a pertussis toxin- 
sensitive G— protein. No significant difference in AA. 
release or arachidonyl-PtdA formation was observed for 
any agonist in combination with pertussis toxin compared 
to the agonist on its own. These findings would therefore 
disagree with those of Murayama and Ui (1 9 8 5 ). The pertussis 
toxin used in this experiment was kindly donated by Dr G. 
Milligan from a batch which? from his own experiments? was 
known to be active.
3*3*3 The effects of dexamethasone in combination with serum
and PDGF on inositol lipid metabolism in Swiss 3T3 cells
Having failed to abolish agonist-induced AA release from 
3T3 cells with pertussis toxin? an attempt was made to do 
this by a different method. In Section 3*2 it was seen 
that dexamethasone can abolish? in a dose-related manner? 
the effects of flurbiprofen and BW7 5 5C o*1 inositol lipid 
metabolism. Dexamethasone is thought to act by indirectly 
inhibiting PLA2 (via lipocortin) and thus prevent the 
formation of AA due to this enzyme (or group of enzymes).
In Sections 3*3*1*2 and 3*3*1*3 the results suggested 
that combining a high concentration of BW7 5 5C with 5^ (v/v ) 
D.S. (a submaximal concentration of D.S.) enhances the 
increase in inositol lipid metabolism observed for serum 
on its own. Thus? dexamethasone might reduce the effect 
of serum on inositol lipid metabolism? if the theory is 
correct.
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3*3*3*1 The effect of dexamethasone in combination with
serum on C^h I -InsP formation
The data in Figure 39 show that, as in previous experiments,
0*1 p,M dexamethasone abolishes the increase in InsP observed
with 100 p,M BW755C. Unfortunately, no significant reduction
in the effects of 5% (v/v ) U.S. or 10^ (v/v) D.S. was observed
with dexamethasone.
Dexamethasone did, however, reduce the effect of PGF_2a
on inositol lipid metabolism, although it did not abolish it.
Previously, it was noted, in Section that the
combination of BW755C with PGF^a enhanced the increase in
InsP observed for PGF^, on its own. In combination these2a
two pieces of evidence suggest that the effects of P G F ^  
on inositol lipid metabolism in Swiss 3T3 cells, might be 
due, in part, to positive feedback on PLA^.
Bombesin remained unaffected by combination with 
dexamethasone, which would agree with the data shown in 
Section 3*3«T.4.
3 .3 .3 .2 The effect of dexamethasone in combination with
serum on C3h1 -AA release and on L^ Hjf -arachidonyl
PtdA formation
The same general pattern of results seen in Section 3 .3 .3 .I 
appears when the effects of the agonists on AA release are 
examined, when they are combined with dexamethasone (0.1 p,M).
Figure kO shows the increase in AA recorded with BV755C 
is abolished in the presence of dexamethasone. Also dexa­
methasone does not significantly reduce AA release in
[5 H ] - I n s P  ( d p m / w e l l  x 1 0 - 2 )
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Figure 3 9 : The effect of dexamethasone on agonist-
induced rises in -InsP levels in
Swiss 3 T 3  cells.
Cells were labelled to equilibrium with 5 "H-Ci 
-inositol/well. Half the samples were 
incubated with 0.1 pM dexamethasone for 2k hr 
prior to the experiment. 10 mM LiCl-containing 
BSS was used throughout the experiment and 
drug incubations were for 10 min. The above 
data are from a representative experiment 
carried out in triplicate and repeated once.
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Figure k O j The effect of dexamethasone on agonist-induced 
rises in -AA release From Swiss 3T3 cells.
Cells were labelled to equilibrium with 0.5 pCi 
-AA/well. Half the samples were incubated 
with O.l pM dexamethasone for 2k hr prior to the 
experiment (control samples received an equal 
volume of ethanol vehicle). Drug incubations 
were for 10 min. The data shown above are from 
a representative experiment conducted in triplicate 
and replicated once.
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response to D.S. (5$ (v/v) or 10% (v/v)). AA release 
in response to P G F ^  is, as before* significantly reduced* 
but not abolished, by dexamethasone. The response to 
bombesin* once again* remained unaffected by dexamethasone 
treatment•
The effects of the agonists combined with dexamethasone 
on arachidonyl PtdA formation (Figure -^l) are* for the most 
part, similar to those seen for InsP levels and AA release. 
The one exception is that in one of two experiments 
dexamethasone significantly reduced the effect of 10% (v/v) 
D.S. on arachidonyl PtdA formation. However, this was not 
observed in the second experiment and so it was not possible 
to reach a firm conclusion on any effect of dexamethasone 
on InsP formation, AA release or arachidonyl PtdA formation 
in response to D.S.
It was disappointing to find no significant reduction 
of the above serum-stimulated responses with dexamethasone. 
However* as we saw in Section 3»3•!> combining D.S. with 
other drugs can lead to far more complicated results than 
anticipated. The responses observed with D.S. may be due, 
in part, to other unidentified growth factors. Thus, it is 
not possible to directly relate the effects of dexamethasone 
on serum to PDGF. By using the highly purified PDGF it was 
hoped to reveal if this was the case. However, before this 
could be done, it was necessary to test the activity of the 
PDGF preparation.
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Figure 4l: The effect of dexamethasone on agonist-induced
rises in CPHj -arachidonyl PtdA levels in Swiss 
3T3 cells.
Cells were labelled to equilibrium with 0.5 pCi 
Q EG -AA/well. Half the samples were incubated 
with 0.1 pM dexamethasone for 2k hr prior to the 
experiment (control samples received an equal 
volume of ethanol vehicle). Drug incubations 
were for 10 min. The data shown above are from 
a representative experiment conducted in triplicate 
and replicated once.
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3»3«3»3 The effect of PDGF on inositol lipid metabolism 
in Swiss 3T3 cells
Figure k2 shows the effects of 1 ng/ml and 10 ng/ml 
PDGF on -InsP formation. 1 ng/ml PDGF gave a similar
increase in InsP to that observed with 1.5$ (v/v) D.S.
(an increase of approximately 67$ above basal). 10 ng/ml 
PDGF gave a 3-^ - fold increase in InsP levels above basal.
1 nM bombesin gave a similar increase in InsP levels as 
10 ng/ml PDGF and PGF2a (l.6 pM), as noted before* caused 
about a doubling in InsP levels.
3.3*3*^ The effect of dexamethasone in combination with 
PDGF on inositol lipid metabolism
Knowing, now, that the highly purified PDGF was active 
in increasing inositol lipid metabolism, an experiment to 
investigate the effect of dexamethasone (0.1 pM) on (purified) 
PDGF-stimulated responses was carried out. Unfortunately, 
due to the availability of PDGF, this experiment was carried 
out only once. However, the results appear quite clear.
The data in Figure k3 reveal the results of this 
experiment. The effect of BW755C on hJ —InsP levels, as 
before, abolished by dexamethasone. Again, dexamethasone 
significantly reduced the response seen with PGF2^» The 
most important finding of this experiment was that the increase 
in InsP levels observed in response to 10 mg/ml PDGjC was 
significantly reduced by dexamethasone (by approximately 20%).
Obviously, this experiment would have to be repeated 
before any firm conclusions could be arrived at. However, 
this experiment does suggest that AA might indeed have a 
role in mediating the action of PDGF on inositol lipid 
metabolism in Swiss 3T3 cells.
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Figure_42; The effect of PDGF on C3h 1 -InsP levels in 
Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 y.Ci 
L 3hJ -inositol/well. Samples were incubated 
with drugs for 10 min (for other experimental 
details see Methods section)* The data shown 
above is from one experiment carried out in 
triplicate.
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The effect of dexamethasone on PDGF-induced rises 
in L^ H.1 -InsP levels in Swiss 3T3 cells.
Cells were labelled to equilibrium with 5 pCi C3h] - 
inositol/well. Half the samples were pre-incubated 
for 2k hr with 0.1 pM dexamethasone (the other half 
receiving ethanol vehicle)° Drug incubations were 
for 10 min. The above data are from one experiment 
carried out in triplicate.
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4. Discussion
Enhanced inositol phospholipid metabolism in response 
to a Ca -mobilizing agonist has been demonstrated in a 
number of different cells using a variety of agonists 
(Michell, 1975> 1979; Berridge, 1980; Putney, I9 8I).
As previously mentioned, (Section 1.1.4) the fatty 
acid on the 2—position of Ptdlns (and the polyphospho­
inositides) is mainly arachidonic acid, the precursor of a 
number of important molecules, such as the prostaglandins, 
prostacyclin, thromboxanes, leukotrienes and lipoxins. How 
arachidonic acid is released and to what extent each phospho­
lipid contributes to the release has been the subject of 
many recent studies (see Irvine, 1 9 8 2, for a recent review). 
The results have been divergent, but most investigators 
believe that AA is released by deacylation of diacylglycerols, 
formed by phosphodiesterase (phospholipase C) attack on 
Ptdlns or its phosphorylated forms (Emilsson and Sundler, 
1984), or by direct deacylation of phospholipids by phospho- 
lipase(s) of the A t y p e  (Rittenhouse-Simmons, 1981; Billah 
and Lapetina, 1 9 8 2 ). However the relative importance of 
these pathways in different cells and the mechanism of 
activation are still poorly understood.
The observation that receptors which induce changes in 
inositol lipid metabolism and produce a Ca signal can 
also liberate AA, influenced Berridge (1981, 1982) to 
speculate that inositol lipid metabolism might represent 
a general transducing mechanism for generating a number of 
important intracellular signals. He noticed that activation
2+
of Ca -mobilizing receptors is almost invariably associated 
with the formation of prostaglandins and related metabolites.
Swiss 3T3 cells? utilized in this study produce prosta­
glandins (notably PGE^ and PGF^) from liberated AA. Because 
it begins very rapidly upon mitogen stimulation? release of 
AA and subsequent prostaglandin production has been suggested 
as a potential causal step in the mitogenic response 
(Ftirstenberger and Marks? 1 9 8 0). One of the released products?
J>GF2a’ ±S ±tself a potent mitogen for 3T3 cells (Jimenez de 
Asua est al. ? 1975 )•
Studies with PGF^a iu Swiss 3T3 cells? in which measure­
ments of Ptdlns and 1?2 DG were made (Macphee _et al. , 1984), 
revealed that the prostaglandin caused an increase in inositol 
lipid metabolism. This was particularly interesting in the 
light of later experiments by a number of investigators? who 
showed that PDGF stimulated the breakdown of PtdlnsP^ to 
yield InsP^? thereby stimulating the release of intracellular 
free Ca^+ (Berridge et al•? 1984; Moolenaar at al.? 1984b) 
and also had a stimulatory effect on the metabolism of AA 
(Habenicht et al.? 198l). Thus, our interest grew in 
investigating the possible role of AA and/or its metabolites 
in controlling inositol lipid metabolism in Swiss 3T3 cells 
and? in particular? whether such an action might link PDGF 
receptor activation with stimulated inositol lipid metabolism.
4.1 PGF stimulates inositol lipid metabolism in Swiss 3T3 cells 
  2a  ---------------------------------
At the outset of this study, it was known that PGF2a 
was a mitogen for 3T3 cells and that it caused increased 
inositol lipid metabolism (Macphee et al. , 198'*). However,
-  105 -
a detailed study of the effects of PGF on the individual
metabolites of the inositol phospholipid cycle? and on the
other major phospholipids of the plasma membrane was lacking.
Thus? the initial intention of the project was to carry out
such a study. In a broader sense? however? we also wished
"to investigate the role of AA and/or its metabolites in
controlling inositol lipid metabolism in Swiss 3T3 cells.
To do this? cells were labelled with —inositol
and in a series of experiments? the levels of various inositol
metabolites were measured in. response to PGF„ . It was2a
found? as in many other cell types? for example GH^ pituitary
tumour cells? that by the inclusion of 10 mM LiCl in the
balanced salt solution? the PGF0 -stimulated increase in2a
InsP levels could be amplified (Figure 6) (Hallcher and 
Sherman? 1980; Berridge et al. ? 1982; Drummond and Raeburn? 
1984)• In addition? an interesting finding from these 
experiments was that lithium did not have the same depleting 
effect on inositol levels as has been observed in certain 
other tissues? such as the adrenal gland (Sherman et al•?
1986). This would suggest that Swiss 3T3 cells may contain 
a large pool of free inositol? which is consequently 
difficult to deplete. The resistance of the cellular 
inositol levels to lithium—induced depletion differs markedly 
from GH^ cells (one of the best understood systems for this 
aspect). This raises the possibility that cellular diversity 
in respect of inositol depletion could contribute to the 
selective action of lithium on the central nervous system,
if these cells were particularly prone to depletion (Drummond,
1987).
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Also of interest? is the apparent inability of lithium 
to enhance the response to PGF^ measured as increases in 
InsP^ and InsP^ content. An explanation of* this might be 
that the enzymes that metabolize these substances? which* 
in any case* are notably less sensitive to lithium than the 
Ins-l-P ase(s)* might be working at low capacity and* therefore 
because Li+ is an uncompetetive inhibitor (Hallcher and 
Sherman* 1 9 8 0 )* be rather incompletely blocked.
HPLC analysis of the acid—soluble fractions in Swiss 
3T3 cells* did not shed any great light on the above findings. 
It did reveal* however* that the majority of InsP present is 
the 1-phosphate isomer, although a little 4-phosphate can 
be detected. The major bisphosphate isomer appears to be 
the Ins(l,4)P2 isomer; no Ins(4*5)P2 and only a trace of 
what is presumably Xns(39k)'P^ can be detected (Figure 14). 
These findings would be in agreement with Heslop erfc al. (1 9 8 6) 
who reported the presence of a second InsP^ other than 
Ins(l,4)P2. The nature of the InsP^ isomer(s) has not been 
fully clarified. Heslop _et al. (1 9 8 6) showed the presence 
of Ins(l,4,5)P^ and Ins(l,3>4)P^. Unfortunately, due to 
the small amount present in the cells and the age of the 
column used in this series of experiments we were unable 
to confirm this. If the Ins(l*3>4)P3 isomer does exist, 
then presumably Ins (l * 3 > 4* 5 ) is also produced in 3T3 
cells. Once again* as the data from the Dowex columns had 
indicated, no InsP^ was detected. Obviously, further HPLC 
analysis will be necessary to ascertain which isomer(s) 
of InsP3 are present in S w i s s  3T3 cells and to confirm
the existence of InsP^ in these cells, which has been 
found by Heslop et al. (1 9 8 6 ).
The concentration of P G F ^  required to cause the
maximum increase in inositol lipid metabolism is about 1 p,M
(Figure 7). Concentrations of PGF2a as low as 1 nM can
elicit a very small increase in inositol lipid metabolism
(Figure 7)> and this illustrates the potential importance
of this mitogen. Hammarstrom (1977) has shown that up to
7*25 ng/ml P G F ^  could be released into the surrounding
medium by 10 3T3 fibroblasts, in response to 50^ (v/v)
serum. Therefore in 2 x 10^ cells (in each multiwell)/2 ml
it can be calculated that 2 .9  ng/ml PGF could be produced.
This is equivalent to 2 - 2.5 uM P G F ^  in the surrounding
medium. Thus, the finding that a concentration of PGF 2^a
as low as 1 nM is able to elicit a small increase in 
inositol lipid metabolism, suggests that it may be 
physiologically relevant.
The time course of the effects of P G F ^  on the metabolites 
of the inositol lipid cycle (Figures 8, 9> 10> 12, 1 3 )
reveals that V G F ^  rapidly stimulates the turnover of inositol 
phospholipids. The separation of the polyphosphoinositides 
proved difficult by the method outlined by Jolles et al.
(1981), due to the presence of an undefined substance which 
had a similar R_^  value as PtdlnsP on the T.L.C. plate. This 
is most likely lyso Ptdlns, which migrates in this area.
Thus, initially, only the total polyphosphoinositide content 
was measured (i.e. PtdlnsP + PtdlnsP^, Figure 8). This 
revealed a rise in cellular polyphosphoinositide levels
within 40 seconds in response to 1.6 uM PGF . However,
2a
no initial decrease in these levels was detected, which
might have been expected by analogy with the responses of*
other cell types to hormones (e.g. GH^ cells, Macphee and
Drummond, 1984). This decrease in PtdlnsP and PtdlnsP^
occurs when hormone—stimulated hydrolysis of PtdlnsP^ is
tiated, yielding InsP^ and 1,2 DG. Breakdown of the
lipid occurs rapidly, presumably before resynthesis of*
PtdlnsP (and PtdInsP2) can occur. Using the method of
Creba _et al. (1 9 8 3) separation and measurement of the de-
deacylated polyphosphoinositides was facilitated. Lyso-
Ptdlns, in this separation, would be eluted with Gro P Ins
from the column and so would not contaminate Gro P InsP.
Examination of shorter incubation periods with PGF„
2a
(Figure 9) shows that a slight decrease in PtdlnsP and, to 
a lesser extent PtdlnsP^, does occur in the first 10 seconds
in PGF0 -stimulated 3T3 cells. Levels of both polyphospho-
2a
inositides then increase rapidly above control values to a 
maximum within 1-2 minutes of PGF2a administration* After 
this time, levels of the polyphosphoinositides begin to 
decline, but remain elevated above controls even after 20 
minutes stimulation with PGF2a»
Ptdlns levels are not significantly affected by PGF2a, 
although there is a suggestion from the data in Figure 9b 
that a decrease in Ptdlns levels occurs at the time when 
the 3T3 cell polyphosphoinositide levels begin to increase. 
This would be in agreement with the findings of Macphee and 
Drummond (1984) in GH^ cells, although m  that system,
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polyphosphoinositide levels are more clearly reduced at 
early time points.
From these results, it is no surprise that the effects 
of P G F ^  on the inositol phosphates is also very rapid 
(Figures 10, 11, 12, 13)* InsP^ levels are elevated to a 
maximum within 3 seconds of stimulation with PGF2 (Figure 
1 3 c) and begin to decline back to basal after 20—30 seconds. 
InsP2 levels do not rise quite as rapidly, reaching a 
maximum value after 20 seconds stimulation with PGF
2 a
(Figure 13b). XnsP^ levels decline very rapidly after this 
time. InsP levels reach a maximum value after 40 seconds 
stimulation with PGF2a (Figure 13a). However, levels of 
InsP, although decreasing after 2 minutes, remain elevated 
above basal values for over 20 minutes, in cells stimulated 
with PGF2a in the presence of 10 mM LiCl (Figure 10).
It is not clear whether this persistently elevated 
InsP level is sustained, as seems most likely, by a 
continual, although more modest, flux of metabolites through 
inositol phosphate metabolism, or whether it reflects 
complete inhibition, by lithium, of InsP degradation. The 
former view receives support from the fact that cellular 
PtdA levels are also persistently elevated in response to
PGF2a (Figure 13)*
The time course of InsP accumulation is compatible 
with the view that InsP is not produced directly from Ptdlns, 
but is formed by the hydrolysis of the InsP^• Nevertheless, 
it is difficult to be definitive o n  such aspects and in the 
light of c o n t r a r y  r e p o r t s  ( e . g .  I m a i  a n d  G e r s h e n g o r n ,  1 9 8 6), 
i t  might be wise t o  d i s p l a y  s o m e  d e g r e e  o f  c i r c u m s p e c t i o n .
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From Table 3, it can be seen that PGF2a (l.6 pM) 
causes a 2-3 fold increase in PtdA levels after 3 minutes 
incubation in Swiss 3T3 cells labelled with £3HJ -glycerol. 
Ptdlns, PtdS, PtdE and PtdCho levels are unaffected by PGF
2a
As in most cell types, the most abundant phospholipids 
of the plasma membrane appear to be PtdCho and PtdE. Similarly, 
the ratio of Ptdlns to PtdS is about 1:1. The ratio of 
PtdA present in resting Swiss 3T3 cells compared with Ptdlns 
is about 1:20.
It is interesting that a far greater response to PGF 2a
is seen in PtdA formation compared with InsP formation
where levels, at most, only double. Also, Macphee j|t al.
(1984) only recorded an increase above basal of about 23°fo
in 1,2 DG levels with 1.6 pM PGF_ • The differences in the2a
levels of the above metabolites in response to P G F ^  might 
be best explained by variations in the kinetics of the enzymes 
responsible for PtdA formation, compared to those involved 
in InsP and 1,2 DG formation.
The time course of the effects of PGF2a on PtdA levels 
is similar to that of InsP formation (Figure 13) PtdA 
formation in response to 1.6 pM a "*"S max-*-ma-®- "within
40 seconds. In this case, however, levels of PtdA are 
maintained above basal over the 20 minutes stimulation
period with PGF0 .2a
Thus, from these results, it would appear that PGF2^ 
in Swiss 3T3 cells, acts to stimulate the formation of the 
two second messengers of the inositol lipid cycle, namely,
InsP a n d  1,2 DG. M a c p h e e  e t  a l .  ( 1 9 8 4 )  r e c o r d e d  a n  i n c r e a s e
in 1*2 DG in Swiss 3T3 cells in response to PGF and
2a
here, it has been shown that PtdA levels rise# Morris 
ejfc al. (1984) recorded an increase in Ca2+ . after 10
i
seconds, in 3T3 cells, in response to 0.3 jiM (100 ng/ml)
PGF2a whicl1 was maximal within 60-90 seconds. The above 
results show that in response to 1.0 p,M PGF2a> InsP^ levels 
rise to a maximum within 3 seconds and therefore the kinetics 
oP ihe rise in J^ Ca could be accounted for by the increase
in InsP^ levels.
The two second messengers of the inositol lipid cycle, 
as discussed in Section 1.1.4, have been implicated in cell 
proliferation (Berridge, 1984; Berridge and Irvine, 1984). 
Thus PGF^^ can be envisaged to act as a mitogen for Swiss 
3T3 cells (Jimenez de Asua jet al. , 1981), by stimulating 
a rise in CCa2+]. via InsP^ and by activating protein kinase 
C via 1,2 DG. Protein kinase C may directly or indirectly 
enhance Na+/H+ exchange resulting in increases in cytoplasmic 
Na+ and pH (Dicker and Rozengurt, 1981; Schuldiner and 
Rozengurt, 1982; Cassel _et al. , 1983; Moolenaar et al. ,
1983; Rosoff et al., 1984).
The link between the formation of InsP^ and DG, and 
the onset of cell proliferation is not understood. However, 
it has been shown that the expression of the c—fos proto- 
oncogene (see Section 1.2) is induced within a few minutes 
after exposure of fibroblasts to either PDGF or the tumour- 
promoting phorbol ester, phorbol 12-myristate 1 3-acetate), 
which is an activator of protein kinase C (Kruijer ejfc al., 
198^; Mflller et al. , 198^; Rabin et al. , 1986).
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The two second messengers, InsP^ and DG, initiate 
a cascade of protein phosphorylation. However, only limited 
information is available on the phosphoproteins, and their 
activity, involved in this cascade and also, on those 
phosphorylated by PDGF-dependent tyrosine kinase (Cooper 
at al., 1982; Ek and Heldin, 1984; Kohno, 1 9 8 5). Therefore, 
i"fc remains unknown how the inositol lipid turnover and the 
tyrosine kinase are connected to the induction of cell 
proliferation by PDGF.
It has been shown that P G F ^  and insulin have synergistic 
effects on cell proliferation in Swiss 3T3 cells (Jimenez 
de Asua et al., I98I). From the above data it can be seen 
that PGF^^ induces an increase in inositol lipid metabolism 
in Swiss 3T3 cells. Insulin activates tyrosine kinase 
(Kasuga et al., 1982a,b, and see Section 1.1.3 ) but does 
not induce inositol lipid metabolism (Macphee e_t al. , 1984; 
Farese ejt al • , 1984). Therefore, it is possible that inositol 
lipid metabolism-activated kinases and tyrosine kinase act 
synergi s tic ally in the initiation of cell proliferation.
An intracellular domain of the PDGF receptor has been 
shown to exhibit tyrosine kinase activity. However, the 
mechanism whereby PDGF stimulates inositol lipid metabolism 
remains elusive. The occupied PDGF receptor may act directly, 
to stimulate phospholipase C. It also seemed possible 
that PDGF may act by increasing the production of free AA 
which could be metabolized to active prostaglandins and/or 
leukotrienes (see Section 1.3 a-nd Figure 5)» One of the 
pieces of evidence which supports this idea is that PGF^,
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as we have seen from the above data, stimulates inositol 
lipid metabolism. Also, it has been shown that PDGF causes 
an increase in free AA levels in 3T3 cells (Habenicht 
et al., 1981).
Thus in order to show if the prostaglandins were 
intermediatory in the action of PDGF on inositol lipid 
metabolism, it was necessary to be able to inhibit their 
formation.
■^•2 Cyclooxygenase inhibitors stimulate inositol lipid 
metabolism in Swiss 3T3 cells
The results detailed in Section 3*2 are somewhat of 
a surprise (Figure 17)• Flurbiprofen, a water-soluble 
inhibitor of cyclooxygenase (Figure 16) causes a 2-3 fold 
increase in PtdA formation in 3T3 cells. The effect is 
maximal with a concentration of flurbiprofen between 10 
and 100 p,M (Figure 18). This increase in PtdA formation 
is comparable in magnitude to that seen with 1.6 p,M PGF^. 
AA, itself, causes about a 2-fold rise in PtdA levels 
(Figure 17). Although the data is not shown, this effect 
is also seen with 10 indomethacin.
To explain this unusual finding, it might be suggested 
that the flurbiprofen is not efficient in inhibiting 
cyclooxygenase, allowing a small amount of prostaglandin 
to be produced. Evidence that the C.o. inhibitors are 
effective, however, comes from studies where 3T3 cells are 
labelled with j/V] -AA. Flurbiprofen, in a dose-dependent 
manner, causes an increase in the level of free {_ AA
in the m e d i u m  surrounding the cells, m  tandem with an
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increase in the formation of —arachidonyl PtdA
(Table 6 and Figures 19 and 2 0). Indomethacin, likewise
increases the level of [^HJ — AA in the medium and the 
-3  _
formation of j_ Hj -arachidonyl PtdA (Table 7).
The time course of flurbiprofen's effects on AA release 
and arachidonyl PtdA formation are outlined in Figures 19 
and 20. AA release increases within 10 minutes of the 
addition 30 ]iM flurbiprofen and continues to increase 
gradually between 10 and 40 minutes. The accumulation of 
arachidonyl PtdA peaks at 10 minutes and then declines, 
reaching basal levels within 25-40 minutes. From this it 
appears that the formation of arachidonyl PtdA and, to a 
lesser extent, the release of free AA, stimulated by 
flurbiprofen is relatively short-lived. One possible 
explanation for these data is that AA exerts a negative 
feedback effect on PLA^ activity. Indeed, there is evidence 
(Ballou and Cheung, 1 9 8 5) that, in human platelets, PLA^ 
can be inhibited by unsaturated fatty acids. It is clear, 
however, that the transience of the effects of these drugs 
on inositol lipid metabolism contrasts with the data 
reported for PDGF (Hasegawa-S&sahi, 19S 5),
4.3 BW755C, an inhibitor of both P . O .  and J L . O .  stimulates 
inositol lipid metabolism
Another possible explanation for flurbiprofen's effects 
on inositol lipid metabolism, could be that the flurbiprofen, 
by inhibiting C . O . ,  redirects the AA towards the lipoxygenase 
pathway (see Section 1.1.6). This effect has been seen in, 
for example, guinea-pig spleen, where indomethacin causes a
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redirection of AA metabolism via the lipoxygenase pathway 
(Hamberg, 1976; see also Slepian et al., 1 9 8 5 ).
Thus, a lipoxygenase metabolite might be produced 
which causes the increase in inositol lipid metabolism seen 
with flurbiprofen. The best way to test this idea, would 
be to block the lipoxygenase enzymes. Unfortunately, highly 
selective inhibitors of all the different l.o. enzymes 
(see Section 1.1.6) are not yet widely available. BW755C 
has, however, been reported to inhibit the 5 , 12 and 15 lip­
oxygenases, in addition to c.o. (Higgs e^fc al., 1979; Shoam and 
Razin, 1 9 8 5 ; Needleman e_fc al_. , 1 9 8 6).
Data similar to that obtained with flurbiprofen are 
obtained with BW753C. This substance causes an increase in 
the level of free |_ h] -AA in the medium surrounding the 
Swiss 3T3 cells, and an increase in |_ Hj -arachidonyl PtdA 
(Figures 21 and 22). These responses are maximal with a 
concentration of BW755C of 100 ]iM. This concentration of 
BW755C has been reported to cause the maximum inhibition 
of LTB^ and TxB^ synthesis by human polymorphonuclear 
leukocytes (Salmon, 1 9 8 6 ). BW755C also increases the 
formation of InsP in a dose related—manner (Table 8 ).
One important point about all of the experiments in 
which flurbiprofen and BW755C were used, is the variability 
of the cells * responses. In 4-9 out of 57 experiments the 
drugs were effective at causing an increase in the level 
of InsP in Swiss 3T3 cells. However, in the remainder of 
experiments the drugs had no effect. As new preparations 
of drugs were used for each experiment it is unlikely that
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the drugs' effectiveness had expired due to, for example, 
oxidation. One possibility could be that transformation 
o:^  "the cells might have occurred in areas on the petri—dish 
which were undetected, possibly leading to enzymatic changes 
in the cells. In the majority of experiments (86%), where 
the drugs were effective, the maximum response was also 
somewhat variable. For example, in one experiment the same 
concentration of flurbiprofen might cause a doubling in 
cellular InsP levels whereas in another experiment the 
increase might only be 60% above control values. This again
might have resulted from the same conditions described above.
It is worth noting, however, that if, as seems likely, the
drugs are producing their effects by blocking arachidonate
metabolism, then their effects will depend critically on 
the basal flux through the enzymes. In the light of this 
consideration, the variability becomes more readily explained.
The results obtained in the studies with BV755C make 
it appear unlikely that a stimulatory lipoxygenase metabolite 
is the cause of the increase in inositol lipid metabolism 
seen with flurbiprofen although it remains a possibility 
that BW755C does not effectively block the production of 
all lipoxygenase metabolites. This is an important point, 
for in the studies which measured AA and PG- levels (Figure 
23), it is possible that some hydroxyacids of AA, e.g.
15-HETE and 15-HPETE, might still be produced even in the 
presence of BW755C. These hydroxyacids would co-migrate 
with AA in the TLC separation used, and would, therefore, 
have been undetectable (Dr D. E. MacIntyre, personal 
communication).
Another possibility is that oxidation of* AA by a
cytochrome p450 enzyme could occur resulting in the
formation of 19-hydroxy- and 19-oxo-eicosatetraenoic acid,
2 0—hydroxy-eicosatetraenoic acid and eicosatetraen—1 , 20—
dioic acids (Needleman et al., 1 9 8 6). This has been shown
to occur in rabbit renal cortex (Morrison and Pascoe, I9 8I;
Oliw et al. , 1987). Recently, a cyt—p450 enzyme capable
of metabolizing AA. has been localized to cells in the loop
of Henle of rabbit kidney (Ferreri et al. , 1984). Incubation
rl4 -»
of the cells with |_ CJ -AA produced major products that 
were chroma to graphic ally different from known l.o. products 
and their synthesis was not inhibited by indomethacin, but 
was partially inhibited by SKF-525A and carbon monoxide9 
suggesting that they were produced by a cyt-p450-dependent 
reaction.
Thus, by inhibiting q.o» and 1.0. enzymes with BW755C, 
AA could be redirected towards a cyt-p450-dependent enzyme 
in 3T 3 cells, to produce a metabolite which, in principle, 
could be stimulatory in respect of inositol lipid metabolism. 
Such an enzyme has not been reported in these cells, however, 
a trace amount could theoretically exist.
The most logical conclusion from the data, is that the 
unsaturated fatty acid, itself, causes the increase in 
inositol lipid metabolism seen upon treatment of 3T3 cells 
with flurbiprofen or BW755C. These drugs would act to 
prevent the breakdown of AA and, thereby, allow it to 
accumulate. The persistance of elevated AA m  the medium 
bathing the cells indicates, also, that reacylation reactions 
must be relatively, slow in fibroblasts.
AA stimulates inositol lipid metabolism in Swiss 3T3 cells
The idea that AA could itself stimulate the inositol
lipid cycle in cells has been suggested by other workers.
For example Zeitler and Handwerger (1 9 8 5) reported that in
human placental cells, AA stimulated the rapid appearance
of* InsP. The effect of AA was specific for hydrolysis of
phosphoinositides and phosphatidylserine and did not involve
other phospholipids. Hashimoto e_t al. (1 9 8 5) showed that
high concentrations of AA (60 p,M) induced platelet aggregation
and serotonin release that was not blocked by C.o. blockers.
Such concentrations of AA also caused an increase in the
levels of PtdA and 1,2 DG, although these increases were
not thought to induce the platelet aggregation and serotonin
release. Furthermore, AA has recently been reported to
2+increase the intracellular Ca concentration in rabbit
neutrophils and several long chain fatty acids have been
2+demonstrated to release Ca sequestered by the sarcoplasmic
reticulum of skeletal muscle (Cheah, 1981; Volpi et al.,
1984). Wolf _et al. (1 9 8 6) showed that AA indue ed. .a rapid 
2 +release of Ca from isolated pancreatic islets, which was 
not due to the metabolites of AA. Comparison of AA-induced
p i
Ca release with InsP^-induced Ca release, revealed 
similar molar potency of AA and InsP.
Thus, because of the possibility that AA stimulated 
inositol lipid metabolism in Swiss 3T3 cells, the level of 
InsP was measured in response to various concentrations of 
AA (Figure 24). From these experiments, it appears that 
AA does, indeed, stimulate the inositol lipid cycle. However,
a high concentration of AA (100 p,M) is necessary to yield 
the maximum response.
The question arises, as to the physiological significance 
of this finding in the light of the need for such a high 
concentration of AA. One contributory factor, here, is that 
a large amount of the exogenously applied AA is likely to 
bind to albumin in the medium surrounding the cells (Hoak
• > 1967)« This would be expected to markedly reduce the 
concentration of free (dissociated) AA which, presumably, 
is the active stimulant of inositol lipid metabolism.
To investigate this, the effect of AA on inositol lipid 
metabolism in 3T3 cells in albumin—free conditions was 
examined (Figure 28). It is evidence from these data that 
0.1 p,M AA, under albumin-free conditions, gives an equivalent 
increase in InsP formation as 100 p,M AA in the presence of 
albumin (0.1% w/v). Further, in experiments where the effects 
of BW755C and indomethacin on AA release and on arachidonyl 
PtdA formation were studied, the results are consistent with 
the idea that endogenously released AA binds to albumin in 
the BSS surrounding the cells (Figures 29 and 30). Thus,
£3h} -AA release from cells appears greater when albumin 
is present in the surrounding BSS, due to it being "bound" 
outside the cell (Figure 29). |~3hJ -Arachidonyl PtdA
formation (Figure 30) > on the other hand, is greater where 
the cells are in albumin—free BSS, as the endogenous AA 
released by the cell remains dissociated, thereby allowing 
it, presumably, to interact with, e.g., cell surface receptors.
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These results could, in principle, be complicated by
the possible binding of the drugs, themselves, to albumin.
While it is likely that indomethacin will be bound by
albumin, BW753C does not bind appreciably to albumin (Dr
R. MacMillan, I.C.I., Cheshire, personal communication).
Unfortunately, the mass amount of AA contained in 3T3
cells has not been directly established. However, Habenicht
ejfc al. (1 9 8 5b), have studied the effect of NaF and PDGF on
AA release and PGE2 formation in Swiss 3T3 cells. In response
to 12 ng/ml PDGF, PGE2 production rose by about 25 ng/lO^ cells/
ml of medium. From the data shown in Figure 23, about 95%
~3 -of [_ Hj -AA derived radioactivity co-migrates with AA itself 
(in control and flurbiprofen-stimulated 3T3 cells). Thus the 
amount of PGE^ present in 3T3 cells is equivalent to less 
than 5% of the AA content of the cells. Therefore if 25 ng/lO 
cells/ml PGE^ is formed in response to 12 ng/ml PDGF, then 
this might be equivalent to about 4-75 ng/lO^ cells of free 
AA (in 1 ml medium). The multiwells, used in this project, 
contained about 2 x lCr cells, and so the amount of AA,
ET
here, could be calculated to be about 95 ng/2 x 1CU cells.
This is equivalent to 0.3 AA/2 x  10 cells. Thus, the 
concentration of AA required to induce inositol lipid metabolism 
in 3T3 cells (in albumin-free conditions, Figure 2-B ) of
about 0 . 1  v-M/ 2  x  1 0^ cells is close to the figure calculated
for endogenous AA levels.
It is of interest that the mass of free AA released 
by 3T3 cells, at rest, is many times greater than the mass 
of the prostaglandin metabolites (e.g. PGE2) of AA formed
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under such conditions, assuming that the labelling employed, 
allowed full equilibration of [3Hj -AA with the different 
cellular pools of the fatty acid. This is consistent with 
the possibility that AA, itself, may play some mediator 
function that does not require its oxidation to a metabolite. 
Other investigators have also suggested this possibility 
based on the large amounts of unmetabolised arachidonate 
metabolites released in other stimulated systems (Hokin,
1985; Kolesnick and Gershengorn, 1 9 8 5).
Also, consistent with this idea, is that if flurbiprofen 
and BW755C stimulate inositol lipid metabolism via an increase 
in endogenous free AA, in 3T3 cells, then their effects on 
InsP levels would not be expected to be additive with 
exogenously applied AA. The data shown in Figure 31 would 
support this.
Other unsaturated fatty acids, structurally related to AA 
can stimulate inositol lipid metabolism in 3T3 cells
If AA, itself, is a direct stimulant of inositol lipid 
metabolism, then the question arises as to its mechanism of 
action. A number of possibilities exist* For example, AA 
may bind to a receptor, which is coupled, via a G—protein, 
to phospholipase C. This receptor might be specific for AA, 
or the AA might bind to a "general11 unsaturated fatty acid 
receptor. It is also possible that AA can bind to the 
receptor for PGF„ that is thought to exist on these cells 
(Macphee et al. , 1984). Another possibility is that AA 
could have a "fluidising" effect on the cell membrane
(Dave e_t al. , I98I; Shier and Durkin, 1 9 8 2). This might 
increase the mobility of the enzyme components within the 
cell membrane, e.g. a G—protein, such that they are in a 
better position to interact with the catalytic moiety, i.e. 
phospholipase C • Indeed, Dave et al. (1 9 8 1 ) found that in 
membrane preparations of liver homogenates from C^H mice,
AA (4 pg/ml) stimulated an increase in ovine prolactin 
release of 73%> which they suggested was due to an increase 
in the number of receptor sites. The AA was also shown to 
decrease membrane microviscosity by 22%, which indicated 
that the membrane lipids became more fluid as a result of 
treatment with AA.
If a receptor existed which bound AA, then analogues of 
AA, or other unsaturated fatty acids might also stimulate 
responses in 3T3 cells, similar to those seen with AA itself. 
Dihomo— ^ -linolenic acid and linoleic acid, unsaturated 
fatty acids related in structure to AA, do appear to possess 
some activity, although not as great as AA itself (Figure 2 5 )*
However, this does not clarify the mechanism of action 
of AA in stimulating inositol lipid metabolism, as these 
analogues could act at specific AA receptors, ''general" 
unsaturated fatty acid receptors, PGF2a receptors or also 
have a fluidising effect on the cell membrane. Binding 
studies, with radiolabelled AA, could be carried out, which 
might reveal the presence of "receptors" on the plasma 
membrane. Fluidify of the membrane could be measured by 
fluorescence polarization of membrane preparations from 
Swiss 3T3 cells, treated with or -without AA, using- the
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lipid probe 1,6-diphenylhexatriene, as outlined by Dave 
et al. (1 9 8I).
31
P-NMR—spectrum analysis of pure phospholipids, 
existing as hydrated bilayers, (e.g. pure yeast PtdCho), 
before and after addition of AA, might indicate a reorganisation 
of the tightly packed bilayer structure to one of an undefined 
nature (Dawson e_fc al. , 1984).
Regardless of the transduction pathway utilised by AA, 
in stimulating inositol lipid metabolism, in Swiss 3T3 cells, 
the mechanism whereby PDGF might stimulate the production 
of AA has yet to be established.
The theory proposed in Section 1 . 3  is that PDGF binding 
to its receptor, activates tyrosine kinase catalysis. This 
leads to the inhibition of p36 (lipocortin, an anti-PLA^ 
protein), thereby freeing the PLAg euzyme(s) to hydrolyse 
membrane lipid and liberate free AA.
Recent work on p36 (Calpactin I, lipocortin II) has
shown that it binds Ca2+ (Glenney, 1 9 8 5* 1986a). Of particular
2+interest, with respect to Ca regulation, is that the 
affinity of p36 for Ca2+ can be greatly enhanced by anionic 
phospholipids in a manner similar to the effect of phospho­
lipids and Ca2+ on protein kinase C activity (Glenney, 1983? 
1986a, b). Studies by Wallner et al. (1 9 8 6) indicated that 
pronounced sequence similarities existed between p3 ^ and 
the human PLA2 inhibitor lipocortin II. In the light of 
the finding that the calpactins I  and I I  ( p 3 6  and p 3 5 )  served 
as substrates for tyrosine kinase (Huang et a l ., 1986;
Saris et al., 1986), these studies supported the theory
outlined in Section 1.3*
However, some doubts have been raised about this
theory. Saris _et al. (1 9 8 6) suggested that although p36
has been shown to inhibit porcine pancreatic VLA^ with a
specific activity similar to the inhibitory activity of
lipocortin I (Huang et al., 1 9 8 6), the possibility that the
inhibitory activity of p36 is an incidental consequence of
2+
its ability to bind Ca and phospholipid cannot be ruled out. 
Recent evidence from Davidson et al• (1 9 8 7) indicated that 
"this may be the case, as they reported that the most likely 
explanation for calpactin I (p36) inhibition of pancreatic 
PLA^ in vitro is substrate depletion. If true, this would 
imply that the inhibition might not be specific for PLA^ 
in terms of enzyme-inhibitor interactions. Further work is 
necessary to settle this issue. If PLA^ is the most active 
enzyme in binding to these phospholipids, a specific blockade 
will still result.
Whichever way PLA^ is activated, the result is the 
release of AA from membrane phospholipid. Hong and Deykin 
(1 9 8 1 ) produced direct evidence, from measurements of lyso- 
Ptdlns levels, for the in vivo activation of PLA^ acting on 
Ptdlns, in transformed BALB/c 313 cells.
Habenicht et al. (l98l) showed that PDGF could stimulate 
the release of free AA in Swiss 313 cells. However, they 
suggested that AA is produced via the phospholipase C/ 
diglyceride lipase pathway and they later showed that this 
pathway contributes, to some degree, to AA release in PDGF- 
stimulated Swiss 3T3 cells (Habenicht et al., 1985b).
In an effort to show that PLA2 also contributed to 
PDGF-stimulated AA release in Swiss 3T3 cells, studies 
were carried out using the PLA2 activator, melittin (Rozengurt 
et al., 1981; Vincentini et al., 1984; Mix et al., 1984), 
and the indirect PLA2 inhibitor, dexamethasone (Hirata, 1983; 
Dartois and Bouton, 1 9 8 6 ).
^ •5 Melittin stimulates AA release and arachidonyl PtdA
formation in Swiss 3T3 cells
Melittin appears to stimulate a dose—related increase
in both AA release and inositol lipid metabolism (seen as
an increase in arachidonyl PtdA) in Swiss 3T3 cells (Table 9).
Mix eb al. (1984) have shown that melittin can induce a rise
2 +m  intracellular free Ca in human fibroblasts. This 
would be consistent with the theory that AA can control the 
inositol lipid cycle in fibroblasts, since melittin, by 
stimulating PLA2 activity, would cause an increase in AA 
release and a subsequent fatty-acid dependent stimulation of 
inositol lipid metabolism. This would lead to an increase 
in Ins(l,4,5)P^ formation, which as has been widely reported, 
(see Section 1.1.4), acts as a second messenger involved in 
£Ca2+J± mobilization. Importantly, a rise in intracellular 
Ca2+ coupled with the addition of phorbol esters, (which 
are thought to stimulate protein kinase C), can lead to the 
activation of PLA2 (Touqui et al. , 1986). The protein kinase 
C is thought to act, here, by phosphorylating the anti—PLA2 
protein, lipocortin, and suppressing its anti-PLA2 activity. 
Several long chain unsaturated fatty acids, including AA, 
have been demonstrated to release Ca2+ from intracellular
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stores (e.g. Volpi et al., 1984) and AA, and other 
unsaturated fatty acids have been shown to activate protein 
kinase C. Kinase C activation by AA requires calcium and is 
enhanced by diolein, but does not require exogenous PtdS 
(McPhail _et al_. , 1984). Thus, it may be possible that AA 
could act by stimulating both inositol lipid metabolism and 
■^•^2 activity. The PLA^ activity may later decrease due 
to the AA having a negative feedback control on the enzyme 
(Ballou and Cheung, 1 9 8 5).
4• 6 Dexamethasone abolishes the increase in inositol phospho­
lipid degradation observed with flurbiprofen and BW7 5 5C 
in Swiss 3T3 cells 
Further data indicating the importance of the PLA^ 
pathway, for the production of AA, are shown in Figures 26 
and 27. In cells which were pre-incubated for 24 hours with 
30 hM dexamethasone, 100 p,M flurbiprofen does not induce a 
rise in InsP formation (Figure 26). Similar findings are 
obtained with BW755C (Figure 27)- This effect of dexamethasone 
appears to be dose-related, as the increase in InsP formation 
observed with 100 jiM BW755C can be reduced by a concentration 
of dexamethasone as low as 0.1 hM, and abolished with 10-100 hM 
dexamethasone. This is an important finding, as the low 
concentrations of dexamethasone necessary to reduce BW7330- 
and flurbiprofen—induced inositol lipid metabolism, are 
indicative of a specific glucocorticoid-receptor mediated 
action, perhaps on activity*
The phospholipase C/diglyceride lipase pathway may 
also be involved in the production of AA. However, since 
dexamethasone is so effective in abolishing the increase in 
inositol lipid metabolism, it would appear that the production 
of AA in 313 cells is dependent, to some extent, on PLA^ 
activity. In order to test for the involvement of the PLC/DG 
lipase pathway, experiments could be carried out using the 
potent inhibitor of DG lipase, RHC 80267 (Chau and Tai, 1 9 8 3 ). 
Unfortunately, neither the drug nor time was available to 
investigate this aspect further.
If released AA contributes to the effect of PDGF on 
inositol lipid metabolism. Then, by using dexamethasone to 
block production of AA, it might be possible, at least partially, 
to inhibit the effects of the growth factor in inositol lipid 
metabolism.
However, further strategies are necessary to prove the 
involvement of AA in PDGF action on the inositol lipid cycle.
For example, it might be inferred that flurbiprofen and 
BW755C, by causing an accumulation of free AA, in Swiss 3T3 
cells, and blocking its catabolism, could combine with a 
submaximal concentration of PDGF to increase inositol lipid 
metabolism, in an additive or, more likely, synergistic 
fashion. Synergy should occur since PDGF, by stimulating 
AA production and BW755G, by blocking AA metabolism, act by 
different mechanisms. However, since BW755C is active by 
itself, an additive interaction might result if the degree 
to which AA can stimulate inositol lipid metabolism is limited. 
For example, additivity or even mutual competition might
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possibly be observed, if free AA at high concentrations, 
could exert a negative feedback control on the enzymes 
that release it from phospholipids. Such control has been 
described in human platelets (Ballou and Cheung, 1 9 8 3).
A third approach, that might be useful in elucidating 
any mediatory involvement of AA (and its metabolites) in 
PDGF stimulation of the inositol lipid cycle, is derived 
from the work of Murayama and Ui (1 9 8 3). They suggested 
that, in thrombin—stimulated 3T3 cells pertussis toxin 
could selectively block agonist-stimulated AA release, 
leaving the increase in inositol lipid metabolism unaffected. 
Thus, it is possible that if PDGF’s effects on inositol 
lipid metabolism to PDGF, since PDGF is the major (but not 
the only) growth factor contained in serum (Rozengurt, 1 9 8 0).
4.7 Dialysed newborn calf serum is less powerful than non— 
dialysed serum in stimulating inositol lipid metabolism 
in Swiss 3T3 cells 
The ability of newborn calf serum to stimulate phospho- 
inositide degradation was compared with newborn calf serum, 
dialysed so as to retain peptide mitogens with a molecular 
weight greater than 3>300, e.g. PDGF, whilst removing lower 
molecular weight growth factors like GRP, PGF^^ and vasopressin.
Serum was dialysed using the method of Besterman et al. 
(1986). They found that in BALB/c3T3 cells almost 70% of 
the capacity of foetal calf serum to stimulate phosphoinositide 
degradation was lost from dialysed serum compared to non- 
dialysed serum.
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The data shown in Figure 32 indicates that the ability 
of newborn calf serum to phosphoinositide degradation is 
reduced by up to 90% when the serum is dialysed, and that 
30% (v/v) dialysed serum gives an increase in InsP formation 
equivalent to that seen with about 3% (v/v) non-dialysed 
serum.
^ • & Pertussis toxin does not affect dialysed serum-stimulated 
responses in Swiss 3T3 cells
It might have been expected that pertussis toxin would 
inhibit serum-stimulated AA release, based on the results 
of Murayama and Ui (1 9 8 5) and that arachidonyl PtdA formation 
would also be reduced if released AA exerted control on 
inositol lipid metabolism. Murayama and Ui (1 9 8 5) suggested 
that, in thrombin-stimulated 3T3 cells, pertussis toxin 
inhibited a G-protein involved in the release of AA, but 
did not affect stimulated inositol lipid metabolism. Bokoch 
and Gilman (1984) also reported that pertussis toxin prevented 
FMLP receptor-mediated functions of neutrophils, including 
AA release, but the toxin's effects on inositol lipid 
metabolism were not studied.
The results of experiments in which 3T3 cells were pre­
incubated fox’ 18 hours with 100 ng/ml pertussis toxin 
(Figure 37) indicates that the toxin does not reduce AA 
release, in response to 10/» (v/v) dialysed serum, 100 pM 
BW755C, 1.6 pM 'PGE'2 0:r 0.1 pM bombesin. Also, pertussis 
toxin has no effect on arachidonyl PtdA formation in response 
to the above agonists (Figure 38). This batch of toxin
was demonstrably active on the adenylate cyclase system, 
both prior and subsequent to this experiment (Dr G. Milligan, 
Glasgow University, personal communication), although not 
in this particular batch of 3T3 cells.
It is difficult to explain why these findings are so 
different from those described by Murayama and Ui (1 9 8 5 ).
Such differences may have resulted from variations in the 
experimental methods used in each case. Murayama and Ui 
pre—incubated their cells with pertussis toxin for only 3 
hours prior to the experiment. In the data shown in Figures 
37 and 38 the cells were pre-incubated for 18 hours prior 
to experimentation. It may be that a longer stimulation 
with pertussis toxin results in a change in the radio­
labelling pattern of the phospholipids such that, upon 
stimulation with BW755C, a different pattern of Q"^ Hj -AA 
release is observed. Also, Murayama and Ui pre-incubated 
their cells for 10 minutes with a buffer containing 30 yM 
AA (non-radioactive). This, they suggested, reduced the 
non-specific background of release during the subsequent 
release assay. Thus, in the data illustrated in Figure 
the AA release may be non-specific, arising possibly from 
degradation of DG by the PLC/DG lipase pathway, and not 
through the PLA^ pathway• While it is also possible, that 
the pertussis toxin did not gain access to the G-proteins 
on 3T3 cells, the most likely implication is that AA release, 
seen here, is not mediated via a pertussis-sensitive G-protein. 
Indeed, Burch and Axelrod (1987) found that, in bradykinin- 
stimulated 3T3 cells, pertussis toxin dxd not affect PGE2 
synthesis or InsP formation.
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gW 735C can have synergistic effects with submaximal 
concentrations of dialysed serum to increase inositol 
lipid metabolism in Swiss 3T3 cells 
As discussed above, the most logical explanation of the 
effects of BW755C (and flurbiprofen) on inositol lipid 
metabolism in Swiss 3T3 cells, is that BW753C leads to an- 
accumulation of free AA which, itself, stimulates inositol 
lipid metabolism. Thus, if AA is intermediatory in the 
effects of PDGF on the inositol lipid cycle, then, the 
increase in inositol lipid metabolism, in response to sub- 
maximal concentrations of PDGF or, as in this case to 
dialysed serum, might be enhanced with BW755C.
The results from experiments designed to test this 
indicate that a more complicated situation exists in 3T3 
cells. It appears that a submaximal concentration of BW755C 
can be inhibitory or additive with a submaximal concentration 
of dialysed newborn calf serum in increasing inositol lipid 
metabolism and AA release (Figures 33> 34 and 33)* However, 
when a maximal concentration of BW755C is used, the results 
are different. Here, synergism between 100 >iM BW755C occurs 
with a submaximal concentration of dialysed serum. That is, 
the increases in inositol lipid metabolism and AA release, 
in response to a combination of 100 ]iM BW735C und 3% (v/v) 
dialysed serum, are greater than the predicted additive 
increases from both agonists. A significant inhibitory 
effect of BW733C is only observed for serum—stimulated AA 
release (Figure 3*0- However, this effect appears to be
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reproducible (in two experiments, carried out in triplicate). 
It is difficult to explain why such an inhibitory effect of 
a low concentration (submaximal) of BW735C on a submaximal 
concentration of dialysed serum occurs. In view of the 
complexity of the system under investigation it might be 
inappropriate to comment on this finding, without carrying 
out further investigation.
The additivity observed for the two growth factors, 
both at submaximal concentrations, might indicate that the 
AA.—induced mechanism is not saturated by the drugs themselves, 
however, it might imply that the two agents act on different 
pathways in stimulating inositol lipid metabolism and AA 
release.
The synergistic effects observed with a maximal 
concentration of BW735C and a submaximal concentration of 
dialysed serum might suggest that the two drugs operate by 
different pathways to increase the concentration of free AA 
which, if our theory is correct stimulates inositol lipid 
metabolism. Based on our working hypothesis, we might have 
expected to observe synergism between BW733C and serum, 
although it is surprising that it does not occur at lower 
concentrations. A possible explanation of how synergism 
occurs, is that the agonists, by increasing AA production 
and accumulation, initially stimulate phosphoinositide 
degradation and, as a result, protein kinase C activation. 
Touqui et al. (1 9 8 6) suggested that protein kinase C could
phosphorylate the anti—PLA^ protein, lipocortin, ultimately 
leading to production of AA. The increase in phosphoinositide
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hydrolysis could also lead to increased [Ca2+J., via 
InsP^ formation, which could stimulate AA production via 
the Ca -dependent PLA2 enzyme. A positive feedback 
mechanism might exist for protein kinase C activation of 
PLA^. If production pathways for AA were saturated, using 
higher concentrations of the agonists, a threshold for 
inositol lipid metabolism might be reached whereby the 
positive feedback mechanism is activated and thus synergy 
could occur. The signal pathway through protein kinase C, 
is separate from and often synergistic to, the Ca2 + signalling 
pathway for the control of various cellular functions and 
proliferation (Nishizuka, 1 9 8 6).
The results from these studies are inconclusive in 
that additivity and synergy could be explained in terms of 
the proposed theory that AA is involved in serum or PDGF- 
stimulated inositol lipid metabolism. Thus a more definitive 
experimental approach is necessary to demonstrate whether or 
not the theory is correct.
4.10 Dexamethasone can partially inhibit the serum or
PDGF-induced increase in inositol lipid metabolism
in Swiss 3T3 cells
If the additivity and synergy observed for BW755C and 
dialysed serum, in increasing inositol lipid metabolism, is 
at least consistent with the view that the agonists act 
through pathways which lead ultimately to an increase in 
free AA, then dexamethasone, which can abolish the BW755C- 
induced increase in inositol lipid metabolism, might also 
inhibit the serum-induced increase in inositol lipid metabolism.
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Unfortunately, the data, shown in Figures 391 4-0 and
4l do not fit well with the above theory. That is,
dexamethasone does not significantly reduce the effects of
5% (v/v ) dialysed serum or 1 0% (v/v) dialysed serum on
inositol lipid metabolism or AA release. Dexamethasone
does, however, reduce the effect of PGFn on the inositol
2a
lipid cycle, although it does not abolish it. This is 
noteworthy, in light of the finding that BW7 5 5C enhanced the 
^ ^ 2a"”induced increase in inositol lipid metabolism (Figure 
36)• In combination, these two pieces of evidence might 
suggest that part of F G F ^ ' s  effects on inositol lipid 
metabolism, in Swiss 3T3 cells, might be due to stimulation 
of PLA^. Thus PGF^^ could act directly on its receptors to 
stimulate phosphoinositide hydrolysis. This would lead to
Gi p ^Ca mobilization. As
explained above, PUA^ activation could result from both of 
these responses and the subsequent release of AA might, 
by itself, stimulate inositol lipid metabolism, thereby 
contributing to the effect of PGF^. Why a similar effect 
is not found with other agonists e.g. vasopressin, is 
unclear (Figure 36).
At the end of the time available for this project, 
it was possible to use highly purified PDGF (Figure 43).
In this case, the results appear to be somewhat different. 
The PDGF—induced increase in inositol lipid metabolism 
(10 ng PDGF/ml) is significantly reduced by 0.1 pM 
dexamethasone. However, as indicated in Section 3»3»3«4, 
it was only possible to carry out this experiment once and 
therefore, it would be imperative to replicate these data in
further experiments.
At the very most, however, it might be suggested 
that PDGF may act, in part, to stimulate the inositol lipid 
cycle, via activation of PLA^. This would lead to an increase 
in free AA formation which could stimulate inositol lipid 
metabolism directly, or be oxidated to, for example, PGF
2a
which could also stimulate the inositol lipid cycle.
The fact that dexamethasone does not abolish the PDGF- 
induced increase in inositol lipid metabolism, might indicate 
the potency of the growth factor, in that PDGF is thought to 
stimulate a number of metabolic pathways which could interact 
with each other. This is more clearly illustrated in Figures 
1 7 9 28, 39 and 42, where the relative size of the inositol 
lipid response to PDGF is compared to that of other agonists. 
From the data shown in Figures 17> 28 and 39 it appears that 
100 pM flurbiprofen, 1.6 pM PGF2 , 100 pM BW755C, 0.1 pM AA 
(in albumin-free conditions) and 0.1 pM vasopressin, all 
give a similar sized increase in inositol lipid metabolism. 
However 0.1 pM bombesin and 10 ng/ml PDGF are far more 
powerful than these agonists in increasing inositol lipid 
metabolism (Figures 39 and 42). Both bombesin and PDGF are 
thought to employ more than one signal transduction pathway 
in stimulating cell proliferation (Table l).
Activation of the phospholipase c/diglyeeride lipase 
pathway is also a potential route for PDGF action. This 
pathway would lead to the production of AA, but would not 
be inhibited by dexamethasone, and has been shown by 
Habenicht et al. (198 5k) to ke active in 3T3 cells. The
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diglyceride lipase inhibitor RHC 80267 (Chau and Tai,
1983) could be used to determine the importance of this
pathway in PDGF-induced inositol lipid metabolism in 3T3 
cells.
4•11 Conclusions
This study has characterised PGF^^—induced changes in
inositol lipid metabolism in Swiss 3T3 cells. It has indicated
that hydrolysis of inositol phospholipid is extremely rapid,
occurring within 10 seconds of administration of PGF •
2a
It has also suggested that the concentration of intra- 
or extracellular free AA may have a role in controlling 
inositol lipid metabolism. However, it remains possible 
that an as—yet-unidentified metabolite could also act to 
stimulate inositol lipid metabolism in Swiss 3T3 cells, 
although, the bulk of experimental evidence from this study 
would favour the former idea.
Further, this study has investigated whether the mechanism 
of action of PDGF, in leading to inositol phospholipid 
hydrolysis depends on an action of released free AA. This 
data, while clearly preliminary, might suggest that the action 
of PDGF on inositol lipid metabolism is mediated, in part, 
via AA production. However, the role of AA may be only minor.
The pathway of AA production has still to be resolved 
in these cells* While it appears that PIA^ is active, as 
suggested by the potent inhibitory effects of dexamethasone, 
it is still possible that the phospholipase C/diglyceride 
lipase pathway also has a role in the production of AA. This 
latter area of study should prove an interesting avenue of 
research for the future.
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